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ABSTRACT 
 
Background 
The systemic postprandial glycaemic response following the ingestion of glucose-containing 
meals (i.e. sugar/ starch) is governed by a complex, systemic regulatory interaction. Primarily, 
the rates of glucose appearance (Ra; from both endogenous and exogenous sources) are 
balanced by the rate of glucose disappearance (Rd), and when total Ra exceeds Rd, systemic 
glycaemia increases. This regulation is also under the direction of a number of complex and 
interacting factors, including β-cell insulin secretion, tissue insulin sensitivity and glucose 
effectiveness. Only under physiological conditions, such as when glucose is ingested, are all 
of these regulatory factors simultaneously required. However, much of the existing literature 
that has investigated the effects of lifestyle interventions on the glucoregulatory systems have 
utilised experimental conditions that, although informative for specific outcomes, do not 
emulate this physiological postprandial state. Thus, there is a need to utilise measurement 
techniques that can determine the regulation of physiological postprandial glucose flux in 
response to lifestyle interventions, in order to determine the initial steps in the alteration of 
normal glucose metabolism. 
The aims of this thesis were therefore to firstly determine the optimal rates of infusion of 
intravenous stable-isotope glucose tracers in order to minimise changes to postprandial tracer-
to-tracee ratios during the triple tracer technique, achieving as close to isotopic steady state as 
possible. This then allowed for the accurate determination of postprandial glucose fluxes 
following a mixed meal by the triple tracer technique, to be utilised in the subsequent lifestyle 
intervention studies. Thus, the aims of studies 2 and 3 were to determine the physiological 
effect of endurance exercise training and mixed nutrient overfeeding on postprandial glucose 
metabolism, with specific regard to glucose fluxes, as determined in healthy young men. 
xi 
  
 
Methods 
Pilot study: Healthy males (n=4), underwent a tentative format of tracer administration (using 
a priori knowledge about the behaviour of glucose fluxes), to verify that stable tracer-to-tracee 
ratios occurred. If these ratios were not stable, the format of tracer administration in the 
subsequent experiment was refined, and repeated until satisfactory results were obtained.  
Experimental testing: Participants underwent mixed meal tolerance testing, combined with a 
variable infusion, triple-stable isotope glucose tracer approach to determine glucose fluxes 
(meal Ra, Rd and EGP) under postprandial conditions. 
Exercise study: Healthy, lean and sedentary males (n=10, aged 21.9 ± 0.1 y [mean ± SEM]) 
underwent a single acute bout of endurance exercise (70.66 ± 0.14% VO2max) and 4 weeks of 
endurance exercise training (71.11 ± 0.12% VO2max). At baseline, and 21 ± 1 h following both 
acute and chronic exercise, participants underwent experimental testing as described above. 
Overfeeding study: Healthy, lean and sedentary males (n=8, aged 22.9 ± 0.3 y [mean ± SEM]) 
underwent 4 weeks of mixed nutrient overfeeding (+45.55% energy, 31.0% fat, 48.6% 
carbohydrate, 16.7% protein). At baseline, and after both 5 and 28 days of overfeeding, 
participants underwent experimental testing as described above, as well as body composition 
DEXA scans. 
Results 
Pilot study: The overall tracer-to-tracee ratios obtained for the intravenously infused tracers 
were successfully optimised within an acceptable range of 2-fold during the triple tracer 
technique, despite large individual variability.  
xii 
  
Exercise study: Postprandial glucose and insulin responses were reduced to the same extent 
following acute and chronic training. Interestingly, this was not accompanied by measurable 
changes to rates of meal Ra, Rd or degree of EGP suppression. Glucose clearance (Rd relative 
to prevailing glucose) was, however, significantly enhanced to a similar degree with acute and 
chronic exercise. Furthermore, the duration of EGP suppression was significantly shorter with 
acute and chronic exercise, with EGP returning toward fasting levels more rapidly than pre-
training conditions. 
Overfeeding study: Postprandial glycaemia was significantly increased after 28 days of 
overfeeding despite remaining unaltered after 5 days. Surprisingly, this occurred despite no 
alteration to total postprandial suppression of EGP following both acute and chronic 
overfeeding. Additionally, visceral adipose volume was significantly increased after 5 days but 
not increased further after 28 days of overfeeding. Interestingly, meal glucose Ra and Rd were 
elevated following both acute and chronic overfeeding, although glucose clearance was only 
significantly improved following acute, not chronic overfeeding. 
Conclusion 
These findings suggest that endurance exercise subtly influences the efficiency of the 
glucoregulatory system by increasing glucose clearance, such that pre-training rates of glucose 
disposal and production were achieved at lower glucose and insulin levels. Notably, there was 
no effect of chronic training over and above that of a single exercise bout on postprandial 
glycaemia or rates of glucose flux, providing further evidence that the benefits of endurance 
exercise on glucose metabolism are largely attributed to the residual effects of the last exercise 
bout. Additionally, 5 days of overfeeding with a normal macronutrient composition induced a 
rapid, albeit moderate, increase in meal glucose Ra into the circulation, which was matched by 
an appropriate rise in Rd, as the postprandial suppression of EGP was not altered, thus 
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maintaining postprandial glycaemia. However, following chronic overfeeding, glycaemic 
excursions did modestly deteriorate, while glucose fluxes were maintained without the need to 
induce large increases to insulin secretion. Thus, it seems that maintaining appropriate rates of 
glucose flux can also occur at the expense of increasing postprandial glycaemic and 
insulinaemic responses. Thus, the findings of this thesis demonstrate that the alterations to 
glucose metabolism observed under conditions that are representative of normal living 
conditions are more subtle than with common techniques such as the clamp. Indeed, the 
glucoregulatory system can compensate for lifestyle intervention induced alterations to insulin 
action, by inducing subtle regulatory changes with the aim of maintaining appropriate rates of 
glucose flux. 
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1.0 Chapter 1: Literature Review - Introduction 
 
Glucose is the primary energy source for many tissues including the brain and as such is tightly 
regulated in a narrow range in healthy individuals (1). This tight control is maintained despite 
periods of fasting and feeding, due to a complex system of glucoregulatory processes that work 
to balance the rate of glucose appearance (Ra) and disposal (Rd) into and from the systemic 
circulation (2). Thus, the systemic postprandial glycaemic response following the ingestion of 
glucose-containing meals (i.e. sugar/ starch) is governed by the interaction of three key 
physiological parameters; meal Ra into the circulation from the gut, the suppression of 
endogenous glucose production (EGP) and the stimulation of glucose Rd (3). Furthermore, the 
ability to suppress EGP and stimulate glucose Rd following a meal is further determined by a 
balance of three more complex and interacting factors; β-cell insulin secretion, tissue insulin 
sensitivity and glucose effectiveness (4).  
Understanding this simultaneous regulation is important as meals tend to be taken every few 
hours, and because impairment to one or more of these processes can potentially result in 
alterations to glycaemic control, including the development of type 2 diabetes (T2D). 
Considering that in 2013 it was estimated that approximately 382 million people worldwide 
were affected by diabetes and that the prevalence could double by 2030 (5), developing a 
greater understanding of the processes underlying glucose homeostasis during fasting 
conditions, as well as after a meal is critical. It is also critical to highlight that only under 
physiological conditions, such as when glucose is ingested, are all of these regulatory factors 
simultaneously required. For example, when glucose is infused into a peripheral vein, this 
bypasses potent regulatory mechanisms of the gut, alters the function of pancreatic β-cells, and 
shifts much of the glucose uptake typically deposited into hepatic tissues to peripheral tissues 
such as skeletal muscle (6, 7). 
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Importantly, once a person has presented with a metabolic disorder such as T2D it is no longer 
possible to determine the initial cause of dysregulation leading to the development of the 
disease. Utilising lifestyle interventions known to affect glucose metabolism, such as diet and 
exercise in healthy individuals can provide a model to determine the initial steps in the 
alteration of normal glucose metabolism. For example, one of the foundations for the 
prevention and treatment of T2D is endurance exercise due to its multifaceted influence on 
metabolic health, improving insulin action and glucose tolerance (8). On the other hand, the 
broad availability of inexpensive, highly palatable and energy dense foods in western diets is 
one of the main factors responsible for the increase in obesity and metabolic diseases such as 
T2D, due to the widespread overconsumption of energy, as well as fat and sugar, impairing 
insulin action and glucose tolerance (9, 10). 
However, much of the existing literature that has investigated the effects of lifestyle 
interventions on the glucoregulatory systems have used techniques such as the euglycaemic-
hyperinsulinaemic clamp (10-21) or the intravenous glucose tolerance test (IVGTT) (13, 22-
24) that are not representative of normal living conditions. Although these techniques have 
extensively contributed to our understanding of insulin action and glycaemic regulation, the 
artificial maintenance of conditions that do not mimic the physiological responses of normal 
meal glucose ingestion limits their generalisability to everyday living conditions (4). However, 
if variable-infusion glucose tracer dilution techniques are used under physiological 
postprandial conditions, dynamic and accurate measurements of glucose flux can be 
determined simultaneously without artificially altering normal glucose metabolism (3). 
Therefore the aim of this PhD was to extend knowledge beyond techniques such as the 
euglycaemic hyperinsulinaemic clamp or IVGTT to examine what effect lifestyle interventions 
such as exercise and overfeeding have on glucose flux in young, sedentary adults during 
physiologically relevant conditions. To achieve this, a variable infusion, triple-stable isotope 
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glucose tracer approach, combined with a mixed meal tolerance test was utilised. Thus, for the 
first time, assessment of meal Ra, EGP, and Rd was made simultaneously under physiological 
postprandial conditions in response to exercise and overfeeding interventions. The current 
studies provide an integrated picture of physiological postprandial glucose metabolism, above 
simple indices of insulin sensitivity, in response to diet and exercise interventions, that cannot 
be observed when using non-physiological techniques and provide a more representative 
picture of the glucoregulatory system under real life conditions. 
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1.1 Glucose Homeostasis 
 
Glucose homeostasis is the process of tightly regulating systemic glycaemia within a narrow 
range (i.e. normoglycaemia) and is a product of glucose entering the systemic circulation (via 
both endogenous or exogenous sources) versus glucose leaving the circulation by disposal into 
peripheral tissues (1). Although free fatty acids (FFA) are the main fuel for most organs, 
glucose is the primary fuel source for the brain under physiologic conditions due to limitations 
of transport across blood-brain barriers (2). Although after prolonged fasting ketone bodies 
may be used by the brain to a significant extent, under normal conditions their circulating 
concentrations are low (25).  
Therefore, understanding the systemic regulation of glycaemia is significant, where glucose is 
the primary energy source for not only the brain but also red and white blood cells and gonads, 
and dysregulation of this process can have a range of deleterious consequences (2, 25). For 
example, the brain cannot synthesise glucose or store as glycogen more than a few minutes 
supply (25) and low blood glucose concentrations (hypoglycaemia; <3.9mmol/l) can lead to 
acute adverse effects on the central nervous system. This includes impairment of cerebral 
function, or in the case of more severe and prolonged hypoglycaemia, can result in loss of 
consciousness and death (2). On the other hand, chronic exposure to excessively high blood 
glucose concentrations (hyperglycaemia; >10mmol/l) can result in blindness, renal failure and 
vascular disease and is a significant contributing factor to the development of T2D (2). 
Therefore, in healthy individuals blood glucose is strictly regulated within a narrow range 
between approximately 4 and 9mmol/l (2).  
The maintenance of normal glucose homeostasis in healthy individuals is a product of a 
complex glucoregulatory system; comprising an intricate regulatory and counter-regulatory 
neuro-hormonal system  (26, 27). Insulin, a hormone secreted from the pancreatic β-cells, is a 
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primary regulator of blood glucose concentration, stimulating glucose uptake into the periphery 
and liver, as well as hepatic glycogenesis, and suppressing the rate of EGP in response to rising 
glucose (Refer to Figure 1.1) (27). Conversely, in response to decreasing glucose 
concentrations as little as ~1.1mmol/l (i.e. from 5 to 3.9 mmol/l), the release of insulin is 
suppressed and the subsequent activation of the sympathetic nervous system will trigger the 
release of counter-regulatory hormones (glucagon, catecholamines, growth hormone)(28). 
These changes increase glucose release into plasma and decrease its removal in order to 
maintain normoglycaemia (28). The hormone glucagon is secreted from the pancreatic alpha 
cells (27) and its control is multi-factorial, regulated primarily by glucose and insulin, as well 
as neural signals and other substrates (i.e. FFA and amino acids). Glucagon acts to promote 
EGP primarily via hepatic glycogenolysis in response to hypoglycaemia but is suppressed by 
hyperglycaemia (27) (Refer to Figure 1.1). 
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Figure 1.1: Basic regulation of glucose homeostasis. An imbalance in systemic glycaemia 
results in rapid action from the pancreas to release insulin or glucagon. Insulin works to limit 
postprandial glycaemic excursions by stimulating glucose uptake into the peripheral tissues, 
and glycogen formation in the liver, while simultaneously suppressing EGP to prevent 
hyperglycaemia. Glucagon is secreted in response to declining blood glucose and stimulates 
glycogen breakdown and EGP from the liver to avoid hypoglycaemia. Adapted from (29). 
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1.1.1 Fasting glycaemic regulation 
 
The most immediately significant regulators of glycaemia are hormones (insulin, glucagon, 
and catecholamines), exerting effects within minutes, along with sympathetic nervous activity 
and other substrates such as FFA (27). Over periods of hours or days, other factors such as 
cortisol and growth hormone, as well as diet and exercise, and changes to the sensitivity of 
organs to hormones become significant (27). In the fasted state, glucose uptake by the brain, 
blood cells, renal medulla, and splanchnic tissues occurs largely independent of insulin, and 
basal plasma insulin concentrations are low (<10uU/ml) (1). Thus, under postabsorptive 
conditions glucose Rd is determined almost primarily by tissue demands, glucose 
effectiveness, and tissue-specific glucose transporters as opposed to the action of insulin (2, 
30). Thus, insulin can be described as playing a permissive role (27), and counter-regulatory 
hormones work to modulate the sensitivity of tissues to the effect of insulin, in order to 
stimulate disposal of glucose (31). 
The low circulating levels of insulin in the postabsorptive state (∼5–10 μU/ml) inhibit glucose 
and FFA release by 30– 50% (counteracting the effect of glucagon and the sympathetic nervous 
system) while having a trivial effect on tissue glucose uptake (2). However, increases in plasma 
FFA can induce significant metabolic consequences (32), including the stimulation of hepatic 
and renal gluconeogenesis, inhibition of glucose transport into muscle, and to compete with 
glucose for oxidation (33). Levels of circulating FFA are regulated by the sympathetic nervous 
system which works to increase plasma FFA, and by insulin which works to suppress lipolysis 
and increases FFA clearance (34).  
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1.1.2 Fasting glucose turnover 
 
Plasma glucose concentrations are determined by the relative rates at which glucose both enters 
and leaves the circulation. Thus, plasma glucose concentrations will increase when glucose Ra 
exceeds its Rd and, conversely, plasma glucose concentration will decrease if Rd exceeds its 
Ra (4). To maintain relatively stable plasma glucose concentrations, increases in Ra into the 
systemic circulation (e.g., when a glucose-containing meal is ingested) require a comparable 
increase in Rd from the circulation. Or during exercise, when the body’s utilisation of glucose 
increases, glucose Ra (via EGP) is increased to compensate for the increased Rd, thereby 
maintaining systemic glycaemia (35, 36).  
In the fasted or postabsorptive state, maintenance of steady-state glucose levels is relatively 
simple, occurring when glucose Ra into the systemic circulation via EGP approximates the 
amount of glucose removed from the circulation via glucose Rd. Indeed, for healthy individuals 
in the fasted state, Rd occurs at a constant pace and EGP is maintained to match this rate due 
to low basal secretion of insulin and glucagon (27). Many tissues can synthesise glucose via 
gluconeogenesis, as well as convert glycogen into glucose, however the liver and kidneys are 
the only tissues containing significant amounts of the enzyme glucose-6-phosphatase necessary 
for the release of glucose into the circulation (27). Thus, under normal physiological 
circumstances where the contribution of the kidneys to glucose production is small (<10%), 
the liver is effectively the sole source of EGP (37). Glucose release in the postabsorptive state 
is derived from both liver glycogenolysis and the synthesis of new glucose via the 
gluconeogenic pathway, where gluconeogenesis increases with the duration of fasting as 
glycogen stores become depleted (38). In addition, the splanchnic bed contributes ~25% of 
whole-body glucose utilisation under postabsorptive conditions in humans (39, 40).  
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However, the majority of glucose Rd occurs primarily by the central nervous system (~50% of 
basal glucose uptake) (1, 39, 40). Although there is a prevailing view that skeletal muscle is 
responsible for a large portion of basal glucose uptake due to a high metabolic rate, insulin-
dependent tissues (primarily skeletal muscle) only account for the remaining 25% of 
postabsorptive glucose use (39, 40). In fact, skeletal muscle has a relatively low resting 
metabolic rate compared to the brain, liver, heart and kidney, whereby skeletal muscle accounts 
for only 20-30% of resting energy expenditure despite accounting for ~40% of body mass (41, 
42). Although modern humans spend little of the day in the postabsorptive state, skeletal 
muscle still accounts for only approximately one third of glucose uptake under sedentary 
postprandial conditions. Thus, while skeletal muscle glucose metabolism clearly plays an 
important role in whole body glycaemic regulation, it seems that the prevailing view that 
skeletal muscle is the most quantitatively important organ for maintenance of glucose 
homeostasis via glucose disposal needs to be re-evaluated. 
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1.2 Postprandial glucose homeostasis 
 
In the postprandial state (the period of up to ~3-5 hours that comprises and follows ingestion 
of a meal) regulation of glucose metabolism becomes more complex than during fasted 
conditions. The challenge of understanding postprandial glucose regulation stems from the fact 
that glucose originates from both endogenous sources as well as exogenous glucose from the 
ingested meal, providing the meal contains glucose (starch or sugar). Glucose ingestion induces 
a complex and integrated hormonal response that occurs both in the gut and in the pancreas, 
ultimately orchestrating the glycaemic response (1). The systemic glycaemic response 
following a meal is governed by the interaction of three physiological parameters; the rate of 
appearance of ingested glucose from the gut (meal Ra), the suppression of EGP and the 
stimulation of Rd (3). The ability to suppress EGP and stimulate Rd following a meal is further 
determined by a balance of three complex and interacting factors; β-cell insulin secretion, tissue 
insulin sensitivity and glucose effectiveness (4, 26, 43). It is important to note that this 
regulation is dependent largely on feedback systems that alters the key glucose fluxes over time 
to respond to the dynamic changes in glucose availability (44).  
Understanding these complex, interrelated factors regulating postprandial glucose homeostasis 
is significant as the majority of the day is spent in this state; people usually eat at least three 
meals per day and often snack between meals, and complete assimilation of ingested nutrients 
can take up to seven hours (45). Additionally, postprandial hyperglycaemia represents a major 
risk factor contributing to T2D-related health complications and represents the core pathology 
of pre-diabetes, i.e. impaired glucose tolerance (IGT) (46). Furthermore, epidemiological 
studies have shown that postprandial hyperglycaemia, even in the absence of overt T2D, is a 
direct and independent risk factor for cardiovascular disease, and a major predictor of 
microvascular complications, neuropathy and retinopathy in T2D (46-50).  
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1.2.1 Regulation of postprandial glycaemia  
 
In healthy individuals after ingestion of a glucose-containing meal, plasma glucose levels 
typically peak within 30 to 90 minutes, rarely exceed 10mM,  and slowly decrease over several 
hours back to, or slightly below that of fasting levels (51). Despite the relatively rapid return 
of glycaemia to fasting levels, complete assimilation of a meal containing all nutrients takes at 
least 6 hours (52). The tight regulation of postprandial glucose levels occurs due to both 
suppression of EGP by the liver and stimulation of glucose uptake (above fasting levels) into 
skeletal muscle, liver and adipose, largely under the direction of insulin, but also glucose 
effectiveness (as discussed in detail in below) and the concerted decline in glucagon secretion 
(2).  
Insulin is arguably the most important acute glucoregulatory hormone in the postprandial state 
due to its ability to affect Rd and EGP within minutes, although glucose itself is a potent 
regulator of its own disposal and production (glucose effectiveness) (2). In response to an oral 
glucose load, suppression of glucagon secretion by endogenous insulin also occurs via the 
paracrine route (communication with the islet cells) (1). The resulting increase in the portal 
vein insulin to glucagon ratio has a potent effect on the suppression of EGP (6) and this signal 
is further amplified by incretin signals (53) and those from the central nervous system (1). 
However, glucagon is also very rapidly and potently secreted in response to amino acid 
ingestion in the absence of change to systemic glucose concentration (54). Thus, during a 
mixed meal, glucagon secretion increases (55), with its timing and magnitude dependent on 
the absorption speed of the protein eaten (54). 
Regulation of hepatic glucose metabolism occurs via a range of mechanisms, including the 
provision of substrates (such as glucose or glycerol), allosteric control by metabolites (acetyl-
CoA, glucose and glucose-6-phosphate), and hormonal balance of insulin and glucagon (56-
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58). Additionally, the intra-hepatic processes (glycogen synthesis, glycogenolysis and 
gluconeogenesis) involve independent mechanisms of regulation (57, 58). Thus, this complex 
integrated regulation is most greatly stimulated by conditions that mimic the postprandial state, 
where hepatic glucose uptake is potently affected by portal venous hyperglycaemia and 
hyperinsulinaemia (6). Importantly, many common measurement techniques (i.e. the 'gold-
standard' test of peripheral and hepatic insulin sensitivity — the hyperinsulinaemic 
euglycaemic clamp, as will be discussed in detail in section 1.3.3) do not recreate this specific 
physiological hepatic regulatory milieu (4, 6). For example, the maintenance of euglycaemia 
as opposed to physiological portal venous hyperglycaemia does not promote net hepatic 
glycogen synthesis (59). Additionally, peripheral infusion of insulin decreases the normal 
concentration gradient of insulin between the portal and systemic veins (60, 61), thus the 
insulin level that is detected by the liver will not change.  
However, quantifying EGP in humans under postprandial conditions is difficult and the 
challenging nature of EGP measurement has resulted in controversies in the literature (2). 
Studies using constant-infusion dual-tracer methodologies have demonstrated that these 
conditions  lead to a rapid, near-total suppression of EGP (2). However, this near-complete 
suppression of EGP is a function of non-steady state error derived from inadequate 
measurement techniques (62)(as will be discussed in detail in section 1.4). Indeed, more recent 
studies utilising variable tracer techniques to eliminate non-steady state error demonstrate that 
EGP is never completely suppressed (63-68). This is due to the fact that physiological 
hyperinsulinaemia inhibits hepatic glycogenolysis but not gluconeogenesis (69, 70). Near-
complete suppression of EGP requires the constant suppression of gluconeogenesis, which can 
only be achieved by prolonged supraphysiological hyperinsulinaemia (70) and therefore does 
not occur under physiological postprandial conditions. 
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Significantly, the timing and pattern of insulin secretion is as important as the insulin dose, and 
the degree of insulin sensitivity, for limiting prandial hyperglycaemia (71, 72). Over 20 years 
ago it was recognised that there is a critical role for insulin release within the early stages of 
the postprandial period for appropriately regulating postprandial glucose (72). In response to a 
mixed meal in subjects with T2D, infusion of 1.8 units of insulin within the initial 30 minutes 
of the postprandial period was more effective than 3.6 units spread over the initial 60 minutes 
for lowering the glycaemic response (72). Similarly, when patients with T2D were given an 
injection of a rapidly absorbed insulin analogue prior to an oral glucose load, compared to an 
injection of regular human insulin, the analogue was associated with a reduction of plasma 
glucose excursion by almost 50%. This improvement persisted over a 5 hour period, despite 
plasma insulin levels being lower from the second hour (71). In a similar regard, glucose 
intolerance could be induced in healthy insulin sensitive individuals with normal glucose 
tolerance when endogenous insulin secretion was inhibited by somatostatin and insulin 
replaced intravenously in a diabetic (delayed) profile (73). These studies highlight the critical 
role that the timing of insulin secretion plays in postprandial glucose homeostasis, with the 
appropriate early release of insulin dictating both the initial and late phases of the glycaemic 
response.  
Insulin also has an indirect effect on glucose homeostasis via the suppression of postprandial 
lipolysis. In adipose tissue, insulin inhibits the release of fatty acids from adipocytes by 
decreasing the activity of hormone-sensitive lipase and adipose triglyceride lipase (74). As 
fatty acids are a competitor of glucose for oxidation (2), the consequent reduction in circulating 
fatty acids leads to greater oxidation of glucose. Studies using magnetic resonance have 
demonstrated that in the first hours following meal ingestion there is no net accumulation of 
glycogen, despite markedly increase glucose uptake, suggesting that glucose is taken up as 
oxidative fuel in place of fatty acids (75). 
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In addition to stimulating the secretion of insulin, glucose also has an important regulatory role 
on its own metabolism. Termed ‘glucose effectiveness’, this phenomenon describes the ability 
of glucose, under basal insulin conditions, to stimulate its own disposal and suppress EGP (76, 
77). This is elegantly demonstrated by the fact that glycaemia can return to normal fasting 
values following IVGTT in dogs when the insulin secretory response is prevented (via 
somatostatin infusion), albeit not as rapidly as when the physiological insulin secretory 
response takes place (Refer to Figure 1.2) (77) (76). 
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Figure 1.2: The ability of glucose itself to regulate its own concentration (glucose 
effectiveness). Comparison of glucose dynamics during intravenous glucose tolerance tests 
with two experimental designs: in the standard intravenous glucose tolerance test (IVGTT; 
represented by closed circles), and with artificial suppression of dynamic insulin and glucagon 
(open circles). Thus, the mass effect of glucose is able to regulate its own disposal and 
production in order to maintain glycaemia, albeit less efficiently than when combined with 
normal hormonal regulation, where basal concentrations of insulin are necessary in a 
permissive role for glucose to stimulate its uptake and suppress its release. Figure adapted from 
(76). 
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1.2.2 Postprandial glucose turnover 
 
Under postprandial conditions, ingested glucose derived from a meal is drained from the small 
intestine whereby it enters the portal vein. The resulting portal vein hyperglycaemia and 
hyperinsulinaemia are a strong stimulus for liver glucose uptake, and importantly this effect is 
not evident when an equivalent intravenous glucose dose is performed (4, 6, 7). The glucose 
can then pass through the liver and be released into systemic circulation, incorporated into 
glycogen via the direct pathway, or first degraded to three carbon precursors, such as lactate 
and alanine, then resynthesised via the indirect gluconeogenic pathway back to glucose-6-
phospate, which in turn can then be either incorporated into glycogen or dephosphorylated and 
released into the systemic circulation as glucose (78). Total glucose Ra (meal Ra and EGP) is 
determined by the rate of gastric emptying, as well as the ability of the liver to buffer the entry 
of glucose from the portal vein into the systemic circulation. The liver also minimises plasma 
glucose excursions through simultaneous suppression of its glucose-producing pathways and 
stimulation of pathways of glucose disposal (79). Rates of glucose appearance into the systemic 
circulation therefore represent the sum of meal glucose not taken up by first-pass hepatic 
extraction from the portal vein and the rate of EGP from the liver and kidneys.  
Approximately 15% of an oral carbohydrate load is sequestered initially by the liver before 
even reaching the systemic circulation (Refer to Figure 1.3) (51). Additionally, when glucose 
concentration outside the liver rises, the insulin-independent glucose transporter GLUT2 
stimulates rapid uptake of glucose from the systemic circulation (80). By this mechanism, the 
liver is able to dispose of an additional 10-15% of an oral glucose load (Refer to Figure 1.3) 
(81). Insulin works by binding to receptors on the hepatocyte membrane and stimulates 
glycogen synthase while simultaneously inhibiting glycogen phosphorylase (80). Taking into 
account the systemic glucose ‘conserved’ by the simultaneous suppression of hepatic glucose 
production, the liver is quite possibly the more important organ for glucose homeostasis in the 
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postprandial state. Moore et al. (59) suggest that the liver is actually responsible for the disposal 
of 60-65% of an oral glucose load when taking into account both hepatic glucose uptake, and 
the suppression of glucose production; where glucose-requiring tissues must thereby uptake a 
greater portion of the absorbed glucose.  
Of the remaining glucose that reaches the circulation, approximately 40-50% is taken up into 
skeletal muscle via facilitated diffusion, utilising glucose transporter carrier proteins (Refer to 
Figure 1.3) (74). Together with the activation of key enzymes in glucose metabolism by insulin, 
this leads to a marked increase in skeletal muscle glucose oxidation. By virtue of its size and 
metabolic capacity, skeletal muscle plays a vital role in disposal and oxidation of oral glucose 
(82), and for this reason, the widely prevailing view is that skeletal muscle is the predominant 
site of postprandial glucose disposal. Although this is certainly true under euglycaemic 
hyperinsulinaemic clamp conditions where muscle is responsible for 70–80% of glucose 
disposal, this is not the case under postprandial conditions (39). In fact, the splanchnic bed 
(liver and gut) provide approximately equal contributions to the disposal of meal-derived 
glucose, when compared to skeletal muscle (4, 6). Additionally, the liver is the major source 
of EGP under normal conditions as well as a major site of glycogen storage, and therefore it 
plays a pivotal role in regulation of plasma glucose concentrations postprandially (7).  
Approximately half of the oral glucose taken up into skeletal muscle is oxidised to compensate 
for insulin’s suppression of lipolysis and subsequent reduction in fat availability for oxidation 
(74). The remainder is either stored, presumably as glycogen, or released as potential 
precursors for hepatic gluconeogenesis such as lactate, alanine and pyruvate (83). The 
remaining glucose in the systemic circulation is taken up into either the brain as a substitute for 
the endogenous glucose it would normally oxidise, or other tissues such as adipose and the 
kidneys (Refer to Figure 1.3). Importantly, robust changes to glucose flux (i.e. disposal) are 
shown under hyperinsulinaemic clamp conditions, but not in real life conditions such as those 
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demonstrated using forearm balance techniques (84, 85). In fact, classic organ balance studies 
measuring forearm muscle glucose uptake (84, 85) demonstrated that postprandial glycaemia 
was significantly altered without changes to absolute rates of glucose utilisation. Additionally, 
Sathananthan et al. (65) recently demonstrated that 12 weeks of caloric restriction in subjects 
with T2D significantly lowered fasting and postprandial glucose concentrations to values that 
approached those typically observed in people who do not have diabetes without altering either 
postprandial Meal Ra, simulation of Rd or the peak suppression of EGP. 
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Figure 1.3: Sites of postprandial glucose disposal. Of 100 g of ingested glucose 15% is initially 
taken up by first pass hepatic extraction. Of the remaining glucose released into the systemic 
circulation, ∼20% is further extracted by the liver, ∼20% is taken up by the brain, ∼40% is 
taken up by skeletal muscle, and the remaining 20% is taken up by kidney, adipose tissue, skin, 
and blood cells (82). 
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1.3 Common techniques for quantifying glucose metabolism 
 
Despite the importance of quantifying the factors regulating glucose metabolism in vivo, a 
fundamental problem with human biology is the difficulty of sampling from non-accessible 
pools or portions of the system (such as the liver and gut) in which glycaemic regulation occurs 
(86). Additionally, it is important to recognise the key differences between physiologically 
representative techniques, and those that are not representative of normal living conditions (i.e. 
euglycaemic hyperinsulinaemic clamp, IVGTT) (4). Many techniques have been developed in 
order to further the understanding of individual glucoregulatory parameters, such as insulin 
action in the absence of stimulating insulin secretion, insulin secretion in the absence of 
confounders such as gut absorption and the incretin effect, and determining the dose-response 
characteristics of insulin and glucose-induced suppression of EGP and stimulation of Rd (4, 
70). However, in order to determine these parameters, techniques must necessarily employ 
measurement conditions that are not representative of normal, physiological glucoregulation. 
It is important to note that to properly understand normal, everyday glucose metabolism, 
measurement techniques must closely reflect the dynamic conditions observed in the 
postprandial state such that the coordinated integration of the glucose absorption, disposal and 
endogenous production components, together with insulin secretion, are taken into account. 
1.3.1 Oral glucose and meal tolerance tests 
 
The standard 75g oral glucose tolerance test (OGTT) is used as a diagnostic tool for 
determining impaired glucose tolerance and T2D, but is also commonly performed to provide 
a simple, somewhat physiological representation of whole body glucose metabolism (87). 
However, the typical OGTT provides a pure glucose bolus that does not provide the same 
coordinated physiological response as that of a mixed meal (86, 88-90). Other nutrients derived 
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from protein or fat intake also contribute to glycaemic regulation (i.e. by modulating the 
secretion of pancreatic hormones), and are not present in a pure glucose load (86, 88-90).  
Compared to glucose alone, ingestion of a meal containing glucose combined with fat and 
protein (mixed meal tolerance test) can result in reduced postprandial glucose excursions (89) 
and increased insulin clearance (91). Gastric emptying is slower during the mixed meal 
tolerance test, by virtue of its solid nature and greater size (90), but also the presence of dietary 
fat (92), and may contribute to reduced glucose excursions (90). Utilising tracer and forearm 
catheterisation techniques, McMahon et al. (93) demonstrated that glucose, insulin, C-peptide 
and meal Ra were lower during the first 15 min of a mixed meal versus glucose drink containing 
identical glucose levels. However, despite differences in circulating hormone concentrations, 
after the first 15 min meal Ra, EGP, incorporation of carbon dioxide into glucose, and glucose 
and lipid oxidation as well as non-oxidative glucose storage were virtually the same after the 
mixed meal and the glucose drink (93). Additionally, Bock et al. (94) demonstrated that meals 
containing non-glucose nutrients resulted in comparable glucose areas above basal, when 
compared to glucose alone. However, while glucose-induced insulin secretion was higher and 
insulin action lower during the meal than the pure glucose, the decrease in insulin action after 
meal ingestion was compensated by an appropriate increase in insulin secretion resulting in 
equal disposition indexes (94). 
Additionally, β-cell function and incretin secretion (89, 95) have also been demonstrated to be 
greater during a mixed meal tolerance test versus a glucose challenge alone. The secretion of 
the gastrointestinal incretin hormone GIP was demonstrated to be twofold greater following a 
mixed meal compared to an isolated glucose challenge (96). Considering the regulatory role of 
incretins in the postprandial state, the lower rise in glycaemia following a mixed meal could be 
related to increased incretin secretion (89, 96). Incretins have a synergistic effect on β-cell 
function, as well as gastric emptying and gut motility in the postprandial state, improving the 
22 
  
glycaemic response; while the presence of fatty acids (97) and proteins (55) have also been 
reported to improve β-cell insulin secretion. Therefore, it is important to consider the 
composition of meals in regards to the postprandial glycaemic response that is observed. 
 
1.3.2 Intravenous versus oral glucose delivery  
 
When glucose is infused intravenously, this bypasses the potent gut-based regulation that 
occurs during nutrient ingestion; the incretin effect. The stimulation of these gut-based peptides 
by nutrient ingestion, including glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide 
(GIP), are important in the hormonal regulation of glucose disappearance (53, 98), and have 
synergistic effects on glycaemic regulation such as augmenting insulin secretion (26, 53). This 
phenomenon is demonstrated when the ingestion of food is compared to glucose infused 
intravenously, leading to widely different patterns of insulin secretion, hepatic insulin 
extraction (99), EGP and Rd (100) (Refer to Figure 1.4). Additionally, even before food causes 
any rise in plasma glucose levels, the cephalic phase of insulin secretion (neurogenic signals 
reflexively triggered by food-related sensory stimuli) primes the liver, increasing the rapidity 
of the ultimate response to eating (26), a response not seen during intravenous infusion of 
glucose. 
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Figure 1.4: Time courses of responses to oral and IV glucose; including rate of appearance 
(Ra glucose; A), glucose disposal (Rd; B), endogenous glucose production (EGP; C), plasma 
insulin (D) and insulin secretion rate (ISR; E) during 75g oral glucose tolerance test (OGTT) 
or isoglycaemic intravenous glucose tolerance test (IVGTT) as determined by the constant 
infusion dual tracer technique. Demonstrating the differences between identical oral and 
intravenous glucose loads; where oral glucose has a potent effect for stimulating gut-based 
regulation of glucose metabolism (i.e. the incretin effect). Figure adapted from (100, 101). 
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Furthermore, it is important to consider that the relative disposition of glucose in muscle and 
liver differs considerably after administration by the oral and intravenous routes (60, 61). Under 
physiological postprandial conditions, ingested glucose is drained from the small intestine into 
the portal vein, and the levels of glucose and insulin within the portal vein are much higher 
than in the peripheral circulation. This cannot be replicated when either glucose, insulin, or 
both are injected or infused into any other blood vessel or body space. The resulting portal vein 
hyperglycaemia and hyperinsulinaemia are a strong stimulus for liver glucose uptake, an effect 
not evident when an equivalent intravenous glucose dose is performed (4, 6, 7). Thus, it has 
been consistently demonstrated that techniques involving the administration of glucose and/or 
insulin into a peripheral blood vessel (non-hepatic portal route), as performed during an IVGTT 
or euglycaemic hyperinsulinaemic clamp, bias the stimulation of glucose uptake away from the 
liver and towards peripheral sites such as the muscle (4, 6, 7). During hyperinsulinaemic clamp 
conditions, the ‘over-insulinisation’ of the systemic circulation and reversal of the normal 
portal-to-peripheral insulin gradient (102) leads to ~75% of insulin-mediated glucose disposal  
occurring in skeletal muscle (103), whereas under physiological conditions of a mixed meal 
this figure is roughly 30% (104, 105) (Refer to Figure 1.6). The lack of portal vein 
hyperinsulinaemia and complete absence of both portal and systemic hyperglycaemia prevents 
net hepatic glucose uptake and glycogen synthesis, which normally occur following a meal (4, 
6).  Specifically, in conscious dogs when glucose is infused peripherally and somatostatin used 
to set the plasma insulin and glucagon levels to match the response to oral glucose, the liver 
takes up glucose at a rate of less than half that seen during postprandial conditions (106), an 
effect that is also seen during glucose infusion in the absence of somatostatin (107).  
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Figure 1.5: Sites of glucose uptake in response to intravenous infusion of insulin and glucose 
versus postprandial conditions. In conscious dogs, under hyperinsulinaemic clamp conditions, 
over 75% of insulin-mediated glucose disposal occurs in skeletal muscle, due to the peripheral 
bias of intravenous techniques to introduce glucose and/or insulin to the system. Whereas, 
under physiological postprandial conditions, the liver and splanchnic tissues take up an 
equivalent amount of glucose compared to peripheral tissues (skeletal muscle and adipose 
tissue) in part due to normal portal to peripheral insulin gradient. Adapted from Cherrington 
(6). 
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1.3.2 IVGTT 
 
The IVGTT is a relatively non-invasive tool to assess glucose turnover and insulin sensitivity 
in vivo (80). By utilising an intravenous glucose challenge, this technique can avoid the 
complications of glucose absorption from the gut and its stimulatory action on the 
gastrointestinal hormones and neural factors (108), providing a more reproducible and 
responsive index of insulin sensitivity by mathematical modelling than during an OGTT (109). 
However, the clear limitation of this method is the non-physiological intravenous glucose 
challenge (80, 110) and considerable caution has to be exercised in extrapolating from such 
data as the time course of changes after eating are not reproduced by intravenous methods (6, 
7, 60, 61, 99, 100). 
1.3.3 Euglycaemic and isoglycaemic hyperinsulinaemic clamp 
 
The euglycaemic hyperinsulinaemic clamp is considered the gold standard for measuring 
insulin sensitivity under steady-state conditions and has been fundamental in furthering our 
understanding of in vivo glucose metabolism (111, 112). The clamp prolongs elevation of 
insulin, and artificially maintains euglycaemia by intravenous glucose infusion (87), thus the 
glucose infusion rate needed to maintain euglycaemia is a reflection of insulin action. The main 
advantage of using the glucose clamp to estimate insulin sensitivity/resistance in humans is 
that it directly measures whole body glucose disposal at a given level of insulinaemia under 
steady-state conditions. Thus, the clamp is its highly quantitative and reproducible in nature, 
and when glucose tracers are used under clamp conditions it is possible to quantify both hepatic 
and peripheral insulin sensitivity. 
When utilising groups that differ in their prevailing glycaemia (i.e. individuals with T2D versus 
healthy subjects), clamping glucose at euglycaemia versus this prevailing glucose 
concentration has differing effects. For example, when subjects with T2D were studied using 
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the isoglycaemic clamp (i.e. at their normal hyperglycaemic blood glucose levels), whole body 
glucose disposal and muscle glucose uptake were the same or actually higher than when 
compared with non-diabetic controls (4, 113-115). However, only when the T2D patients were 
rendered euglycaemic by prior insulin infusion were the defects in muscle glucose disposal 
made evident (113, 115). This highlights an important consideration in regards to clamping 
blood glucose concentration, such that hyperglycaemia has a potent metabolic effect in its own 
right to stimulate glucose uptake and suppress EGP and so clamping an individual at 
euglycaemia is not representative of their free living state. 
Additionally, although the clamp techniques have a clear benefit, their obvious limitation is 
that these steady-state restrictions do not accurately reflect the dynamic conditions of normal 
glucose regulation following a meal (116). Insulin and glucose are maintained in a steady state, 
whereas during a normal physiological postprandial state both insulin and glucose 
concentrations are dynamic, and the timing of insulin release has potent effects on systemic 
glucose flux (71, 72). Additionally, the fate of postprandial glucose is determined not only via 
skeletal muscle and hepatic insulin sensitivity but involves the complex interplay of gastric 
emptying, intestinal absorption, splanchnic glucose uptake, pancreatic  β-cell function and 
renal glucose flux; factors which are not accurately replicated during the clamp (117).  
1.3.5 Glucose isotope tracers  
 
An isotope-labelled tracer is a substance which can be used to follow (trace) a naturally 
occurring substrate (i.e. tracee), allowing for the quantification of pool sizes and flows between 
compartments (62, 118). Typically the tracer has the same chemical composition and structure 
as its tracee, however it has a subtle difference in its molecular mass, with one or more of its 
composite atoms containing extra neutrons (118). The number of neutrons in the atom does not 
affect the chemical properties of the atom, however the labelled atom is a different mass and 
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so its abundance can be detected by utilising mass spectrometry, allowing it to be differentiated 
from its native, unlabelled tracee (62).  
Glucose tracers are commonly used to study glucose metabolism in vivo, where the tracer 
dilution method is routinely used to quantify the appearance and disappearance of glucose (the 
tracee) into the systemic circulation (62). The basic premise of the tracer dilution technique can 
be explained when a tracer is added into the circulation via IV infusion at a constant rate (119). 
As the applied tracer will equilibrate throughout the entire pool, dilution of the tracer occurs 
when unlabelled glucose (via EGP) dilutes the tracer present in the system (119). In the fasted 
state, this can simply be reduced to a single compartment, represented as a tub of water. Water 
enters the tub via the tap (EGP) and leaves via the drain (Rd). The water level is constant when 
EGP=Rd but changes if EGP>Rd or Rd>EGP. If a dye (i.e. a tracer) was added to the tub of 
water, any further water loss via the drain (Rd) would not change the concentration of the dye 
in the tub. However, when water enters from the tap (EGP) it has no dye and thus will dilute 
the concentration of dye in the tub (119).  
By determining the degree of dilution of the tracer by the abundant natural tracee, it is possible 
to quantify the rate of appearance of the tracee (i.e. glucose) into the circulation. The fact that 
the tracer is heavier than the tracee allows for determination of the ratio of tracer to tracee (that 
is, enrichment) by measuring the mass of the molecule of interest, and the ratio of tracer to 
tracee is used for the calculation of tracee kinetics. This is under the assumption that the tracer 
experiences the same metabolic fate as the tracee and that the label (i.e. the heavier atoms) used 
in a tracer does not recycle into the compartment being studied after first leaving (118). Once 
the Ra is determined, mass balance can be used to then infer the glucose Rd, providing the 
system is in a metabolic steady state, as is generally the case in the acute postabsorptive 
(fasting) state (such that Ra = Rd). Glucose tracer quantification can occur with such precision 
that it need only be administered in trace amounts (62, 118), and thereby does not impact on 
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the metabolism of the tracee. Thus, a major benefit of glucose tracer dilution techniques is that 
they can be applied under physiological postprandial conditions without unnecessarily 
perturbing the glucoregulatory system.  
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1.4 Glucose tracer techniques for the quantification of postprandial glucose flux  
 
1.4.1 Glucose tracer dilution in human metabolic research; basic principles and assumptions 
 
In the fasted (postabsorptive) state, the blood glucose concentration (glucose mass) remains 
highly stable, therefore signifying that the amount of glucose entering the systemic circulation 
is near equal to that leaving the circulation (~Ra = Rd)(3). Furthermore, glucose Ra is 
exclusively coming from endogenous sources (liver and kidneys) as there is no glucose arriving 
via the gut from food digestion. Under these metabolic steady state conditions, determination 
of glucose flux is simple; that is via a constant glucose tracer infusion, providing that a constant  
isotopic steady state is achieved (constant tracer enrichment)(3). In this case glucose Ra can be 
calculated by measuring the tracer enrichment (tracer-to-tracee ratio) in the infusate and plasma 
and then applying Steele’s steady state equation:  
𝑅𝑎 =
𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑒
𝑡𝑟𝑎𝑐𝑒𝑟 𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
𝑥
𝑇𝑟𝑎𝑐𝑒𝑒 𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
1
 
Since under these steady state conditions, Ra = Rd, both parameters are calculated 
simultaneously from the one equation, thus providing a glucose turnover rate.  
However, in the postprandial state, the situation becomes substantially more complicated as 
glucose Ra is no longer exclusively from endogenous sources, with glucose also appearing via 
the gut from the ingested meal (total Ra = EGP + Meal Ra). Furthermore, the system is no 
longer in a metabolic steady state, as both Ra and Rd are changing over time and unequal, thus 
resulting in a fluctuating blood glucose concentration (3). However, with the use of tracer 
dilution techniques, Ra of the ingested glucose, EGP and glucose Rd can be calculated 
simultaneously (64). However, in the postprandial state, the calculation of substrate kinetics is 
limited by the non-steady state nature of the glucoregulatory system (120), where calculations 
are based on a number of potential limitations. For example, small measurement errors 
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propagate into large estimation errors, where the Rd is calculated from both meal Ra and EGP, 
and any error in Ra and EGP will multiply into the estimation of Rd (121). This is particularly 
relevant when considering the methodological limitations of early tracer techniques. 
1.4.2 Dual tracer technique 
 
The constant-infusion dual tracer approach was pioneered in the 1960’s by Steele et al. (122) 
and utilises two glucose tracers; one ingested and one infused intravenously at a constant rate, 
in an effort to simultaneously measure both the systemic meal Ra and postprandial EGP. This 
experimental approach has been used by a large number of investigators to study postprandial 
glucose metabolism, in both humans and in animals (122-127). These studies have provided 
pivotal data contributing to our understanding of glucose turnover in healthy populations and 
individuals with diabetes, as well as the effect of interventions on postprandial glucose 
metabolism. However, as endogenous glucose (i.e. the tracee) is suppressed following glucose 
ingestion, its concentration varies markedly, and therefore the ratio of the tracer to endogenous 
glucose (tracer-to-tracee ratio, the key variable for the calculation of EGP) is far from constant. 
As shown by non–steady state theory, this introduces errors when EGP is calculated from data 
where the tracer-to-tracee ratio is not steady (3). 
Thus, results obtained from the constant-infusion dual-tracer method have not always been 
consistent, with values for EGP varying widely (64, 128, 129). Glucose ingestion has been 
reported to lead to rapid, near-complete suppression of EGP, slow but partial EGP suppression, 
suppression of EGP to negative values, or an apparent initial paradoxical increase followed by 
a subsequent fall in EGP (64, 128, 129). These errors are a product of the marked non-steady 
state conditions that occur following a meal (62). Firstly, the rapid change in the plasma tracer-
to-tracee ratio in the first 120 minutes after meal ingestion results in a marked underestimation 
of both total Ra and meal Ra (86). These errors introduce an even greater error in EGP, as it is 
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calculated by subtracting a large erroneous number (meal Ra) from an equally large erroneous 
number (total Ra). Furthermore, Rd is incorrect as it is calculated by subtracting the change in 
glucose mass from an erroneous total Ra. The initial “paradoxical” increase in EGP and the 
subsequent “negative” rates of EGP are due to unequal errors that occur during the rapid change 
in the tracer-to-tracee ratio used to calculate meal Ra and total Ra (86). However, by utilising 
a variable infusion dual tracer technique, whereby the pattern of tracer infusion matches the 
anticipated pattern of EGP suppression, the errors of this technique can be largely minimised 
by minimising the changes to the tracer-to-tracee ratio (Refer to Figure 1.6).  
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Figure 1.6: Schematic of the variable tracer infusion technique to minimise tracer-to-tracee 
ratios. In order to minimise tracer-to-tracee ratios during glucose tracer techniques it is 
necessary to infuse the tracer in a pattern that is anticipated to mimic the rate of the tracee. It 
is sufficient to change the infusion rate of the tracer in a ‘staircase’ pattern after each blood 
sample, thus keeping the rate constant between samples, and the average infusion rate in 
proportion to the change in tracee. Importantly, the frequency of blood sampling should be 
increased when the change in tracee is most rapid or there is expected to be a high variability 
among subjects, such as the first 30 minutes of the postprandial period when EGP is rapidly 
suppressed in response to rising glucose and insulin concentrations. 
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In order to minimise the change in plasma tracer-to-tracee ratios, this method requires a priori 
general knowledge of the temporal pattern of change of meal Ra or EGP. Such knowledge can 
be relatively easily gained by conducting a few pilot studies that start with tracer infusion 
profiles that are anticipated to mimic postprandial changes in meal Ra and EGP and then 
modifying them (if necessary) so as to minimise the change in plasma tracer-to-tracee ratios.  
Thus, a variable infusion dual tracer technique can be used to individually measure EGP or 
meal Ra, along with Rd. However, when all three parameters need to be measured 
simultaneously, then the variable infusion of the intravenous tracer will match the pattern of 
EGP (suppressed) but not the pattern of meal glucose Ra (increased), leading to widely 
mismatched ratio of the tracer to meal glucose concentration. To circumvent these weaknesses 
of the dual tracer method, and allow the simultaneous determination of EGP, meal Ra and Rd, 
the addition of a third tracer was proposed by Basu et al. (64). This works to minimise tracer-
to-tracee ratios, decreasing the non-steady state correction proposed by Steele et al. (122) to a 
negligible number, thus allowing model-independent quantification of glucose flux 
(comprehensively discussed below in section 1.4.3). Utilising this triple tracer technique, 
Toffolo et al. (67) determined that the dual-tracer method significantly underestimated rates of 
glucose Rd, meal Ra and EGP, and also showed a biologically implausible pattern of EGP. 
1.4.3 Methodological premise of the triple tracer technique 
 
The triple tracer method utilises two intravenously infused tracers together with an orally 
ingested tracer in order to minimise changes in both meal and endogenous glucose tracer-tracee 
ratios. Non-steady state theory (130, 131) suggests that the accuracy of the estimation of 
glucose appearance can be enhanced if the tracer is infused during the non-steady state in such 
a way as to reduce the changes in the tracer-to-tracee ratio (Refer to Figure 1.6). In theory, if 
the tracer-to-tracee ratio is maintained perfectly constant (or near-perfectly, such as during 
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fasting glucose turnover tracer dilution methodology) during the experiment, an accurate 
estimate of glucose appearance can be obtained irrespective of the model used to interpret the 
non-steady state.  
This is achieved by intravenously infusing the second tracer in a manner anticipated to mimic 
the Ra of the meal tracer, while at the same time, altering the infusion of the initial tracer (i.e. 
the tracer originally infused in a constant manner to determine basal EGP) in a pattern to mimic 
the anticipated pattern of EGP suppression (Refer to Figure 1.7)(64). The purpose of this 
approach is to smooth the pattern of the isotopic enrichments, thus increasing the accuracy of 
the modelling of glucose kinetics. Measurement of meal Ra, as well as postprandial EGP 
suppression, is more accurate as a result of these minimised tracer-to-tracee ratios and this 
increased accuracy propagates into the calculation of Rd, which is based off mass balance 
principles (67). 
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Figure 1.7: Schematic of variable infusion rates used to mimic the anticipated pattern of 
endogenous versus meal glucose.   
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Toffolo et al. (67) observed that the substantial error in the estimation of both rate and pattern 
of postprandial glucose fluxes associated with the constant infusion dual tracer technique was 
minimised by the variable infusion triple tracer technique. The constant infusion dual tracer 
technique resulted in a paradoxical initial rise in EGP after glucose ingestion, followed by a 
decline to negative levels, and both meal Ra and Rd were under-estimated by 20-25% 
compared to the variable infusion triple tracer technique. The dual-tracer technique resulted in 
a variable tracer-to-tracee ratio characterised by a large overall (~5-fold) change, with rapid 
point-to-point differences in the initial hour leading to erroneous calculations, whereas the 
triple tracer technique resulted in less than a 2-fold change to tracer-to-tracee ratios over 6 
hours, providing more accurate data (67). Importantly, the authors noted that attaining perfectly 
constant tracer-to-tracee ratios is near impossible (this would require exact knowledge of the 
time course of  meal Ra and EGP), however, in practice this is not necessary as only an 
approximate knowledge is required to adjust the tracer infusion rates during the triple tracer 
technique in order to minimise enrichment variability and therefore obtain sufficiently accurate 
data (67).  
The triple tracer method is therefore model independent; yielding essentially the same results 
when interpreted using steady-state or non–steady-state assumptions and either a one- or two-
compartment model (62, 120). To understand the term ‘model-independent’, consider a general 
compartment model describing tracer and tracee dynamics (3). It is assumed that the tracee 
system is in steady state before the tracer experiment is undertaken. A primed continuous 
infusion is undertaken until there is a tracer steady state throughout the system, which is 
represented by denoting the steady state as TTRss. Ingestion of a meal would lead to a 
perturbation of the system, causing a non-steady state, denoted by Ra (t) which will change in 
time and is the sum of Rameal (t) and EGP(t), which both also change in time.  
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If it is assumed that a system is made up of n compartments, Rizza et al. (3) propose that 
 
Where Qi refers to the amount of tracee in the ith compartment, k1i is the rate constant between the ith 
compartment and the accessible compartment, ttri is the tracer-to-tracee ratio in the i
th compartment 
and tṫr1(t) denotes the derivative of ttr1(t) (3).  
The key aspect of the equation is that when the tracer administration is infused in a pattern in 
order to induce no changes in ttr1(t) over time, then ttr1(t)=TTRss, the time derivative of ttr1(t) 
in the accessible pool is zero, the ttr equilibrates in all compartments (ie. ttri(t)=ttrss), thus 
nullifying the second and third term in the equation and as a result Ra(t) can be shown as; 
 
Therefore, determination of Ra(t) becomes model-independent as it hinges only on what can 
be measured in the accessible pool. Using variable infusion patterns to perfectly mimic the 
shape of Ra(t) is practically impossible, though the reduction in the rate of change of ttr1(t) will 
provide results far less dependent on the validity of the model used. 
1.4.4 Limitations and assumptions associated with the triple tracer technique 
 
Clearly the cost of utilizing and analysing three tracer enrichments will be greater than the use 
of just two tracers, and it is important to consider that only two tracers are required if the goal 
is to measure only meal Ra or only EGP. However, when the goal is to simultaneously 
determine both meal Ra and EGP, the increment in cost to use the triple-tracer approach needs 
to be considered in light of the cost of undertaking an entire scientific investigation (i.e. 
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recruiting, experimenting, and measuring various hormones and substrates), particularly as the 
dual-tracer method yields inaccurate and potentially misleading information. 
The triple tracer technique provides model-independent estimates of meal Ra, EGP, and 
through mass-balance equations Rd, as long as the tracer-to-tracee ratios of the meal tracer over 
the meal-mimicking tracer, and the initial tracer over endogenous glucose, do not change over 
time. However, for practical reasons, variations in these ratios are inevitable, and small errors 
of unknown magnitude may arise as a result. This is especially the case in regards to the meal-
mimicking tracer and the meal tracer at the start of the experiment, which start initially from 
zero. The measurement errors associated with the meal tracer and the meal-mimicking tracer 
at the early portion of the experiment are large, and tracer-to-tracee ratios will begin from 
infinity, where one value is zero. This has been addressed previously by excluding the initial 
portion of the data from calculations, however this is only necessary for the first 5 to 10 minutes 
of the postprandial period. 
1.4.4.1 Radioactive versus stable isotopes 
 
Radioactive tracers should not be used in certain settings (e.g., when studying children) and 
cannot be used in some countries. Fortunately, sophisticated mass spectrometry techniques 
permit the use of the triple-tracer approach with three stable tracers, e.g., [6,6-2H] glucose, [1-
13C] glucose, and [U-13C] glucose (17). However, care needs to be taken to correct for carbon 
recycling if [6-13C] glucose or [1-13C] glucose is used as a tracer.  
1.4.4.2 Tracer recycling 
 
An important assumption underling tracer methodology is that the label used in a given tracer 
does not recycle into the compartment being studied after it leaves the compartment with the 
tracee. If this is the case, Ra will be progressively underestimated as more and more isotope 
recycles back into the pool being measured. Quantification of the three tracers in a sample is 
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not straightforward, due to interference between tracers (e.g. the M+ 2 component of [l-13C] 
glucose tracer interfering with the M+ 2 component related to [6,6- 2H] glucose tracer)   
Use of [U-13C] glucose decreases potential problems associated with the other tracers of 
recycling label that underestimate glucose production (39). This assumes that the likelihood of 
two triply labelled 3-carbon precursors (M + 3) (re-)combining to form [U-13C] glucose (M + 
6) during gluconeogenesis is extremely small. However, the use of the [U-13C] glucose tracer 
poses an additional problem, since the 13C label can recycle through gluconeogenesis, leading 
to a contribution to the M+ l glucose isotopomers derived from [l-l3C] glucose and the M+ 2 
isotopomer of the [6,6- 2H] glucose tracers. However, previous studies suggest that the impact 
of recycling on estimates of meal Ra and EGP is minimal, where the cumulative 7 h appearance 
of ingested glucose was only slightly underestimated (2%) by the presence of recycling. 
 
1.5 Pathological glucose metabolism 
 
Considering the increasing global prevalence of T2D (5), understanding the regulation of 
glucose metabolism, the genesis of its impairment, along with strategies for T2D prevention 
and treatment are imperative. T2D is associated with obesity and is a major risk factor for 
coronary heart disease, stroke and microvascular complications such as retinopathy, 
nephropathy, neuropathies, as well as limb amputation (49, 132). The mechanisms responsible 
for  T2D development, particularly at the temporal, organ and molecular level are incompletely 
understood (132).  
While a detailed discussion on the specific mechanisms that drive and maintain the 
hyperglycaemic state are beyond the realms of this thesis, it is clear that for any deviation in 
the blood glucose concentration to occur, there needs to be an imbalance between the glucose 
Ra and Rd system. A rise in glucose levels can only occur when Ra exceeds Rd, while 
40 
  
conversely a drop in glucose concentration can only occur when Rd exceeds Ra. However, in 
conditions where blood glucose levels are chronically altered, such as in diabetes, the situation 
becomes substantially more complex, as expanded or contracted glucose pool sizes can be 
maintained, at least for certain periods of time, even when glucose Ra and Rd are approximately 
equal (133-136).      
Ultimately however, at some point in time in those with T2D, hyperglycaemia manifests and 
is maintained when either EGP and/ or Rd are inappropriately regulated, both in relation to one 
another and to the prevailing glucose and insulin concentration (134, 135, 137). At the core of 
T2D development lies insulin deficiency, be it absolute or relative (depending on the severity 
and duration) and insulin resistance. Once manifest, hyperglycaemia appears to exacerbate both 
defects, thereby closing a pathological feedback loop (Refer to Figure 1.8) (138).  
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Figure 1.8: Schematic of a hyperglycaemic pathological feedback loop resulting from insulin 
resistance or deficiency. Deficiency in insulin secretion from the pancreatic β-cells as well as 
insulin resistance in peripheral and/ or hepatic tissues leads to inappropriate glucose uptake 
and EGP, resulting in hyperglycaemia that in turn exacerbates these preceding defects, 
completing a pathological feedback loop. 
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1.5.1 Glucoregulatory mechanisms in T2D 
 
Impaired insulin-stimulated Rd into the periphery is an early defect in glucose metabolism, 
present before any noticeable hyperglycaemia occurs (139-141). Although studies in 
individuals with T2D demonstrate that insulin-stimulated Rd as measured during a 
euglycaemic hyperinsulinaemic clamp is decreased by 50% or more (142), this is does not 
occur under isoglycaemic hyperinsulinaemic clamp conditions, i.e. clamps performed at the 
ambient fasting glucose concentration of the patient with T2D (113, 115, 127, 143). Such 
studies demonstrate that the hyperglycaemia in insulin-resistant subjects with T2D (that is 
abrogated under experimentally induced euglycaemia) is able to compensate, due to its mass 
action effect, for muscle insulin resistance, ensuring normal or even higher absolute rates of 
muscle glucose uptake in the basal and postprandial/insulin stimulated states (52, 78, 127, 143). 
Accordingly, under normal physiological conditions, such as after a meal, absolute rates of 
muscle glucose uptake are actually normal or higher in those with T2D when compared to 
normal subjects (139-141), however, they are inappropriate for the prevailing conditions. 
Specifically, if the prevailing fasting or postprandial hyperglycaemia and hyperinsulinaemia 
(early phase of T2D continuum) that occurs in patients with T2D would be replicated in 
metabolically healthy people, Rd would be stimulated even more profoundly (143, 144). Thus, 
it is important that the defects in disposal present during euglycaemic clamp conditions are 
unlikely to be occurring under normal free living conditions or scenarios that are more 
representative of the actual postprandial state (i.e. OGTT/MTT) due to the metabolic 
compensations that occur under hyperglycaemic conditions.  
While it has previously been thought that the hyperglycaemic state could not completely 
compensate for the defects in EGP suppression that accompany T2D (114, 143, 145), recent 
work utilising more accurate tracer methodology (triple glucose tracer technique) during a 
mixed meal tolerance test, suggest that suppression of EGP may be only minimally impaired 
43 
  
in individuals with T2D, despite markedly decreased glucose tolerance (146), due to effective 
compensation by hyperglycaemia and hyperinsulinaemia. However, it is important to 
appreciate that the participants in this study had well-controlled T2D, and that differences are 
likely present across the spectrum of glucose tolerance, such as those with grossly impaired β 
-cell reserves (146).  
Although defects in tissue insulin action contribute to impaired glycaemic regulation, it is 
ultimately the manifestation of β-cell impairment that is the key factor that drives the 
development of the hyperglycaemic state, be it impaired glucose tolerance or overt T2D (39, 
137, 147). Loss of first phase insulin secretion in the early stages of T2D results in postprandial 
hyperglycaemia, following which progressive rises in glucose levels, fatty acids and insulin 
resistance place further stress on the β-cell, leading to the eventual decline in absolute secretory 
capacity (148). Considering the systemic nature of glucose regulation, it is obvious that defects 
in a number of tissues and metabolic processes contribute to T2D, including impaired β-cell 
insulin secretion, inefficiencies in the stimulation of muscle Rd and inhibition of liver glucose 
production. Therefore, it is important to gain a better understanding of the simultaneous 
regulation of these processes under physiologically meaningful conditions.   
1.5.2 Glucose allostasis 
 
The mechanisms responsible for impaired glucoregulation under experimentally induced 
conditions of euglycaemia are not necessarily generalisable to real physiological 
circumstances, where complex compensatory adaptations can work to maintain normal rates of 
glucose flux. Such a phenomenon has been termed glucose allostasis, literally meaning ‘stable 
through change’ (149). For example, when a stressor such as insulin resistance occurs 
chronically, glucoregulation becomes allostatic to maintain homeostasis. Under these 
circumstances, glucose fails to return to the concentration that was present before the chronic 
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stressor was introduced, and this insulin resistance-induced increase in glycaemia continuously 
stimulates the β-cell, thus ensuring the homeostatic response to the next glucose load (i.e. a 
greater insulin secretory response) (149). However, this maintenance comes at a price (i.e. 
hyperglycaemia or hyperinsulinaemia,) placing a heavy workload on tissues such as the 
pancreatic β-cells, thus contributing to a pathological feedback loop. 
Considering that it is impossible to know what the cause of hyperglycaemia is in patients once 
they present with the disease because of this series of complex homeostatic compensations, it 
becomes nearly impossible to precisely determine the primary causes of the dysfunction (i.e. 
Rd vs Ra). Although genetic predisposition plays a significant role in the development of T2D, 
environmental factors such as poor eating habits and sedentary lifestyles are clearly also 
implicated in the manifestation of the disease in genetically predisposed individuals (150-153). 
By utilising interventions such as diet and exercise in healthy individuals prior to the initiation 
of hyperglycaemia, this provides a model to understand the initial defects or adaptations that 
occur to glucose metabolism, independent of the homeostatic compensations that occur once 
overt dysregulation becomes evident. 
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1.6 Effect of endurance exercise on glucose metabolism 
 
One of the foundations of diabetes therapy is physical activity or exercise training, used alone 
or in combination with further interventions such as diet or pharmaceutical options (154). The 
importance of exercise and physical activity for regulating glucose metabolism is in its ability 
to improve glycaemic control, insulin sensitivity and body composition by increased energy 
turnover (155). Additionally, minimizing sedentary behaviour is also a potent strategy to 
improve glycaemic control (156). A recent meta-analysis indicated that even when controlling 
for moderate to vigorous physical activity, excessive sedentary behaviour as demonstrated by 
sitting time still increases the risk of developing T2D (157). Additionally, experimental studies 
in healthy subjects, and those with T2D, have demonstrated that interrupting sitting time with 
brief, low-intensity activity can improve postprandial glucose (158). 
Seminal studies demonstrating that exercise could improve insulin action were performed as 
far back as the 1970s and demonstrated that the insulin response to glucose was significantly 
lower in trained individuals despite improved (159, 160) or unchanged (161) glucose (Refer to 
Table 1.1.1). The earliest of these studies by Per Bjorntorp et al. (159) demonstrated that despite 
~20% lower postprandial glucose levels, the insulin response was almost 3-fold lower in 
trained individuals, suggesting that physical activity and exercise training are at least partially 
responsible for regulating glucose metabolism and plasma insulin by improved insulin action. 
Both resistance (162-164) and endurance (12, 17, 165-168) type exercise has been 
demonstrated to improve glycaemic control and insulin sensitivity, with a single bout of 
resistance exercise improved insulin sensitivity within the first 24 hours post exercise (162-
164). However, compared to endurance exercise which is consistently demonstrated to improve 
insulin sensitivity and glycaemic control, a number of studies have demonstrated no beneficial 
effect of resistance exercise on glucose metabolism (169, 170). 
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Early research also demonstrated that a single bout of endurance exercise had important 
glucoregulatory effects in humans by significantly improving glucose disposal (12, 17, 168), 
intravenous (171) and oral (172) glucose tolerance and insulinaemia (171, 172) in healthy, 
sedentary adults (Refer to Table 1.1.2). The effect of chronic training was examined by 
Defronzo et al. (165) who demonstrated that six weeks of endurance training in previously 
untrained individuals significantly increased glucose uptake during an insulin clamp, with the 
increase in insulin sensitivity correlating with the improvement to physical fitness. Subsequent 
studies also determined that long periods (6-12mo) of exercise training in healthy individuals 
(166, 167) or those with IGT or T2D (167) increases insulin sensitivity during oral (166, 167) 
or intravenous (166) glucose tolerance tests, however, glucose tolerance was not necessarily 
improved in healthy individuals (Refer to Table 1.1.3). 
Certainly not one individual mechanism can be attributed for the entirety or even the majority 
of improvement to glycaemic regulation; rather, the β-cell along with peripheral and hepatic 
tissues likely contribute to an additive effect on glycaemic control, and they may do so at 
different times throughout continued exercise training (173). However, considering the bulk of 
research relating to endurance exercise and glucose metabolism has been compiled from 
studies utilising the euglycaemic-hyperinsulinaemic clamp (12, 16, 17, 21, 168, 174, 175) or 
IVGTT (22, 24, 176) the physiological glucose fluxes that regulate glycaemia following meal 
glucose ingestion in response to exercise are not fully understood.  
A meta-analysis from Snowling et al. (154) concluded that aerobic exercise training has at least 
a small to moderate effect on improving important markers of glycaemic control such as 
glycated haemoglobin, fasting glucose, peak postprandial glucose, and fasting insulin, with 
additional benefits for those with severe disease and an additional synergistic effect with diet 
co-intervention. Boule et al. (173) also demonstrated that insulin sensitivity, disposition index, 
glucose effectiveness, as well as intravenous glucose tolerance and fasting glucose and insulin 
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were improved by 20 weeks of endurance exercise in almost 600 sedentary individuals. This is 
important, as for any lifestyle intervention to have meaningful consequences for diabetes 
prevention and treatment there should be improvements to glycaemia and/or insulinaemia, not 
just insulin action (177). However, research into the effects of endurance exercise on glucose 
metabolism has largely focussed on changes to insulin sensitivity, typically using techniques 
such as the hyperinsulinaemic clamp or IVGTT, and so the prevailing view is that alterations 
to peripheral insulin action are the most quantitatively important effect of endurance training 
(12, 168, 174, 175, 178). Although findings from studies using the clamp and IVGTT have 
been valuable, they do not represent the physiological postprandial state that constitutes normal 
living conditions. Furthermore it is also important to highlight that endurance exercise does not 
necessarily always result in large changes to insulin sensitivity despite improvements to 
glycaemia and other metabolic health parameters (168, 179). 
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Table 1.1 – Studies investigating the effects of acute and chronic endurance exercise on glycaemic regulation 
 
Paper Subjects Status Exercise  Measurement Findings 
Table 1.1.1 Cross-sectional – Trained versus untrained 
Per Bjorntorp et al. 
(159) 
 
Metabolism 
 
1972 
N=31 (M) 
 
54yrs 
 
Trained (15) 
Untrained (16) 
NGT Cross-sectional 
 
Trained  
(2.8 l.min-1 VO2max)  
 
Untrained  
(2.3 l.min-1 VO2max) 
100g OGTT - VO2max ~20% higher in trained individuals 
- Body weight not different but body fat ~30% 
lower in trained individuals 
- Fasting glucose (~12%) and insulin (~5-fold) 
significantly lower in trained individuals 
- AUC (0-120min) of glucose and insulin were 
~20% and ~3-fold lower, respectively, in 
trained individuals 
 
Lohmann et al. 
(161) 
 
Metabolism  
 
1978 
N=6 (M) 
(115 controls) 
 
26yrs 
 
Highly Trained 
 
NGT Cross-sectional 
 
Highly trained 
(~30 min for 10km 
running time trial) 
IVGTT - Basal glucose unchanged but basal insulin 
significantly lower (~50%) in trained 
individuals 
- Glucose kinetics unchanged during IVGTT 
but plasma insulin was ~3-fold lower in 
trained individuals 
LeBlanc et al. (160) 
 
JAP 
 
1979 
N=18 (M) 
 
23.5yrs 
 
Trained (9) 
Untrained (9) 
NGT Cross-sectional 
 
Trained VO2max 
>60ml/kg/min 
(Ave: 71.5) 
 
Untrained VO2max 
<60ml/kg/min 
(Ave 47.1) 
 
IVGTT - Trained individuals were ~10kg lighter and 
had ~3-fold less body fat 
- Glucose response to IV glucose was 
significantly lower in the first 30min in 
trained individuals (Peak ~30% lower) 
- Insulin response to  IV glucose was ~3-fold 
lower in trained individuals 
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Rodnick et al. (180) 
 
AJP Endo 
 
1987 
N=16 (M) 
36yrs 
 
Highly trained 
and untrained 
matched controls 
 
NGT Cross-sectional 
 
Trained (<40min for 
10km running time 
trial) 
 
Untrained – no activity 
5 or 25 mU. m-2 
min-1  
Euglycaemic 
Hyperinsulinaemic 
Clamp   
 
OGTT 
- Glucose tolerance was similar between 
trained and untrained individuals  
- Insulin significantly lower in trained versus 
untrained individuals 
- Insulin-stimulated glucose uptake was 25 and 
38% higher in trained individuals at 10uU 
and 50uU insulin 
Table 1.1.2 Acute Exercise 
Holm et al. (171) 
 
JAP 
 
1978 
N=24 (19F;5M) 
 
Obese (16) 
Lean (8) 
 
41yrs/ 33yrs 
NGT Acute Exercise 
 
1hr 
 
70% maximal work 
capacity 
IVGTT 
 
24hrs post 
48hrs post 
- Basal insulin and glucose unchanged after 
exercise in obese and lean controls 
- Insulin response significantly lower 24 and 
48h after exercise only in obese not lean 
subjects 
- Glucose tolerance (K value) tended to be 
improved at 48h only in obese subjects 
 
Bogardus et al. (12) 
 
JCI 
 
1983 
 
N=20 (M) 
 
Sedentary 
 
24yrs 
NGT Acute Exercise 
 
80-90% Max HR 
 
Interval 2min on/3min 
off  until fatigue 
 
~45mins total 
 
40 or 400 mU. m-2 
min-1   
 
Euglycaemic 
Hyperinsulinaemic 
Clamp   
 
15h post 
- Basal EGP unchanged by exercise 
 
- Glucose disposal increased 10-15% after both 
low and high dose insulin 
Heath et al. (172) 
 
JAP 
 
1983 
N=8 (2F;6M) 
 
Trained 
 
28yrs 
NGT 10days de-training 
 
Followed by 
 
Acute Exercise 
(comparable to usual 
training) 
 
100g OGTT 
 
24hrs post 
- De-training reduced glucose tolerance 10-
25% and increased insulin 55-120% 
- A single bout of exercise returned glucose 
tolerance to trained levels 
- Exercise almost returned insulin to trained 
levels, though this was still significantly 
higher (~20% higher) 
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Devlin and Horton 
(168) 
 
Diabetes 
 
1985 
N=12 (M) 
 
Obese (6) 
Lean (6) 
 
30 yrs 
IR (6) 
 
NGT 
(6) 
Acute Exercise 
 
85% VO2max 
 
Interval 2min on/3min 
off until fatigue 
 
40 or 400 mU. m-2 
min-1   
Euglycaemic 
Hyperinsulinaemic 
Clamp   
 
 
12hrs post 
- Following exercise; 
- Basal glucose ~13% lower and basal C-
peptide 33% lower in lean but not obese 
subjects, with no change to basal insulin 
- Basal EGP 16% lower in lean subjects; no 
change in EGP suppression during low dose 
insulin 
- Glucose disposal was increased 36 and 25% 
in obese subjects during 40 and 400mU 
insulin respectively  
- Insulin sensitivity was unaltered in both 
cohorts 
 
 
Devlin et al.  (15) 
 
Diabetes  
 
1987 
N=5 (M) 
 
Obese 
 
37yrs 
T2D Acute Exercise 
 
85% VO2max 
 
Interval 2min on/3min 
off until fatigue 
 
40 and 400mU  
mU. m-2 min-1 
 
Euglycaemic 
Hyperinsulinaemic 
Clamp   
 
 
12h post 
 
- Following exercise; 
- Basal glucose significantly lower (~17%) 
- Basal EGP 20% lower 
- Glucose disposal increased ~20% during low 
dose insulin 
- EGP suppression was 36% greater during low 
dose insulin  
-  
Mikines et al. (181) 
 
Am J Physiol 
 
1988 
N = 7  
 
25yrs 
 
Untrained 
 
NGT Acute Exercise 
 
64% VO2max 
 
60mins 
2, 4, 13, or 30 
mU/kg  
 
Euglycaemic 
Hyperinsulinaemic 
Clamp   
 
48h post 
 
 
 
- No change in basal insulin or glucose 
following exercise 
- 13% increase in maximal insulin mediated 
glucose disposal following exercise 
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Short et al. (20) 
 
J Nutr Metab 
 
2012 
N=11 (F7; M4) 
 
20-30yrs 
 
Untrained 
NGT Acute Exercise 
 
45min (boxing, 
cycling, treadmill) 
 
<75% Max HR 
 
MTT 
 
1hrs and 17hrs 
post 
- Glucose, insulin and C-peptide AUC were 
decreased 1hrs post (6, 20, 14% respectively) 
- No change to glucose, insulin, c-peptide 
17hrs post 
- Insulin sensitivity was not changed following 
exercise 
Table 1.1.3 Exercise Training 
Defronzo et al. 
(165) 
 
N Engl J Med 
 
1979 
N = 6 (M) 
 
25yrs 
 
Sedentary 
NGT 6wk exercise 
 
4d/wk 
 
60min 
 
70% VO2max 
42 mU. m-2 min-1  
 
Euglycaemic 
Hyperinsulinaemic 
Clamp    
 
48h post 
- No change to body weight but 20% increase 
in VO2max 
- 30% increase in insulin-mediated glucose 
uptake 
- 35% increase of insulin bindings to 
monocytes due to an increase in insulin 
receptor concentration 
- No change to fasting insulin or glucose 
 
Reitman et al. (178) 
 
Diabetes Care 
 
1984 
N = 6 (3F/3M) 
 
Obese 
 
Young (19-41) 
 
T2D 6-10wk  
 
4-5d/wk 
 
60-90% VO2max for 
30min 
 
 
Euglycaemic 
Hyperinsulinaemic 
Clamp 
 
OGTT 
 
36-120h post  
- Increased VO2max with no change in body 
weight 
- Glucose disposal rate increased 25% 
- Improved Fasting glucose and insulin 
- Improved Postprandial 30min insulin and 3h 
integrated glucose response 
Holloszy et al. (167) 
 
Acta Med Scand 
 
1986 
N = 21 (M) 
 
~55yrs 
 
5 T2D 
8 IGT 
8 NGT 
12mo exercise 
 
3-5d/wk 
 
40-60min 
 
60-90% VO2max 
 
100g OGTT 
 
18h post 
  
- VO2max increase ~27% 
- Glucose tolerance improved in T2D and IGT 
but not NGT (~55%, 33% and N/A 
respectively) 
- AUC insulin decreased in all 3 groups (~75%, 
50%, 50% respectively) 
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Rogers et al.  
 
Diabetes Care 
 
1988 
N=10 (M) 
 
53yrs 
 
Overweight 
 
T2D 
(7) 
IGT (3) 
7days 
 
50-60mins 
 
~70% VO2max 
 
OGTT 
 
16-20h post 
- 36% reduction in AUC Glucose 
- 32% reduction in insulin AUC 
- 33% reduction in TAGs 
Kahn et al. (166) 
 
AJP Endo 
 
1990 
N=13 
 
68yrs 
 
Sedentary 
NGT 6mo exercise 
 
5d/wk 
 
45mins  
 
60-85% HR reserve 
 
OGTT and IVGTT 
 
60hrs post 
- 18% increase VO2max 
- Body weight decreased 2.4kg 
- Fasting glucose unchanged 
- Fasting insulin decreased ~21% 
- 36% increase in insulin sensitivity 
- Oral and IV glucose tolerance unchanged 
- Acute insulin response to IV glucose 
decreased ~35% 
-  
Segal et al. (19) 
 
JAP 
 
1991 
N=26 (M) 
34yrs 
 
10lean; 10 obese; 
6 T2D 
 
Sedentary 
20 
NGT 
6 T2D 
12wk  
 
4h/wk 
 
70% VO2max 
40 mU. m-2 min-1 
 
Euglycaemic 
Hyperinsulinaemic 
Clamp   
 
72h post 
 
OGTT 
 
96hr+ post 
 
- 27% increase VO2max 
- No change to body composition 
- Fasting insulin and glucose unaltered by 
training 
- Basal EGP reduced only in T2D subjects 
- No change to clamp EGP suppression 
- No significant effect of training on glucose 
disposal or peripheral insulin sensitivity 
-  
Dela et al. (174) 
 
AJP 
 
1992 
N=7 (M) 
 
23yrs 
 
Healthy, 
sedentary 
NGT 10wk 
6d/wk 
 
70% VO2max 
Single leg 
 
30min/day 
 
28, 88 and 480 
40 mU. m-2 min-1 
 
Euglycaemic 
Hyperinsulinaemic 
Clamp   
 
16h post 
- ~10% increased VO2max in trained legs 
- Glucose uptake increased 50, 45, 35% during 
each step of the clamp, respectively, in 
Trained versus untrained legs 
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Short et al. (24) 
 
Diabetes 
 
2003 
N=90 (47ex/ 
43ctrl)(49M/41F) 
 
Sedentary 
 
20-40yrs (31) 
40-60yrs (25) 
60+ (34) 
NGT 16wk  
 
3-4d/wk 
 
70-80% Max HR 
 
20-40min 
IVGTT 
 
96-120hrs post 
- Exercise increased VO2max (10%) and 
mitochondrial enzymes 
- Exercise reduced body fat (5%) and plasma 
TAG (25%) 
- Insulin sensitivity increased by 72%, 20% 
and 5% in younger, middle-aged and older, 
respectively  
- Insulin sensitivity increased 41% in young 
men; 116% in young women 
- Fasting glucose and insulin unaltered by 
exercise 
-  
Nishida et al. (182) 
 
Diabetes 
 
2004 
N = 8 (7M; 1F) 
~25yrs 
Sedentary 
NGT 12wk 
 
5d/wk 
 
60min/day 
 
50% VO2max 
 
IVGTT 
 
16hrs post and 7d 
post 
- 10% increase VO2max 
- No change to body composition 
- Peripheral glucose effectiveness (Ge) and 
insulin sensitivity increased 16h post 
(IVGTT; 20% and 55% respectively) 
- Peripheral Ge remained increased 1wk post 
- No change to hepatic Ge or insulin sensitivity 
- Basal insulin and glucose unchanged 
-  
Houmard et al. (22) 
 
JAP 
 
2004 
N=154 
(69F;85M) 
~52yrs 
Overweight 
Sedentary 
NGT 6mo  
 
115-170min/wk 
 
40-80% VO2peak 
 
1 (low-volume + 
moderate intensity) 
2 (low volume + 
vigorous intensity) 
3 (high volume + 
vigorous intensity) 
 
IVGTT 
 
24hrs post 
- Fasting insulin decreased in groups 1 and 3 
(30 and 10% respectively) 
- No change to fasting glucose 
- Insulin sensitivity increased in all groups (65, 
30 and 56% respectively) 
Acute insulin response to IV glucose and Ge 
unchanged by training 
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Boule et al. (173) 
 
Diabetes Care 
 
2005 
N=596 
(316F;280M) 
~35yrs 
Overweight 
Sedentary 
NGT 20wk 
 
3d/wk  
 
55-75% VO2max 
 
30-50min 
IVGTT 
 
24hrs post 
 
Fasting 
glucose/insulin 
 
72hr post 
- Decreased Body weight and increased 
VO2max (17%) 
- 10% increase in insulin sensitivity 
- 3% decrease in acute insulin response to IV 
glucose 
- 7% increase in disposition index 
- 11% increase in Ge 
- IV glucose tolerance (glucose disappearance 
index) increased 3% 
- Glucose area decreased 7% 
- Fasting glucose and insulin improved 24hrs 
post exercise 
-  
Shojaee-Moradie et 
al. (175) 
 
Diabetologia 
 
2007 
N = 17 (M) 
50yrs Sedentary  
Overweight 
NGT 6wk  
 
3d/wk at 60-85% 
 
20+ min 
0.3 and 1.5  
mU. kg-1 min-1 
 
Euglycaemic 
Hyperinsulinaemic 
Clamp   
 
72h post 
- 22% increase VO2max 
- No change HOMA-IR or body composition 
- Basal glucose and insulin unchanged 
- EGP during Low-dose insulin significantly 
(~33%) lower following training but not 
control 
- Glucose uptake ~17% higher following 
training but not control 
- Whole-body insulin sensitivity ~15% higher 
following training but not control 
- Basal FFA, glycerol and palmitic acid Ra 
decreased by training 
 
Bloem et al. (183) 
 
J Clin Endo Metab 
 
2008 
N=12 (7F/5M) 
 
68yrs 
 
Obese 
 
IGT 7days 
 
60-70% HR reserve 
 
60mins 
IVGTT - No change to basal insulin or glucose 
- Insulin sensitivity increased ~59% 
- Acute insulin response to IV glucose 
decreased 12%  
Disposition index increased 31% 
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Winnick et al. (21) 
 
JCI 
 
2008 
N=18 (10F;8M) 
 
49yrs 
 
Obese 
T2D 7days 
 
60-70%VO2max  
 
50-60mins 
 
20 and 40 mU  
mU. m-2 min-1 
 
Isoglycaemic 
Hyperinsulinaemic 
Clamp   
 
 
Within 24h 
- No difference in fasting glucose after exercise 
- Whole body and peripheral Insulin sensitivity 
increased during high-dose insulin only 
(~60%) 
- Peripheral glucose uptake improved ~60% 
during high dose insulin after exercise 
- No change in EGP or hepatic insulin 
sensitivity 
-  
Kirwan et al. (16) 
 
AJP Endo 
 
2009 
N=14 (M) 
 
64yrs 
 
Obese 
T2D 7 days 
 
60mins 
 
70% VO2max 
40 and 1000 mU  
mU. m-2 min-1 
 
Euglycaemic 
Hyperinsulinaemic 
Clamp   
 
- Fasting glucose tended to decrease (5%) and 
fasting insulin was decreased (24%) 
- Glucose disposal increased 45% and 17% 
during low and high dose, respectively 
- EGP decreased 20% basally, and 60% during 
low dose insulin 
-  
Coker et al. (184) 
 
J Clin Endo Metab 
 
2009 
 
N=25 (17F;8M) 
 
~55yrs 
 
Obese 
IGT 12 wk 
 
~2500kcal/ wk 
 
With or without 
weight loss 
 
Octreotide, 
glucagon, 
multistage insulin 
infusion 
0.25 and 1 mU. 
kg-1 min-1 
 insulin 
 
72h post 
 
- Exercise without weight loss improved 
insulin suppression of EGP ~12% and 
improved glucose disposal ~14% 
- Exercise with weight loss increase insulin 
suppression of EGP ~ 27% and improved 
glucose disposal ~31% 
- - No change to fasting or OGTT insulin or 
glucose 
 
Schenk et al. (23) 
 
J Physiol 
 
2009 
N = 17 (F) 
 
Obese 
 
30yrs 
NGT Weight loss + exercise 
(until lost 12% BW) 
 
3d/wk 
 
85% HRmax  
 
45min 
 
IVGTT  
 
72h post 
- 12% weight loss vs. 12% weight loss plus 
exercise 
 
- 21% improvement VO2max with exercise 
- No difference to insulin sensitivity between 
groups 
- Exercise improved fatty acid oxidation but 
did not protect against insulin resistance by 
lipid infusion 
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Van der Heijden et 
al. (176) 
 
JCEM 
 
2009 
N=29 (12F;17M) 
Obese (15) 
Lean (14) 
 
Sedentary 
 
16yrs 
NGT 12wk 
 
4days/wk 
 
30min  
 
70% VO2max 
 
Labelled IVGTT 
 
72h post 
- Fasting glucose unchanged 
- Fasting insulin lower (~15%) in obese only 
- Lean mass increased in both cohorts 
- Peripheral insulin sensitivity increased 35 and 
59% in lean and obese subjects, respectively 
- Hepatic sensitivity increased 19 and 23% in 
lean and obese subjects, respectively 
 
Ge, glucose effectiveness; HOMA-IR,  homeostatic model assessment of insulin resistance; ; HR, heart rate; IGT, impaired glucose tolerant; IV, intravenous;  
NGT, normal glucose tolerant; VO2max, maximal pulmonary oxygen uptake.
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1.6.1 Effect of endurance exercise on hepatic glucose metabolism and β-cell function 
 
Interest in the effect of exercise on liver glucose metabolism began in the 1980’s where 
Rodnick et al. (180) provided cross-sectional evidence that hepatic insulin sensitivity was 
enhanced in trained versus untrained individuals during the euglycaemic hyperinsulinaemic 
clamp. Insulin-stimulated glucose uptake during the clamp was ~25% higher and EGP ~50% 
lower in trained versus untrained age- and BMI-matched men (180). Subsequently, Devlin et 
al. (15) observed a decrease in fasting EGP and increased insulin-induced suppression of EGP 
after only a single intense exercise bout in those with T2D. Additionally, 6 weeks of light to 
moderate exercise training in healthy but overweight men (175), and 12 weeks of moderate 
exercise in obese glucose intolerant men (184) also improved insulin-induced suppression of 
EGP. Hepatic insulin sensitivity as determined during the labelled IVGTT was increased by 
approximately 20% in healthy lean and obese adolescents after 12 weeks of moderate intensity 
exercise training (176). Thus, despite the widely-held view that enhancement of insulin-
stimulated peripheral (muscle) glucose uptake represents the principal and most quantitatively 
important effect of endurance exercise on the glucoregulatory system, it is clear that endurance 
exercise also results in enhancement of insulin’s actions in regards to the suppression of EGP. 
Endurance exercise training ranging from 7 days to 8 months has also been shown to improve 
β-cell function in those with impaired insulin secretory capacity such as individuals with T2D 
(183, 185-187). Glucose-stimulated insulin secretion is thought to be decreased with endurance 
exercise training in healthy individuals due to an improvement in peripheral insulin sensitivity, 
thus lowering the insulin secretory demand on the β-cell (188). However, studies have also 
shown that β-cell function and hence insulin secretion can improve somewhere along the course 
of exercise training in healthy individuals (185, 187, 189). The product of glucose-stimulated 
insulin secretion and insulin sensitivity (termed disposition index) has been used as a readout 
of the appropriateness of pancreatic β-cell function as it relates to the prevailing insulin 
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sensitivity. The disposition index has been demonstrated to increase in normal glucose tolerant, 
but not overweight individuals following 8 months endurance exercise (187). This 
improvement may be related to a variety of mechanisms, including reductions in circulating 
glucose requiring a lesser demand on the β-cell, reductions in oxidative stress (190) or cross-
talk between active skeletal muscle and the β-cells via myokines (skeletal muscle-secreted 
cytokines such as interleukin-6) (191).  
Despite this, the effect of endurance exercise on hepatic glucose metabolism and β-cell function 
is still poorly understood. This is partly due to the non-accessible nature of the liver and 
pancreas compared to skeletal muscle. Another common limitation concerns the use of insulin 
concentrations, and common indices such as HOMA-IR, to measure insulin secretion and 
action. Insulin concentrations represent the net sum of insulin secretion, insulin clearance and 
hepatic extraction of insulin from the portal circulation, and so circulating insulin does not 
accurately represent the sum of these parameters. As described earlier, the peripheral bias of 
techniques such as the IVGTT and clamp (4, 6, 7), which involve administration of glucose 
and/or insulin into a peripheral blood vessel, bias the stimulation of glucose uptake away from 
the liver (4, 6, 7). Additionally, high doses of insulin infusion during the clamp near completely 
suppress hepatic glucose production and the lack of nutrients passing through the gut bypasses 
the gut-based secretion of incretins, which have potent effects on hepatic glucose metabolism 
and β-cell function. 
1.6.2 Effect of endurance exercise on peripheral glucose metabolism  
 
As discussed in the section above, although there is substantial evidence showing enhancement 
of insulin’s actions in regards to the suppression of EGP and β-cell function with exercise, it is 
generally accepted that increased insulin-stimulated peripheral glucose uptake, specifically into 
skeletal muscle, represents the largest and most physiologically important effect of endurance 
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exercise on postprandial glycaemic regulation (12, 168, 174, 175, 178). This view has prevailed 
for over 30 years, where it was demonstrated that improvements in glucose metabolism 
following endurance exercise coincided with an enhancement in insulin-stimulated peripheral 
glucose uptake during the clamp (12, 178). Subsequently, studies by other groups utilising the 
clamp and IVGTT confirmed these findings (168, 174-176, 182). These improvements in 
insulin-stimulated skeletal muscle glucose uptake have been attributed to a number of possible 
molecular mechanisms, including an increased skeletal muscle oxidative capacity (138), 
enhanced insulin signalling pathways (192), altered content and composition of metabolically 
active lipid intermediates (193), increased insulin-independent muscle glucose transport 
capacity (24, 194), increased glycogen utilisation (138) or enhanced endothelial function (194). 
Although studies assessing insulin sensitivity via the  clamp technique have shown that 
endurance exercise training can increase insulin-mediated glucose disposal by as much as 60% 
(12, 15, 16, 21, 165, 168, 174, 175, 178), it is important to consider that the ‘clamped state’ 
does not represent normal living conditions and therefore is non-physiological in nature. 
Furthermore, techniques involving peripheral intravenous (non-hepatic portal) infusion of 
insulin and/or glucose bias the stimulation of glucose uptake, redirecting it toward peripheral 
sites, particularly the skeletal muscle (4, 6, 7). Thus, it is possible that the experimentally 
‘induced’ conditions of the clamp favour exercise induced changes to insulin stimulated muscle 
glucose uptake to be more pronounced. In reality, in the normal postprandial state, tissue 
glucose uptake is more evenly distributed across different organ systems and regulatory layers 
(i.e. insulin sensitivity, insulin secretion and glucose effectiveness) (4, 6, 7, 26, 43).  Thus, the 
effect of endurance exercise on postprandial glucose flux remains equivocal and clearly needs 
to be addressed in more detail via techniques that permit its assessment under physiologically 
representative conditions.    
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It is also worthy to mention that numerous studies have demonstrated that insulin sensitivity is 
not always enhanced by endurance exercise and that metabolic health and glucose metabolism 
may be improved without changes to insulin sensitivity. A single acute bout of high intensity 
exercise has been shown to increase insulin sensitivity in obese, insulin resistant subjects, but 
not in healthy controls, despite the fact that the control subjects still demonstrated significant 
reductions in fasting glucose, C-peptide and EGP (5). Furthermore, endurance exercise has 
been shown not to provide any additive benefit to insulin sensitivity above weight loss alone 
in obese women, despite increased aerobic fitness and fatty acid metabolism (23). Importantly, 
other studies involving both lean and obese sedentary male subjects reported no increase to 
insulin sensitivity during a clamp despite decreased visceral adipose mass, improved aerobic 
fitness and a reduction in inflammatory markers with endurance exercise training (179). 
Additionally, Devlin and Horton (168) demonstrated that fasting glucose, C-peptide, EGP and 
Rd were all reduced in lean, healthy men after a single bout of high intensity endurance 
exercise, despite no change to clamp insulin sensitivity. On the other hand, Short et al. (24) 
demonstrated that in healthy men and women, insulin sensitivity during the IVGTT was 
markedly improved after 16 weeks of endurance training, however, there was no resultant 
change to fasting insulin or glucose. Similar findings were also demonstrated in lean 
adolescents, where 12 weeks of endurance training resulted in improved peripheral and hepatic 
insulin sensitivity during the clamp, yet no change to fasting glucose or insulin (176). While 
numerous laboratory based analytical techniques often reveal positive effects of exercise on 
aspects of glucose metabolism under experimental conditions, it is important to consider that 
these improvements need to carry over into real life conditions. Specifically, these measured 
improvements need to manifest into consistent and meaningful reductions to fasting and/or 
postprandial glycaemia and/or insulinaemia, thus ultimately improving metabolic health. 
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Accordingly, it is important to determine to what degree exercise influences postprandial 
metabolism under the most physiologically representative conditions possible. 
1.6.3 Acute endurance exercise versus endurance exercise training 
 
An important consideration in reviewing the effect of endurance exercise is that traditionally, 
any effect on improving glucose metabolism has been attributed to the residual effect of each 
acute bout of exercise, rather than a summative effect of chronic training (19, 172, 195). 
Longitudinal studies involving controlled physical training are potentially difficult to interpret 
because of concomitant changes in other factors, such as body weight, adiposity, muscle mass 
and diet, which have independent, strong effects on glycaemic regulation. Indeed, interest in 
the effects of exercise on glucose metabolism began when cross-sectional data demonstrated 
improved glycaemic control in trained versus untrained individuals (12, 159, 161). However, 
physically trained individuals likely lead healthier lifestyles (i.e. diet), are usually leaner than 
sedentary counterparts, and it is likely that the differences can be attributed to the lower body 
fat rather than the level of cardiorespiratory fitness itself (196).  
Importantly, when measuring both the effect of acute and chronic exercise in matched 
participants, it seems that there is little additional effect of chronic exercise training above a 
single bout for improvements to insulin sensitivity or postprandial glycaemia, both in untrained 
and trained individuals (19, 172, 195, 197, 198). Heath et al. (172) demonstrated that when 
trained individuals ceased training for 10 days, blood glucose concentrations following a 100g 
OGTT were significantly elevated despite an increase in circulating insulin. A single bout of 
exercise then returned both insulin and glucose levels to the initial ‘trained value’, highlighting 
the substantial effect of a single bout of exercise on glucose metabolism that does not 
compound with chronic repetition (172). Likewise, in overweight adults, exercising regularly 
(>2.5h per week for 6 months) was accompanied by a persistent reduction in insulin 
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concentrations during the OGTT that lasted at least 3 days following exercise (197). However, 
just one session of exercise increased insulin sensitivity among matched, sedentary adults to 
levels equivalent to that of the regular exercisers (197). In a similar study design, when already 
endurance-trained individuals undertook a single acute exercise bout, there was no benefit to 
insulin sensitivity as measured during the hyperinsulinaemic clamp, though after 5 days of 
detraining insulin sensitivity reverted back to untrained levels (198). 
A key difficulty lies in defining acute and chronic effects of training (153). When the effect of 
an acute endurance exercise bout, or exercise training, on glycaemic control is measured in 
isolation, how long after cessation of exercise should measurement occur? When measuring 
the effects of a training intervention, measurements within a 0-72h after exercise termination 
can involve residual effects from the last, acute exercise bout (144) while measurements after 
72h may result in detraining, underestimating the overall exercise effect. Several of the early 
studies that observed significant improvements in glucose tolerance (154) and insulin 
sensitivity (155) in response to exercise training obtained post-training measurements within 
12 to 48 h of the last exercise session. In contrast, Segal et al. (17) reported that insulin 
sensitivity was not significantly altered following 12 weeks of endurance exercise training in 
lean and obese individuals and those with T2D, when measurements were obtained 4 days post 
exercise. However, using a crossover design, if measurements are taken ~24 h following acute 
exercise, and then the equivalent period of time following a training period, the net effect of 
exercise training above that of an acute exercise bout can be determined (i.e. training effect 
less the acute effect).  
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1.6.4 Summary and significance  
 
Endurance exercise is one of the most cost-efficient and effective means of public health 
promotion, due to its multi-faceted effects on overall health (8). In relation to glucose 
metabolism, beneficial effects of endurance exercise in both healthy populations and those that 
are metabolically compromised, as in obesity and T2D,  include enhancements to tissue insulin 
sensitivity (21, 22, 24, 166, 168, 182) and glucose effectiveness (182). Despite the fact that 
endurance exercise has been demonstrated to improve hepatic insulin sensitivity and glucose 
effectiveness (15, 175, 176), as well as β-cell function (183, 185-188), it is widely viewed that 
enhancement of peripheral insulin sensitivity via increased insulin-stimulated muscle glucose 
uptake is the main driver of improved glucose metabolism following exercise training (12, 168, 
174, 175, 178). However, much of the existing literature that has investigated the effects of 
exercise on the glucoregulatory systems, especially those investigating skeletal muscle insulin 
sensitivity, have used non-physiological techniques as their primary outcome measures, in 
particular the euglycaemic-hyperinsulinaemic clamp (21, 168, 174) and the IVGTT (22, 24, 
182). Although valuable, these techniques do not mimic the normal physiological responses 
that occur following meal glucose (sugar or starch) ingestion (4).  
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1.7 Effect of overfeeding on glucose metabolism 
 
The past few decades have seen an immense rise in both obesity and T2D (5). Considering the 
rapid and worldwide nature of these developments, it is unlikely that these have been driven 
by genetic factors. Rather, along with epigenetic changes, it is evident that lifestyle factors, 
such as the broad availability of inexpensive, highly palatable foods, are playing a significant 
role in this epidemic (10, 199). This widespread overconsumption of energy dense foods, 
particularly in the form of processed starch, sugar and fat (9, 199) is characteristic of the 
Westernised diet, and is a crucial factor leading to the development of insulin resistance, 
impaired β-cell function and ultimately impaired glucose tolerance and T2D (13). 
However, understanding the physiological implications of overfeeding in humans is 
complicated by the fact that many human overfeeding trials use experimental diets that provide 
an excess of energy, but also alter the proportion of macronutrients, to increase the amount of 
energy derived from fat (13, 14, 200-203). Therefore, it is not clear if the observed impairments 
in glucoregulation are merely a result of the high fat content of the diets provided, a rise in total 
energy intake, or due to a normal metabolic adaptation away from carbohydrate metabolism as 
a result of increased fat availability (204). Furthermore, it is also unclear whether overfeeding 
one specific macronutrient (i.e. fat) is actually representative of a typical real life overeating 
paradigm.   
Additionally, although it is clear that chronic periods of overfeeding result in whole-body 
insulin resistance, glucose intolerance and increased fat mass in humans (200, 203, 205) (Refer 
to Table 1.2.2), it is also important to note that brief, intermittent over-consumption of energy 
dense diets (<1 week) is common in most individuals, such as during holiday-related periods 
of feasting (10). Indeed, overfeeding even for as little as 3-7 days in humans can lead to 
increased fat mass, impaired skeletal muscle insulin signalling (11), reduced glucose tolerance 
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(201, 202), decreased whole-body (10, 13, 14, 206, 207) and hepatic insulin sensitivity (13) 
(Refer to Table 1.2.1). However, the temporal pattern of impairment to glycaemic regulation 
following overfeeding is still unclear in humans, where studies typically assess only acute (1-
7 d) (10, 11, 13, 14, 201, 202, 206-208) or chronic (weeks or months) (203, 205) overfeeding 
in isolation.  
Another factor that complicates the interpretation of studies investigating glucose metabolism 
following periods of overfeeding in humans is the use of non-physiologic measurement 
techniques such as the hypersinulinaemic clamp (10, 11, 13, 14, 200, 203, 206) or IVGTT (13) 
(Refer to Table 1.2). While previous human overfeeding studies have utilised glucose or mixed 
meal tolerance tests to investigate postprandial glucose metabolism (201, 202, 205), it appears 
none have concomitantly utilised glucose isotope tracers to investigate glucose fluxes under 
these conditions. Accordingly, there is a gap in the literature in regard to the effects that 
overfeeding in humans has on postprandial glucose fluxes.  
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Table 1.2 - Studies investigating the effects of acute and chronic overfeeding on glycaemic regulation  
 
 
Paper Subjects Status Diet Measurement Findings 
1.2.1 Acute Overfeeding (≤10 days) 
Chen et al. (14) 
 
Ann Nutr Metab 
 
2016 
N=31 (21F; 10M) 
 
Sedentary, lean 
 
Young 
NGT 3 days 
 
50% Overfeeding 
 
45% fat 
80  mU m-2.min-1 
  
Euglycaemic 
hyperinsulinaemic 
clamp 
- Increased body weight 
- Increased fasting glucose and insulin 
- Increased HOMA-IR 
 
- No change to peripheral insulin sensitivity 
 
 
Cornier et al. 
(10) 
 
Metabolism  
 
2006 
N=22 (12F; 10M) 
 
Lean (13) 
Overweight (9) 
 
35yrs 
NGT 3 days 
 
50% overfeeding  
 
50% CHO, 30% 
fat, 20% protein 
5 and 40 mU m-
2.min-1  
 
Euglycaemic 
hyperinsulinaemic 
clamp 
 
- Insulin sensitivity was reduced ~15% in lean women only (not 
in lean or overweight men or overweight women) 
- Basal EGP was unaffected by diet 
- Total suppression of EGP was reduced from 80 to 60% in lean 
women but no other group 
- Basal and insulin-stimulated Rd were unchanged 
- Overfeeding reduced basal FFA and glycerol (33% both) and 
insulin suppression of FFA and glycerol (10 and 18%, 
respectively) 
 
Clore et al. (209) 
 
J Clin Invest 
 
1995 
N=15 (4F; 11M) 
 
Lean 
  
24yrs 
NGT 4 days 
 
4000kj 
overfeeding 
 
67% CHO, 22% 
fat, 11% protein 
Fasting glucose 
turnover 
(Stable isotope 
tracers) 
 
Calorimetry 
- Increase in fasting plasma glucose (3%) 
- Increase in fasting insulin (150%) 
- Increase in carbohydrate oxidation (280%) and decrease in fat 
ox (400%) 
- Hepatic glucose production increased (30%) and was 
associated with a decrease in gluconeogenesis (50%) and an 
increase in glycogenolysis 
-Increased liver glycogen stores can overwhelm normal 
intrahepatic mechanisms 
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Brons et al. (13) 
 
J Physiol 
 
2009 
N=26 (M) 
 
Sedentary, Lean 
 
30yrs 
NGT 5 days 
 
50% overfeeding 
 
60% fat, 32% 
CHO, 7% protein 
IVGTT  
 
 
80 mU m-2.min-1  
 
Euglycaemic 
hyperinsulinaemic 
clamp 
- Fasting FFA ~39% lower; insulin-stimulated FFA ~33% 
higher 
- Fasting TAG ~20% lower 
- Fasting glucose increased 10% 
- Fasting insulin tended (P=0.07) to increased ~39% 
- Fasting C-peptide increased 29% 
- No change to insulin-stimulated glucose, insulin, c-peptide 
- Increased fasting plasma adiponectin, leptin and GIP 
 
- Basal Rd increased ~30%; no change to insulin-stimulated Rd 
- Insulin-stimulated glycolytic flux decreased ~25% 
- Fasting HGP increased 26%; two-fold increase in hepatic 
insulin resistance 
 
- No change in IVGTT AUC of glucose, but increased AUC 
insulin and C-peptide 
- First phase insulin response increased in first 10min 
- Disposition index increased relative to peripheral but not 
hepatic Si 
 
Adochio et al. 
(11) 
 
Nutr Metab 
 
2009 
N=21 (10F; 11M) 
 
Lean 
 
20-45yrs 
NGT 5 days 
 
40% overfeeding 
 
50% Fat, 30% 
CHO, 20% 
Protein 
 
40 mU m-2.min-1  
 
Euglycaemic 
hyperinsulinaemic 
clamp 
- No change to fasting glucose or insulin, TAG or FFA 
- No change to whole body insulin sensitivity (M or GDR) 
- No change to basal EGP 
 
- Impaired Skeletal muscle insulin signalling  
Adochio et al. 
(11) 
 
Nutr Metab 
 
2009 
N=21 (10F; 11M) 
 
Lean 
 
20-45yrs 
NGT 5 days 
 
40% overfeeding 
 
60% CHO, 20% 
Fat, 20% Protein 
 
40 mU m-2.min-1  
 
Euglycaemic 
hyperinsulinaemic 
clamp 
- Fasting insulin increased 38%, no change to fasting glucose 
- Fasting FFA decreased 30%; Fasting TAG increased 33% 
- No change to whole body insulin sensitivity (glucose infusion 
rate or glucose disposal rate) 
- No change to basal EGP 
 
- Improved Skeletal muscle insulin signalling  
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Lagerpusch et 
al. (206) 
 
Int J Obesity 
 
2012 
N=10 (M) 
 
Sedentary, lean 
 
25yrs 
NGT 7days 
 
60% overfeeding 
 
45% CHO, 35% 
fat, 20% protein 
75g OGTT 
 
100 mU m-2.min-1  
 
Euglycaemic 
hyperinsulinaemic 
clamp 
- 1.6kg increase in mass; 0.7kg increase fat mass 
- Fasting glucose unchanged, fasting insulin increased (~95%) 
- HOMA-IR increased (~100%); Insulin sensitivity (Matsuda) 
decreased (~33%) 
- OGTT; glucose AUC unchanged, Insulin AUC increased 
(~45%) 
- Glucose-stimulated insulin secretion increased (~36%) 
 
- Fasting glucose, insulin, HOMA-IR, insulin sensitivity 
(Matsuda), AUC-glucose and AUC-insulin were all either 
normalised or improved (relative to baseline) by 7d caloric 
restriction after overfeeding 
 
 
Hulston et al. 
(201) 
 
Br. J Nutr 
 
2015 
N=17 (3F; 14M) 
 
Sedentary, lean 
 
24yrs 
 
 
NGT 7 days 
 
50% Overfeeding 
 
65% Fat 
75g OGTT - Mass increased 0.6kg 
- Fasting glucose increased (~6%) and insulin was unchanged in 
control group 
- OGTT Glucose AUC increased 10% and insulin sensitivity 
decreased 27% 
 
 
 
Parry et al. (202) 
 
Brit J Nutr. 
 
2017 
N=9 (4F; 5M) 
 
Lean 
 
23yrs 
NGT 7 days 
 
50% overfeeding 
 
65% fat 
 
3hr MTT 
 
(112g CHO, 30g 
fat, 19g protein) 
- Subjects gained 0.8kg 
- Fasting glucose increased 5.5%; fasting insulin unchanged 
- Decreased fasting FFA (33%) and TAG (30%) 
- Postprandial glucose AUC increased 11.6% and insulin AUC 
increased 25.9% 
- Postprandial suppression of FFA was reduced 
- Fasting GIP increased 50%  
- Postprandial GIP and GLP-1 unchanged 
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1.2.2 Chronic Overfeeding (>10 days) 
Cornford et al. 
(205) 
 
Appl Physiol 
Nutr Metab 
 
2012 
N=9 (2F; 7M) 
 
Sedentary, Lean 
 
24yrs 
NGT 14 days 
 
4000kcal 
 
50% CHO, 35% 
Fat, 15% protein 
MTT 
 
(10 kcal·kg−1 50% 
CHO,15% 
protein, 35% fat) 
- Weight gain (2.4kg) with increased fat mass (1.6kg) 
- Fasting glucose unchanged, fasting insulin increased ~two-fold 
-  Whole-body Insulin sensitivity (Matsuda Index) decreased 
~45% 
- HOMA-IR increased ~85% 
- Whole day insulin AUC was increased ~2-fold and Plasma 
FFA decreased ~30% 
 
-Skeletal muscle markers of insulin resistance and inflammation 
unaltered;  
- Intramuscular lipids not significantly increased 
Samocha-Bonet 
et al. (200) 
Diabetologia 
 
2010 
 
Samocha-Bonet 
et al. (18) 
PlosOne 
 
2012 
N=40 (20F; 20M) 
 
Non-obese 
(25kg/m2) 
Sedentary 
 
37yrs 
NGT 28days 
 
~55% 
overfeeding 
 
45% fat, 40% 
CHO, 15% 
protein 
60 mU m-2.min-1  
 
Euglycaemic 
hyperinsulinaemic 
clamp 
- 2.7kg weight increase after 28days; 1% increase body fat 
- Fasting glucose significantly increased (~2%) and fasting 
insulin increased (~18%) 
- HOMA-IR increased ~22% 
- Glucose infusion rate reduced ~9% 
 
- No change in mitochondrial markers after 28d 
- Skeletal muscle oxidative stress (F2-isoprostanes and protein 
carbonyls) increased after 28d 
Peterson et al. 
(203) 
 
Int J Obesity 
 
2017 
N=29 (M) 
 
Healthy (22-
32kg/m2) 
 
27yrs 
NGT 8 weeks 
 
40% overfeeding 
 
44% Fat, 40% 
CHO, 16% 
Protein 
10 and 50 mU m-
2.min-1  
 
Euglycaemic 
hyperinsulinaemic 
clamp 
- Weight increased 7.6kg (~10%); fat mass 4.2kg (25%) and 
Visceral adipose ~62%;  
- Intra-hepatic lipid unchanged 
- Fasting glucose and insulin unchanged 
-  Glucose infusion rate during low-dose insulin decreased 
~18%; during high dose ~5% 
- Decreased non-oxidative and oxidative glucose disposal at 
low-dose insulin 
 
CHO, carbohydrate; HOMA-IR, homeostatic model assessment of insulin resistance.
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1.7.1 Temporal effects of overfeeding 
 
There is evidence that metabolically active tissues involved in glycaemic regulation respond 
diversely to acute (1-7 days) and chronic (weeks) periods of overfeeding (10, 13, 14, 207, 210-
212). In rodents, a number of studies utilising high fat diet models suggest that hepatic insulin 
resistance precedes the induction of skeletal muscle insulin resistance in response to 
overfeeding by weeks (207, 210-212), although such studies are outside the scope of this 
review. There is some evidence of this temporal pattern of development of insulin resistance 
in humans (10, 13, 14), though previous studies have typically assessed only the short or long-
term effects of overfeeding in isolation, with no actual postprandial glucose flux assessments.  
For example, Brons et al. (13) observed a 26% increase in fasting EGP in healthy young men 
following only 3 days of high fat overfeeding that corresponded to a 2-fold decrease to hepatic 
insulin sensitivity and no change to insulin-stimulated Rd during the clamp. Similarly, Cornier 
et al. (10) demonstrated a reduction in the degree of suppression of EGP during 
hyperinsulinaemic clamp conditions after 3 days of 50% overfeeding in lean women. However, 
both studies ceased observation of participants after 3 days, precluding any further observation 
into glucose metabolism after chronic overfeeding. In a similar light, it has been reported that 
fasting EGP was modestly increased after a single day of high fat overfeeding in already obese 
participants, though this could be viewed as an exacerbation of pre-existing hepatic insulin 
resistance (213).  
In regards to peripheral insulin sensitivity, human studies have demonstrated no change during 
the clamp after 3 days of 45% high fat overfeeding in young men and women (14), whereas 8 
weeks of high fat overfeeding in healthy young men was shown to induce a modest decrease 
to whole body insulin sensitivity which was suggested to be related to decreased insulin 
stimulated glucose disposal (203). Utilising a daylong multiple meal tolerance testing protocol, 
71 
  
Cornford et al. (205) demonstrated increased fasting and postprandial hyperinsulinaemia in the 
absence of changes to glycaemia after 2 weeks of over-eating, although this study did not 
directly examine the site of insulin resistance. Samocha-Bonet et al. (18) recently demonstrated 
that fasting insulin and glucose levels were increased following 3 days of high-fat overfeeding 
in healthy individuals, with these parameters not being exacerbated further by 28 days of 
continued overfeeding. Although hepatic insulin sensitivity was not measured directly in this 
study, the authors suggest that the increase in HOMA-IR that was observed at 3 days supports 
an increase in hepatic insulin resistance (18), although HOMA-IR is dependent upon both 
peripheral and hepatic insulin sensitivity, the contribution of which may differ between 
subjects. Additionally, using the high dose insulin clamp without the use of a glucose tracers, 
it was revealed that following the 28 day overfeeding period, whole body insulin sensitivity 
was significantly reduced (i.e. a lower glucose infusion rate) implying a reduction in glucose 
disposal, with a concomitant increase in markers of oxidative stress in skeletal muscle (18). 
Combined, these findings support the existence of a temporal pattern of insulin resistance 
development, with the liver sensitive to acute periods (<7 days) of both high fat and mixed-
nutrient overfeeding (10, 13, 213), while peripheral tissues are able to initially withstand this 
short-term energy surplus, developing insulin resistance several weeks later (14, 203). 
Although studies utilising techniques such as the hyperinsulinaemic clamp provide the ‘gold 
standard’ method to quantify the temporal pattern for the development of tissue-specific insulin 
resistance (112), no study to date has assessed postprandial glucose fluxes following 
overfeeding. Indeed, glucose fluxes assessed during clamps are quantitative but only assess 
insulin sensitivity in isolation and not under the dynamic conditions associated with a 
postprandial state.  Therefore, studies are now required to examine if this temporal pattern of 
hepatic, followed by peripheral defects occur in regards exists under postprandial conditions, 
in regards to the regulation of glucose flux.  
72 
  
1.7.2 Effect of macronutrient content on the overfeeding response 
 
Many of the recent human studies reporting that overfeeding impairs glycaemic regulation have 
provided a high proportion of dietary fat as well as an excess of energy (13, 14, 18, 200-202). 
Considering that the typical Australian adult diet contains only ~30% of energy derived from 
fats (Refer to Figure 1.9 (214)), it is important to determine whether alterations to glucose 
metabolism previously demonstrated in response to overfeeding diets high in fat content (13, 
14, 18, 200-202), also occur if excess energy is provided to individuals at a normal 
macronutrient content, or if this results in the different metabolic consequences.  
Clearly, by utilising specific macronutrient paradigms in conjunction with overfeeding, this 
biases metabolism toward utilisation of that macronutrient. For example, in both lean and obese 
men, Horton et al. (215) observed that high carbohydrate overfeeding led to storage of only 75-
85% of excess energy, primarily due to a progressive increase in carbohydrate oxidation. Thus, 
in response to overfeeding with excess energy originating predominantly from fats, this biases 
metabolism away from carbohydrates, such that when exposed to a glucose challenge (i.e. 
OGTT), there will be a bias toward impairments in glucose metabolism. 
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Figure 1.9: Typical dietary macronutrient composition of Australians in 2011-12 (214). 
  
74 
  
Overfeeding studies utilising diets high in fat have consistently demonstrated impairment to 
glucoregulatory processes (13, 18, 201-203). Two recent, separate studies in lean, healthy 
adults (201, 202) demonstrated that postprandial glucose is significantly increased by over 10% 
after only 7 days of 50% overfeeding, in which 65% of energy came from fats. Brons et al. (13) 
also demonstrated a range of adverse effects in response to high fat overfeeding (50% 
overfeeding, 60% energy from fat), including elevated hepatic and adipose insulin resistance 
after only 5 days in lean males. Chronic high fat overfeeding has also been demonstrated to 
increase skeletal muscle oxidative stress (18) and decreased glucose disposal (203) in healthy 
subjects. Importantly, overfeeding with excess dietary fat consumption also leads to greater 
relative adipose tissue accumulation than with excess dietary carbohydrate consumption (215), 
which is important considering that increases in body fat (216) and especially the amount of 
visceral fat (217, 218) have been linked to metabolic disease.  
Interestingly, an overconsumption of carbohydrate-rich foods has been reported to enhance 
skeletal muscle insulin signalling, whereas high-fat overfeeding in the same subjects was found 
to impair the same measures (11). Indeed, short-term exposure to a high carbohydrate, 
isocaloric diet has previously been shown to improve glucose metabolism, whereas an 
isocaloric high fat diet in the same cohort impaired insulin sensitivity, particularly at the level 
of EGP suppression (219, 220). Although, while fat overfeeding has been shown to have what 
are considered negative consequences on glucose metabolism, so has carbohydrate 
overfeeding. Clore et al. (209) demonstrated that 4 days of 4000kj overfeeding (67% 
carbohydrate, 22% fat) increased fasting EGP, fasting glucose and insulin in healthy adults. 
Similarly, Cornier et al. (10) demonstrated the development of hepatic insulin resistance after 
3 days of 50% overfeeding (50% carbohydrate, 30% fat) in lean females, however there were 
no changes to insulin sensitivity (EGP or Rd) or glycaemia in lean and obese men. Thus, the 
effect of overfeeding with mixed composition diets deserves further attention. Considering that 
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mixed-composition diets are almost certainly the source for energy overconsumption under 
free living conditions (214), it is necessary to understand how a positive energy balance from 
all macronutrients impacts the glucoregulatory system. 
1.7.3 Skeletal muscle adaptations to overfeeding 
 
Clearly, exposure to excess energy in the form of carbohydrate and fat has a range of adverse 
effects on a number of glucoregulatory tissues including the liver (10, 11, 209, 219, 220) and 
skeletal muscle (9, 18, 210, 211, 221-224). However, a significant issue in regards to 
quantifying the tissue specific adaptations to overfeeding in humans is the non-accessible 
nature of much of the glucoregulatory system. Considering the relatively easily accessible 
nature of skeletal muscle tissue via biopsies, this provides a somewhat simple, if limited model 
to observe the development of peripheral adaptations to overfeeding. In skeletal muscle the 
increased flux of fuel substrates associated with high fat overfeeding leads to lipid 
accumulation (210, 211, 221-223), generation of reactive oxygen species (9, 18, 222, 224) and 
cellular dysfunction (18, 222, 225), ultimately leading to insulin resistance. However, the exact 
sequence of events leading to and mechanisms by which insulin resistance is developed in 
skeletal muscle are not yet fully elucidated, especially considering that much of the current 
evidence is not within the context of overfeeding, but rather using isoenergetic high fat diet or 
rodent models. 
1.7.3.1 Skeletal muscle triglycerides 
 
A number of factors are thought to contribute to increased skeletal muscle lipid accumulation 
with overfeeding, including increases in fatty acid uptake or impaired fatty acid oxidation due 
to decreased oxidative enzyme activity, where lipid supply exceeds oxidation (22, 222, 225-
227). Similarly, various mechanisms have been put forward to explain the insulin resistance 
developed through lipid accumulation. Evidence suggests that lipid metabolites, including fatty 
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acyl CoAs, diacylglycerols and ceramides antagonise insulin action in skeletal muscle (9, 207, 
221, 223). These various lipid species may activate various protein kinases or inflammatory 
signalling pathways which are thought to impair insulin signal transduction, thus leading to a 
loss of insulin action (9, 228). 
Interventions improving insulin action have also shown reciprocal changes in intramuscular 
triglyceride content (228). For example, studies using calorie restriction to improve muscle 
insulin sensitivity have been accompanied by a reduction in intramuscular triglyceride content 
(228, 229). Although intramuscular triglycerides are generally considered inert in regards to 
insulin resistance (230), the expanded pool of triglycerides has been suggested to be capable 
of generating bioactive lipid metabolism intermediates (228). However, there are also instances 
where increases in bioactive lipid content have not correlated with loss of insulin action, 
leaving this relationship somewhat equivocal (230, 231). Examining skeletal muscle 
triglyceride content in response to overfeeding will provide further clarity in regards to the role 
that lipid accumulation in muscle has on the glucoregulatory system. 
1.7.3.2 Skeletal muscle mitochondrial dysfunction and oxidative stress 
 
An alternative concept of muscle insulin resistance involves mitochondrial dysfunction (18, 
222, 225). The mechanism by which a decrease in mitochondrial number or function is 
proposed to cause insulin resistance is accumulation of intra-myocellular lipids caused by a 
decrease in the capacity to oxidise fat relative to fat accumulation (225). However, other studies 
have shown that mitochondrial dysfunction is not required for insulin resistance in humans 
(232-234). Additionally, increases in skeletal muscle oxidative capacity and decreases in 
glucose tolerance have been seen following a high fat diet, suggesting dissociation between 
mitochondrial dysfunction and insulin resistance (223, 225). Thus, the theory of impaired 
muscle oxidative capacity as a cause of muscle insulin resistance is controversial.   
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Another popular mechanism theorised to be causative in the development of muscle insulin 
resistance is excessive reactive oxygen species (ROS) generation. There is increasing evidence 
showing that ROS generated in the mitochondria can impair insulin signalling, with in vitro 
cell (235), in vivo animal (9, 222, 224), and human overfeeding (18, 222) studies providing 
credence to this hypothesis. For example, in sedentary healthy men and women, urinary F2-
isoprostanes (a marker of whole-body in vivo oxidative stress) were increased after 28 days of 
high fat overfeeding, and skeletal muscle protein carbonyls were increase after both 3 and 28 
days without altering markers of mitochondrial content (18). Importantly, protein carbonyl 
levels were significantly correlated with clamp derived measures of peripheral insulin 
resistance, as assessed at 28 days post overfeeding; with insulin sensitivity measurements at 
earlier time points not being conducted (18). Additionally, Anderson et al. (236) observed an 
association between increased mitochondrial hydrogen peroxide (H2O2) emissions and skeletal 
muscle insulin resistance in response to high fat overfeeding in humans. As discussed 
previously, considering the evidence that peripheral tissues do not appear to develop insulin 
resistance after acute overfeeding (< 7 d)(10, 13, 14, 203, 213), it is possible that an acute 
increase in skeletal muscle oxidative stress is not a large enough stimulus to impair skeletal 
muscle insulin resistance, compared to chronically elevated ROS. Examining markers of ROS 
production in skeletal muscle in response to overfeeding in healthy humans should provide 
further information as to the role that excessive muscle oxidative stress plays in regards to 
insulin action and glucoregulation. 
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1.7.4 Summary and significance 
 
Along with sedentary lifestyles, dietary patterns characterised by an over-abundance of highly 
processed, high calorie foods laden with processed starch, sugar and fat have contributed the 
worldwide epidemic of obesity and T2D (10, 199). Accordingly, numerous research groups 
have attempted to define the metabolic consequences of this lifestyle phenomenon by 
investigating the metabolic changes that accompany periods of controlled overfeeding (10, 13, 
18, 201-203, 209, 237). These previous studies, utilising a range of techniques and study 
designs, have focussed on the effects overfeeding has on glycaemic control, whole body and 
tissue specific insulin action, and the tissue specific molecular changes that take place. 
Interestingly, numerous past overfeeding investigations have assessed glycaemic regulation 
and insulin action under very specific experimental laboratory conditions, such as that achieved 
using the hyperinsulinaemic clamp (10, 13, 18, 201-203, 237). While insightful, such 
experimental conditions do not represent the dynamics of the physiological postprandial state, 
thus leaving a substantial gap in our understanding of the metabolic adaptations to overfeeding. 
Surprisingly, to date, there have been no studies investigating the effects of overfeeding on 
actual postprandial glucose fluxes.   
Furthermore, past studies have typically assessed only the short or long-term effects of 
overfeeding in isolation, thus not including temporal observations relating to postprandial 
glucose metabolism (10, 11, 13, 14, 201-203, 205-208). Additionally, in many of these studies 
the experimental diets provided not only an excess of energy, but also a substantial change to 
macronutrient composition, with a particular focus on the use of a high proportion of fat (13, 
14, 18, 200-202). Thus, it is not yet clear if the observed alterations to glycaemic control and/or 
insulin action are a result of the additional energy, the high fat content of the diets, or a 
combination of both. Finally, understanding the effects of overfeeding on postprandial 
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glycaemic regulation in healthy humans may help to identify the early mechanisms underlying 
chronic disease development, thus potentially uncovering future therapeutic targets.   
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1.8 Overall summary of literature review 
 
Glucose homeostasis is under the control of a complex, integrated system of glucoregulatory 
processes originating in the liver, gut, pancreas and skeletal muscle, and involves the action of 
hormones such as insulin and glucagon. In the fasted state, glycaemic regulation is relatively 
simple to quantify, however during the postprandial period where glucose originates from both 
endogenous and exogenous sources, the resultant non-steady state is characterised by a 
complex integrated regulatory response. Insulin sensitivity, glucose effectiveness, and insulin 
secretion work simultaneously to control systemic glucose and avoid excessive periods of 
hyperglycaemia by altering glucose uptake and production. The integrated assessment of 
postprandial glucose regulation is of significant clinical relevance, firstly as postprandial 
hyperglycaemia is an independent risk factor for many health defects, but also because the 
majority of the day is spent in this period; where typically meals are ingested every few hours, 
before complete assimilation of nutrients from the previous meals has been achieved. 
 
However, considering the non-accessible nature of many glucoregulatory tissues such as the 
liver, pancreas, and gut, determination of an integrated picture of postprandial glucose 
metabolism is difficult. This is especially the case as many common measurement techniques 
involve the utilisation of conditions that are not representative of everyday living conditions. 
The euglycaemic hyperinsulinaemic clamp and IVGTT are vital to our understanding of 
glucose metabolism and insulin sensitivity, allowing researchers to quantify individual 
glucoregulatory parameters by controlling measurement conditions, such as insulin action in 
the absence of stimulating insulin secretion. However, it is important to understand the 
limitations of such techniques that prohibit the determination of the coordinated response of 
the gut, β-cell insulin secretion, and the ability of glucose and insulin to regulate glucose 
turnover in peripheral and hepatic tissues. By implementing tracer techniques in combination 
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with the hyperinsulinaemic clamp or IVGTT, a number of these elements can be 
simultaneously determined. However, considering the non-physiological nature of these 
methods, the overall integrative picture of normal glucose metabolism still cannot be 
determined. 
The use of tracer dilution techniques in combination with normal postprandial conditions, such 
as following a mixed meal, can provide a comprehensive picture of physiological glucose 
turnover in peripheral and hepatic tissues, without bypassing the potent regulatory mechanisms 
of the gut and pancreas, or substantially altering the glucoregulatory system. The constant-
infusion dual tracer technique has been commonly used to assess postprandial glucose flux in 
humans and animals, as it is relatively simple and inexpensive, although it suffers from a 
number of methodological shortfalls such as the inability to accurately determine both glucose 
appearance and production, and therefore disposal. The triple glucose tracer technique was 
therefore developed, and although it is the gold standard for accurately determining 
postprandial glucose flux, has been underutilised, especially in regards to lifestyle 
interventions. 
Considering that T2D is a major health care concern for which pharmaceutical treatment 
provides only moderate management of outcomes, utilising lifestyle modifications including 
diet and exercise can provide remarkable therapeutic control at little cost. Since exercise 
reduces postprandial glycaemic excursions and improves glycaemic control, a better 
understanding of how this occurs could enhance the use of exercise in treating T2D. On the 
other hand, overeating is a significant contributor to the T2D and obesity epidemic and 
understanding how nutrient overload affects postprandial glycaemia will help to identify the 
mechanisms contributing to T2D development.  
It is clear that endurance exercise improves whole-body and peripheral insulin sensitivity, as 
well as insulin-stimulated glucose uptake as determined by studies using the hyperinsulinaemic 
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clamp and IVGTT. However, considering the methodological caveats associated with any 
technique involving intravenous infusion of glucose and/or insulin into the peripheral 
circulation, it is important to understand that little is actually known in regards to endurance 
exercise on physiological postprandial glucose flux. Additionally, while it is clear in both 
rodent and human models that overfeeding induces whole-body insulin resistance, there is also 
some limited evidence that the temporal pattern of this development occurs initially in hepatic 
tissues, before induction of peripheral insulin resistance. However, this relationship is still 
relatively unclear in humans, and importantly, the effect of overfeeding on physiological 
postprandial glucose flux has, as far as can be determined, never been examined. Therefore, to 
improve our understanding of exercise and overfeeding effects in free-living humans, there 
needs to be studies employed in which the techniques utilized can assess physiological 
postprandial glycaemia under conditions that are representative of subjects’ natural 
environments. Importantly, postprandial glycaemic excursions better predict a number of 
health outcomes than do static measures, and are highly representative of the state in which the 
majority of people spend their day, and as such should be central in the assessment of glycaemic 
control. 
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1.9 Overall aims 
 
The overall aim of this thesis was to determine the physiological mechanisms by which glucose 
metabolism is altered by both endurance exercise (Study 2) and mixed nutrient overfeeding 
(Study 3) in healthy young men. To accomplish these aims, Studies 2 and 3 involved the 
simultaneous determination of postprandial glycaemia and insulinaemia, insulin sensitivity, β-
cell function, as well as glucose flux, under physiologically representative conditions of a 
mixed meal, by utilising a triple stable isotope glucose tracer approach.  
Importantly, the vast majority of our understanding of how lifestyle interventions impact 
glucose metabolism is based on research that does not represent normal, dynamic living 
conditions following a mixed meal, but rather during non-physiological techniques such as the 
clamp or IVGTT. This is important as most people spend the majority of their waking hours in 
the postprandial state (2, 45) and the triple tracer technique has, as far as can be determined, 
never previously been used during endurance training or overfeeding interventions; and only 
once previously during any lifestyle intervention (65). 
Therefore, the aim of study 1 was to determine the optimal rates of infusion of intravenous 
stable-isotope glucose tracers in order to minimise changes to postprandial tracer-to-tracee 
ratios, achieving as close to isotopic steady state as possible in healthy, young men; allowing 
for determination of postprandial glucose fluxes following a mixed meal for use in subsequent 
studies of this thesis. 
The aim of study 2 was to determine the effect of acute and chronic endurance exercise on 
glucose flux (EGP, Rd and meal Ra), simultaneously with β-cell function, glucose clearance, 
insulin sensitivity and glucose tolerance during a physiologically representative mixed meal in 
healthy young men. 
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The aim of study 3 was to determine the effect of 5 days and 4 weeks of 50% overfeeding at a 
regular macronutrient composition on the temporal development of changes to glucose flux 
(EGP, Rd and meal Ra), simultaneously with, glucose clearance, insulin sensitivity and glucose 
tolerance during a physiologically representative mixed meal in healthy young men. The 
secondary aim was to determine the effect of overfeeding on skeletal muscle oxidative stress 
and energy substrates. 
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2.0 Chapter 2: Study 1 - Optimisation of tracer infusion  
 
The variable infusion triple tracer method utilises two intravenously infused tracers together 
with an orally ingested tracer in order to simultaneously obtain accurate measurement of EGP, 
meal Ra and glucose Rd. Importantly, non-steady state theory suggests that the accuracy of the 
estimation of glucose appearance can be enhanced if the tracer is infused during the non-steady 
state in such a way as to reduce the changes in the tracer-to-tracee ratio (238). Therefore, the 
triple-tracer method uses the tracer-to-tracee ratio clamp to minimise changes in both meal and 
endogenous glucose tracer-tracee ratios following glucose ingestion (64).  
The purpose of this approach is to smooth the pattern of the isotopic enrichments, thus 
increasing the accuracy of the modelling of glucose kinetics by decreasing the non-steady state 
correction proposed by Steele et al. (122) to a negligible number, thus allowing model-
independent quantification of glucose flux. This is achieved by infusing the first intravenous 
tracer in a pattern which is anticipated to match endogenous glucose, while the second 
intravenous tracer is infused in such a pattern as to mimic the appearance of the meal tracer 
into the circulation. Measurement of meal appearance as well as postprandial EGP suppression 
is more accurate as a result of these minimised tracer-to-tracee ratios and this increased 
accuracy propagates into the calculation of Rd, which is based off mass balance principles.  
Clearly obtaining infusion rates that perfectly match the rates of glucose flux is both impossible 
and redundant, as if it was possible to possess such exact knowledge, measurement would not 
be required. However, by using a priori knowledge about the behaviour of glucose fluxes 
during the non-steady state, a tentative format of tracer administration, or ‘estimate’, can be 
designed and confirmed following pilot studies. This occurs whereby the initial ‘estimate’ (i.e. 
tracer infusion profiles that are anticipated to mimic postprandial changes in meal Ra and EGP) 
used during an experiment are later verified by measuring the tracer-to-tracee ratios and if they 
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are not constant, the format of tracer administration in the subsequent experiment is refined, 
and repeated until a satisfactory result is obtained. Previous investigators have demonstrated 
that the dual-tracer technique often results in 6 to 10-fold variation in tracer-to-tracee ratios, 
whereas using the triple tracer technique (following a few pilot trials) this variation can be 
reduced to approximately 2-fold.  
A significant difficulty in regards to determining the initial estimate to begin this approach is 
that very few studies utilising the triple tracer technique have published their infusion protocol 
(68, 239). Additionally, it is particularly difficult to determine the Ra of the ingested tracer, as 
it is influenced by multiple factors including the rate of gastric emptying, the rate of glucose 
absorption, and the rate of hepatic glucose uptake; processes which are high in individual 
variability. Despite this, previous investigators have indicated that variability between 
participants is sufficiently consistent, such that only a few iterations (3-5 subjects) are adequate 
in order to obtain acceptable tracer-to-tracee ratios (64, 68). Toffolo et al. (67) noted that a 
change in tracer-to-tracee ratio of less than 2-fold throughout the triple tracer protocol resulted 
in significantly more accurate data compared to the constant infusion dual-tracer technique, 
during which tracer-to-tracee ratios can vary as much as 5- to 10-fold within the first hour of 
the postprandial period.  
Thus, the aim of study 1 was to determine the optimal rates of infusion of intravenous stable-
isotope glucose tracers in order to minimise changes to postprandial tracer-to-tracee ratios, 
achieving as close to isotopic steady state as possible in healthy, young men and minimise 
point-to-point changes. This allowed for the accurate determination of postprandial glucose 
fluxes following a mixed meal, to be utilised in the subsequent studies.   
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2.1 Methods 
2.1.1 Ethics 
 
This study was conducted according to the Declaration of Helsinki, all subjects provided 
written informed consent after screening via medical questionnaire and all procedure were 
approved by the Deakin University Human Research Ethics Committee (ethics number 2014-
059). 
2.1.2 Participants 
 
Four, young healthy men participated in the study. Exclusion criteria included those with 
diabetes, smoking and body mass index (BMI) > 30kg.m-2, or those currently diagnosed with, 
or with a family history of diabetes. 
2.1.3 Preliminary testing 
 
Initially, a single participant underwent a meal tolerance test which involved consuming 
glucose (1.2g/kg) that was set in jelly and contained 4% of total glucose as [6,6 - 2H] glucose. 
This allowed the determination of load (meal) and endogenous glucose concentrations in 
plasma, thereby providing a baseline, along with previous literature, to verify the initial 
intravenous tracer infusion protocols used in the subsequent pilot trial (Refer to Figure 2.1). 
Load glucose was calculated via the plasma enrichment of [6,6 - 2H] glucose within the meal 
(plasma [6,6 - 2H] glucose enrichment x meal [6,6 - 2H] glucose enrichment /1). The plasma 
concentration of endogenously produced glucose was calculated by subtracting the 
concentration of exogenously derived glucose from total plasma glucose concentration. 
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Figure 2.1  – Isotopic enrichment of [6,6-2H] glucose (m/z ratio 303, M+2) (A), plasma 
concentrations of load (meal) versus endogenous glucose (B) in plasma samples obtained 
during a mixed meal tolerance test containing glucose jelly labelled with [6,6 -2H] glucose at 
4% enrichment. N = 1. 
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Participants ingested a mixed meal (41.84kj/kg, 45% carbohydrate, 20% protein, and 35% fat) 
consisting of eggs, cheese and 1.2 g.kg-1 glucose in sugar-free Jell-O (Aeroplane Jelly, Victoria, 
Australia) as the only carbohydrate source, as seen in Figure 2.1. The glucose was dissolved in 
200 ml water and contained [6,6 – 2H] glucose at an enrichment of 4% w/v. Briefly, to prepare 
the Jell-O, 1.2 g.kg-1 body weight glucose was dissolved in 200 ml water by gentle heating. 
After cooling to room temperature, sufficient [6,6 - 2H] glucose to achieve an enrichment of 
~4% and 4.5g flavoured sugar-free gelatin (Aeroplane Jelly, Victoria, Australia) were added. 
After thorough mixing, an aliquot was obtained for enrichment analysis of [6,6 - 2H] glucose 
by gas chromatography-mass spectrometry (GC/MS). The mixture was then allowed to solidify 
overnight in the refrigerator. The meal was consumed by participants within 10 minutes. The 
receptacle containing the Jell-O was rinsed twice with ~20ml of water, with the resulting 
solution ingested. 
 
Figure 2.2: Mixed meal containing eggs, cheese and isotope labelled glucose jelly (1.2g of 
glucose per kg of body weight with 4% enrichment of [6,6-2H] glucose). 
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2.1.4 Triple tracer technique 
 
Participants arrived at the clinical research facility at Deakin University in Melbourne at 0700 
in the overnight (10 h) fasted state, having refrained from exercise and alcohol consumption 
for 48 h. Participants were provided with a standard meal (765kcal, 70% carbohydrate, 15% 
fat, 15% protein) to consume as the final meal on the day prior to each trial, to ensure that 
muscle glycogen levels were relatively uniform within each subject. A 22-gauge cannula was 
inserted into a forearm vein of each arm for tracer infusions and venous blood sampling, 
respectively. Microbiological and pyrogen tested stable isotopes; [1-13C] glucose; [6,6-2H] 
glucose; and [U-13C] glucose were purchased from Cambridge Isotope Laboratories, (Andover, 
MA, USA) and tested for sterility before use in subjects (Bacterial Monitoring Services, SA, 
Australia). 
Experimental trials occurred as previously described in detail (64, 68) with some modifications. 
A primed-continuous intravenous infusion of [1-13C] glucose was initiated and continued until 
the end of the study. Priming consisted of a bolus of 12 mg.kg-1 infused over 5 min and was 
followed by a constant infusion (0.12 mg.kg.min-1) for the following 150 min. Blood samples 
were taken during the equilibration period at designated time points; -150 (immediately before 
infusion), -60, -30, -20, -10 and 0 min. All basal and postprandial blood samples were 
immediately spun in a centrifuge at 3000g for 15 min at 4°C and plasma was stored at -80°C 
until analysis. 
At designated time point 0min, subjects ingested the mixed meal (Figure 2.2). At 0 min (i.e. 
with the first bite), the infusion of [1-13C] glucose was altered in a pattern so as to approximate 
the anticipated fall in EGP and at the same time, an infusion of [U-13C] glucose was started 
(0.05 mg.kg.min-1) and the rate varied to mimic the anticipated appearance of [6,6-2H] glucose 
from the meal. Blood samples were taken at designated postprandial time points 10, 20, 30, 40, 
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50, 70, 90, 120, 150, 180, 210, and 270 min. The total duration of the experimental trial was 7 
h, with 4.5 h in the postprandial period. 
The infusion patterns used by Elleri et al. (239) and Toffolo et al. (68) were used as a starting 
point for the intravenous infusion patterns used in the pilot trial, with some minor adjustments. 
Elleri et al. (239) utilised a population with type 1 diabetes and Toffolo et al. (68) utilised an 
adolescent population, however they were the only studies utilising the triple tracer technique 
to publish their infusion patterns. Thus, the a priori knowledge of the behaviour of endogenous 
and meal glucose obtained during preliminary testing was used to verify the validity of these 
infusion patterns and the infusion rates (as a percentage of basal infusion rate) used in the initial 
pilot trial (n=1) were as follows (Refer to Table 2.1 and Figure 2.3A and B). 
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Table 2.1: Initial intravenous infusion patterns utilised during the initial pilot trial participant. 
 [1-13C] glucose rate of infusion 
(0.12mg.kg-1min-1) 
[U-13C] glucose rate of infusion 
(0.05mg.kg-1min-1) 
-155 to -150min 12mg/kg/min bolus N/A 
-150-0min 100% N/A 
0-10min 70% 25% 
10-20min 60% 100% 
20-30min 50% 100% 
30-70min 35% 65% 
70-120min 35% 50% 
120-150min 35% 35% 
150-210min 35% 25% 
210-270min 50% 20% 
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Figure 2.3: The proposed infusion patterns of intravenously infused tracers; [1-13C] glucose 
versus the absolute concentration of endogenous glucose in plasma during preliminary testing 
(A), and the proposed infusion pattern of [U-13C] glucose versus the absolute concentration of 
load glucose in plasma during preliminary testing (B). N=1. 
 
  
94 
  
2.1.5 Analysis of total glucose and glucose tracer enrichment 
 
Plasma obtained from lithium-heparin containing tubes was used to determine plasma glucose 
concentration at each time point by the glucose oxidase method.  
Enrichment of all tracers in plasma samples and the labelled meal were assessed using electron-
ionisation GC/MS. Preparation of di-O-isopropylidene derivative was undertaken as described 
by Antoniewicz et al. (240). In brief, 30 μl of plasma was mixed with 300 μl of ice-cold 
methanol and centrifuged for 5 min. 300 μl of supernatant was removed for di-O-
isopropylidene propionate derivatisation and evaporated to dryness under vacuum at 40°C 
using a centrifugal evaporator. Evaporated glucose samples were dissolved in 500 μl of 0.38M 
sulphuric acid in acetone and incubated at room temperature for 60 min. 400 μL of 0.44 M 
sodium carbonate was added to neutralise the reaction, followed by addition of 1 mL of 
saturated sodium chloride. The di-O-isopropylidene derivatives were extracted by partitioning 
with 1 mL of ethyl acetate. One mL of the upper, organic layer was removed and evaporated 
to dryness under a gentle stream of nitrogen. 100 μL of propionic anhydride was added and 
incubated at 60°C for 30 min. 
Samples were injected using a 1:10 split ratio onto a VF-5 capillary column with 10 m inert 
EZ-guard; 5 % Phenyl Methyl Siloxane (30.0 m x 250 μm x 0.25 μm; Agilent technologies, 
Santa Clara, CA, USA) connected to an Agilent 6890 Gas Chromatograph. Target compounds 
were detected via an Agilent 5975 Mass Spectrometer. The GC program consisted of a 25 
°C/min ramp starting at 100 °C. A final temperature of 320 °C was then held for two minutes. 
Helium was used as the carrier gas with a flow rate of 1.1 ml.min-1.  
The MS was operated in the selected ion monitoring mode measuring the molecular ion at mass 
to charge ratios (m/z) 301, 302, 303, 304, 305, 306 and 307, for natural (301, M+0), [1-13C] 
(302, M+1), [6,6-2H] (303, M+2), and [U-13C] (307, M+6) glucose. The ion abundances were 
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determined using the Mass Hunter Workstation (Agilent Technologies, Santa Clara, CA, 
USA). The raw isotopomer data were corrected for natural isotopic background skew using the 
matrix method (241). 
2.1.6 Calculations 
Triple tracer technique 
Glucose fluxes (meal Ra, Rd and EGP) were calculated using Steele’s non-steady state model 
(119) according to previous guidelines (64, 68, 86).  
Briefly, the plasma enrichment of [6,6 - 2H] glucose was used to determine the plasma 
concentration of exogenously derived glucose (plasma [6,6 - 2H] glucose enrichment x meal 
[6,6 - 2H] glucose enrichment /1). The plasma concentration of endogenously produced glucose 
was calculated by subtracting the concentration of exogenously derived glucose from total 
plasma glucose concentration. 
The systemically infused [U-13C] glucose was used to trace the systemic rate of appearance of 
[6,6 - 2H] glucose contained in the meal, whereas [1-13C] glucose was used to trace the rate of 
appearance of endogenously produced glucose. The ratio of plasma concentration of [U-13C] 
glucose to [6,6 - 2H] glucose [tracer-to-tracee ratio, TTR(t)] was used to calculate the rate of 
appearance of ingested [6,6 - 2H] glucose using a single-compartment model (119).   
𝑅𝑎2ℎ2 = [
𝐼𝑁𝐹𝑈−13𝐶(𝑡)
𝑇𝑇𝑅(𝑡)
] − [𝑝. 𝑉.
𝐺2ℎ2(𝑡)
𝑇𝑇𝑅(𝑡)
] ×
𝑑𝑇𝑇𝑅(𝑡)
𝑑(𝑡)
 
where INFU-13C is the infusion rate of [U-13C] glucose, G2h2 is the plasma concentration of [6,6 
- 2H] glucose, V is the volume of distribution, and p is the pool fraction, fixed to 200 ml/kg and 
0.65, respectively, according to previous studies (64). 
The total rate of appearance can be thus calculated as: 
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𝑅𝑎𝑚𝑒𝑎𝑙(𝑡) =  𝑅𝑎2ℎ2(𝑡) × [1 + (
1
𝑇𝑇𝑅𝑚𝑒𝑎𝑙
)] 
where TTRmeal is the ratio of [6,6 - 2H] glucose and unlabeled glucose in the meal. 
Similarly, the ratio of plasma concentration of [1-13C] glucose to endogenously produced 
glucose (tracer-to-tracee ratio, TTR) was used to calculate EGP: 
𝐸𝐺𝑃(𝑡) = [
𝐼𝑁𝐹1−13𝐶(𝑡)
𝑇𝑇𝑅(𝑡)
] − [𝑝. 𝑉.
𝐺𝑒𝑛𝑑(𝑡)
𝑇𝑇𝑅(𝑡)
] ×
𝑑𝑇𝑇𝑅(𝑡)
𝑑(𝑡)
 
 
where INF1-13C is the infusion rate of [1-13C] glucose, Gend is the plasma concentration of 
endogenous glucose [calculated by subtracting the concentration of exogenously derived 
(ingested) glucose (i.e., plasma [6,6 - 2H] glucose concentration multiplied by TTRmeal [6,6 - 
2H] glucose enrichment) from total plasma glucose concentration], V is the volume of 
distribution, and p is the pool fraction, fixed to 200 ml/kg and 0.65, respectively. 
Glucose Rd can then be calculated as: 
𝑅𝑑(𝑡) =  𝑅𝑎𝑚𝑒𝑎𝑙(𝑡) + 𝐸𝐺𝑃(𝑡) − 𝑝. 𝑉. [
𝑑𝐺(𝑡)
𝑑(𝑡)
] (86). 
Dual tracer technique 
In the current experiment, the infusion rate of [1-13C] glucose was varied in a pattern that 
approximated the anticipated pattern of change of EGP, which minimized the change in the 
ratio of [1-13C] glucose to endogenous glucose in order to accurately calculate EGP. However, 
in regards to the dual tracer method which utilizes the ratio of the plasma [1-13C] glucose to 
total glucose in order to calculate total glucose appearance, this pattern of infusion will 
accentuate this change, and the ratio of plasma [1-13C] glucose to [6,6-2H]glucose (used to 
calculate meal appearance with the dual-tracer method). The following analysis can therefore 
97 
  
be described as a worst-case dual-tracer method, as explained by Basu et al. (REF), and will be 
utilized to demonstrate the increased accuracy of the triple tracer technique.  
In regards to the dual-tracer calculations, Ra of the 6,6-2h tracer in the meal was calculated 
using the  equation similar to the triple tracer method, although [U-13C] is replaced with [1-
13c].  
𝑅𝑎2ℎ2 = [
𝐼𝑁𝐹1−13𝐶(𝑡)
𝑇𝑇𝑅(𝑡)
] − [𝑝. 𝑉.
𝐺2ℎ2(𝑡)
𝑇𝑇𝑅(𝑡)
] ×
𝑑𝑇𝑇𝑅(𝑡)
𝑑(𝑡)
 
where INF1-13C is the infusion rate of [1-13C] glucose, G2h2 is the plasma concentration of [6,6 
- 2H] glucose, V is the volume of distribution, and p is the pool fraction, fixed to 200 ml/kg and 
0.65, respectively, according to previous studies (64). 
Meal Ra was calculated as for the triple-tracer method, utilizing the new value for Ra2h2. The 
total Ra for glucose was calculated as for EGP in the triple tracer method, substituting total 
glucose in place of endogenous glucose.  
𝑇𝑜𝑡𝑎𝑙 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑅𝑎(𝑡) = [
𝐼𝑁𝐹1−13𝐶(𝑡)
𝑇𝑇𝑅(𝑡)
] − [𝑝. 𝑉.
𝐺𝑡𝑜𝑡𝑎𝑙(𝑡)
𝑇𝑇𝑅(𝑡)
] ×
𝑑𝑇𝑇𝑅(𝑡)
𝑑(𝑡)
 
EGP was then calculated by subtracting both meal Ra and the infusion rate of [6,6-2H] glucose 
from total Ra. Rd was calculated via mass-balance equations as described above. 
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2.2 Results 
 
2.2.1 Experimental trial 1 
 
Tracer-to-tracee ratios for the first participant who underwent the triple tracer study can be seen 
in Figure 2.4. The greatest difference in the ratio of [1-13C] glucose to endogenous glucose was 
2.63-fold (90 versus 210 min), while the greatest point-to-point difference was 43% (70 versus 
90 min; See Figure 2.4A). The greatest difference in the ratio of [U-13C] glucose to ingested 
[6,6-2H] glucose was 3.09-fold (120 versus 270 min), while the greatest point-to-point 
difference was 52% (120 versus 150 min; See Figure 2.4B). As demonstrated in Figure 2.4E, 
utilizing the worst-case dual tracer technique, the pattern of change of postprandial EGP was 
well-recovered throughout the postprandial period with the dual-tracer compared to the triple-
tracer approach. However, as demonstrated in Figure 2.4C and D, meal Ra and Rd, were 
considerably underestimated by approximately 67 and 55%, respectively, and the pattern of Rd 
demonstrated paradoxical negative values. 
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Figure 2.4: Tracer-to-tracee ratio for [1-13C] glucose (M + 1 ion) to endogenous glucose (A) and [U-
13C] glucose (M + 6 ion) to [6,6-2H] glucose (M + 2 ion), during a 4.5h meal tolerance test in 
experimental trial 1 (B). Glucose Rd (C), meal Ra (D) and EGP € as determined by either triple tracer 
calculation or the worst-case dual tracer calculations. N=1. 
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Following pilot trial 1 the pattern of infusion remained the same, however the basal infusion 
rate of both IV tracers was altered. Briefly, the basal infusion rate of [U-13C] glucose was 
doubled (2mg/kg/min) in order to ensure that it could be appropriately quantified and the 
infusion rate of [1-13C] glucose was halved (6mg/kg prime, 0.06mg/kg/min continuous) to both 
conserve the tracer and minimise its metabolic impact. As the sensitivity of our analytical 
techniques was more than adequate to accurately quantify the tracer enrichment of [1-13C] 
glucose, the basal infusion rate was decreased by 2-fold in order to both minimise the overall 
use of the tracer and importantly to minimise the metabolic impact of the infused tracer. The 
basic premise of tracer research is that the labelled isotope experiences the same metabolic fate 
as the tracee without altering its metabolism, and as such the ideal tracer must be detected with 
such precision as to require administration in trace amounts, thereby causing no quantifiable 
alteration to the system. In Figure 2.5B it can be seen that the integrity of the M+1 ion peak 
(302 m/z) obtained via mass spectrometry are maintained despite the lower infusion rate, 
allowing the accurate quantification of tracer abundance despite minimising the chances of the 
infused tracer altering normal glucose metabolism. Additionally, the [U-13C]-glucose tracer 
could potentially generate M+1, M+2 and M+3 isotopomers via gluconeogenesis, in addition 
to the M+6 isotopomer which could potentially impact the M+1 and M+2 isotopomers derived 
from the [6,6 - 2H] glucose and [1-13C] glucose tracers. The low basal infusion rate of [U-13C] 
glucose used in the first iteration of the pilot trial was chosen to minimise this possibility. 
However, as the plasma enrichment of [U-13C] was in the lower range of sensitivity of our 
analytical techniques, and so the basal infusion rate of [U-13C] glucose was doubled in order to 
ensure the accuracy of quantifying the tracer enrichment. In Figure 2.5B it can be seen that the 
quality of the M+6 ion peak (307 m/z) obtained via mass spectrometry is easily quantifiable, 
thus allowing accurate determination of tracer abundance. 
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Figure 2.5: Total and ion abundance of glucose in plasma determined via electron-ionising 
GC/MS, as obtained during the pilot trials. 
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2.2.2 Experimental trial 2 and 3 
 
Tracer-to-tracee ratios for the second and third pilot trial participants can be seen in Figure 2.6. 
The greatest difference in the ratio of [1-13C] glucose to endogenous glucose was 2.4- and 3.1-
fold (See Figure 2.6A and B), while the greatest point-to-point difference was 64 and 50%, 
respectively. The greatest difference in the ratio of [U-13C] glucose to ingested [6,6-2H] glucose 
was 2- and 3.6-fold (See Figure 2.6C and D), while the greatest point-to-point difference was 
33 and 42%, respectively.  
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Figure 2.6: Tracer-to-tracee ratio for (A; C) [1-13C] glucose to endogenous glucose and (B; D) [U-13C] 
glucose to [6,6-2H] glucose, during a 4.5h meal tolerance test in participant 2 (A; B, n=1) and participant 
3 (C; D, n=1). 
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Experimental trials 1-3 demonstrated a trend for the ratio of [1-13C] glucose to endogenous 
glucose to decline after approximately 120 minutes, while the ratio of [U-13C] glucose to [6,6 
- 2H] glucose increase after approximately 120 minutes (Figure 2.7). Therefore the fourth and 
final pilot trial involved minor changes to the infusion patterns of both IV tracers.  
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Figure 2.7: Average tracer-to-tracee ratios for (A) [1-13C] glucose to endogenous glucose and (B) [U-
13C] glucose to [6,6-2H] glucose, during a 4.5h meal tolerance test for participants 1, 2 and 3 (n=3). 
 
The infusion rate of [U-13C] glucose was decreased from 180-270 minutes in order to minimise 
the increase in tracer-to-tracee ratio. The infusion rate of [1-13C] glucose was increased earlier 
in the trial in order to minimise the decrease in tracer-to-tracee ratio. The modified infusion 
rates were as follows (Refer to Table 2.2). 
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Table 2.2: The final intravenous infusion patterns utilised during the last pilot trial participant. 
 [1-13C] glucose rate of infusion 
(0.06mg.kg-1min-1) 
[U-13C] glucose rate of infusion 
(0.1mg.kg-1min-1) 
-155 to -150min 6mg/kg/min bolus N/A 
-150-0min 100% N/A 
0-10min 70% 25% 
10-20min 60% 100% 
20-30min 50% 100% 
30-70min 35% 65% 
70-120min 35% 55% 
120-150min 35% 35% 
150-180min 35% 25% 
180-210min 40% 20% 
210-270min 50% 10% 
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2.2.3 Experimental trial 4 
 
Tracer-to-tracee ratios for the final pilot trial participant can be seen in Figure 2.8. The greatest 
difference in the ratio of [1-13C] glucose to endogenous glucose was 1.8-fold, while the greatest 
point-to-point difference was 32% (Figure 2.8A). The greatest difference in the ratio of [U-
13C] glucose to ingested [6,6-2H] glucose was 1.7-fold, while the greatest point-to-point 
difference was 68% (Figure 2.8B).  
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Figure 2.8: Tracer-to-tracee ratio for (A) [1-13C] glucose to endogenous glucose and (B) [U-13C] glucose 
to [6,6-2H] glucose, during a 4.5h meal tolerance test in experimental trial 4. 
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2.2.4 Summary 
 
The average tracer-to-tracee ratio for all pilot trials (A; B) and all subsequent baseline (pre-
intervention) experimental trials for studies 2 and 3 (C; D) can be seen in Figure 2.9. 
The greatest difference in the average ratio of [1-13C] glucose to endogenous glucose during 
the pilot trials was 1.8-fold, while the greatest point-to-point difference was 32% (Figure 2.9A). 
The greatest difference in the average ratio of [U-13C] glucose to ingested [6,6-2H] glucose 
during the pilot trials was 2-fold, while the greatest point-to-point difference was 32% (Figure 
2.9B).  
The greatest difference in the average ratio of [1-13C] glucose to endogenous glucose during 
the baseline experimental trials was 1.5-fold, while the greatest point-to-point difference was 
8% (Figure 2.9C). The greatest difference in the average ratio of [U-13C] glucose to ingested 
[6,6-2H] glucose during the baseline experimental was 1.9-fold, while the greatest point-to-
point difference was 22% (Figure 2.9D).  
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Figure 2.9: Average tracer-to-tracee ratios for pilot trial (A and B) and for all baseline trials in all 3 
studies (C and D). Individual results are shown (grey circles) to highlight the large individual variability 
in results. 
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2.3 Discussion 
 
These findings show that the obtained tracer-to-tracee ratios for the intravenously infused 
tracers were successfully optimised within a range of 2-fold during the triple tracer technique 
as demonstrated in previous triple tracer literature, despite large individual variability. 
Additionally, point to point changes in the tracer-to-tracee ratios during the studies were small, 
such that changes tracer-to-tracee ratio within the first 70 minutes of the postprandial period 
never exceeded 100%, whereas with the worst-case dual tracer technique there was a rapid fall 
in tracer-to-tracee ratio within the initial hour. 
Few studies utilizing triple tracer methodologies cite their infusion patterns (68, 239), and of 
those that do, many utilize participants with metabolic abnormalities such as diabetes which 
likely significantly influence patterns of glucose flux, notwithstanding any normal population 
variance. However, the final infusion pattern utilized in the current study has significant 
similarities to that utilized by Toffolo et al. in healthy adolescents (67). Additionally, the 
calculated flux measurements demonstrated similar time to peak, peak and average values for 
EGP, meal Ra and Rd as previously demonstrated (64, 68). Finally, the calculated values for 
glucose fluxes as determined via the ‘worst case’ dual tracer technique were substantially 
underestimated by 50-65% as compared to triple tracer values. 
As suggested above, and by previous researchers, the dual-tracer technique is sufficient to 
quantify meal Ra or EGP, but not both simultaneously (3, 62). As such, the current calculations 
utilizing the ‘worst-case’ dual-tracer method (64) were able to fairly accurately recover rates 
of EGP, while on average meal Ra, and therefore Rd, were underestimated by approximately 
64 and 53% throughout the pilot trial. This occurs as more pronounced variations are obtained 
when the [6,6-2H] glucose was used to trace the Ra of both unlabelled glucose and [1-13C] 
glucose. The rate of infusion of [6,6-2H] glucose was varied as part of the triple-tracer protocol. 
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Because this created even more marked changes in the tracer to tracee ratios, it is referred to as 
a worst-case scenario for the dual-tracer approach.  
Although the final tracer-to-tracee ratios obtained via the pilot trial are not completely steady, 
previous literature (86) suggests that maintaining perfectly stable tracer-to-tracee ratios 
impossible, unless exact knowledge of the tracee pattern was already known; thus nullifying 
the need to undertake the measurement. Additionally, considering that point to point changes 
during the studies were small, during a given time interval of this magnitude (i.e. 4.5 hrs), these 
changes would introduce minimal errors into the calculation of glucose turnover (67). Previous 
literature, both theoretical (131, 238) and experimental (242, 243), has demonstrated that small 
fluctuations in tracer-to-tracee ratios have little effect on the accuracy of this determination. 
For example, Finegood et al. (242) established that the fall in plasma glucose tracer-to-tracee 
ratio (~4 fold over 20min) that occurred during the start of a clamp when unlabelled glucose 
was infused resulted in a marked errors in calculation, generating biologically implausible 
“negative” rates of EGP. However, this error was resolved after the first 2 h when plasma 
glucose specific activity again approached steady state. Furthermore, this error also did not 
occur if the infused glucose contained the tracer in amounts that approximated what was 
present in plasma before the start of the clamp, and therefore did not perturb plasma glucose 
tracer-to-tracee ratios, resulting in small point-to-point changes (242).  
When tracer-to-tracee ratios rapidly decrease 5- to 10-fold within the initial hour of the 
postprandial period (such as during a constant-infusion dual tracer technique), this leads to 
paradoxical patterns of EGP and inaccurate calculation of Ra and Rd. As demonstrated in the 
current study, utilizing the worst-case dual tracer technique, the degree of meal Ra and Rd were 
considerably underestimated and Rd showed paradoxical negative values. However, by 
utilizing the triple tracer technique and minimizing these changes to less than 2-fold over the 
course of the postprandial period, with small point-to-point changes, is almost completely able 
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to minimise these errors (67). This was also demonstrated by Toffolo et al. (67), whereby meal 
Ra, EGP, and Rd were essentially the same when glucose turnover measured with the triple-
tracer method was calculated using either Steele’s one-compartment or Radziuk’s two-
compartment model. Therefore, the infusion pattern used for the final pilot trial participant, in 
which overall tracer-to-tracee ratios and point-to-point differences were minimal, was 
subsequently used in all following trials. 
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3.0 Chapter 3: Study 2 - Measurement of postprandial glucose fluxes 
in response to acute and chronic endurance exercise in healthy 
humans. 
 
A cornerstone of public health promotion is encouraging people to participate in regular 
exercise, as it has been widely established that exercise confers numerous health benefits (8). 
In relation to glucose metabolism, beneficial effects of endurance exercise in both healthy 
populations and those that are metabolically compromised, as in obesity and T2D, includes 
enhancement to tissue insulin sensitivity (21, 22, 24, 166, 168); a benefit that is seen even after 
a single acute bout of endurance exercise and lasts for 24 to 48 hours (244). Although 
enhancement of insulin’s actions in regards to the suppression of EGP have been demonstrated 
across numerous studies (15, 175, 176), it is generally accepted that the enhancement of insulin-
stimulated peripheral (muscle) glucose uptake represents the principal and most quantitatively 
important effect of endurance exercise on the glucoregulatory system (12, 168, 174, 175, 178).  
It is important to highlight however, that for exercise to have any meaningful effects on 
glucoregulation and diabetes prevention, improvements in fasting or postprandial glycaemia 
and insulinaemia should occur. For example, in a normoglycaemic person, if insulin sensitivity 
is enhanced via exercise, then reductions in fasting and/or postprandial insulin secretion should 
be evident, resulting in lower circulating insulin concentrations. This in-turn should ease the 
workload of the β-cell while also simultaneously minimising the body’s exposure to 
hyperinsulinaemia, which is known to have detrimental effects even when occurring in the 
absence of concomitant hyperglycaemia (177, 245).   
However, much of the existing literature examining the effects of exercise on the 
glucoregulatory systems have used techniques that are not representative of normal living 
conditions such as the euglycaemic-hyperinsulinaemic clamp (21, 168, 174) or the IVGTT (22, 
24) to derive primary outcome measures. Although valuable, these techniques do not mimic 
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the physiological responses that occur following meal glucose (sugar or starch) ingestion (4). 
Furthermore, any techniques that involves the administration of glucose and/or insulin into a 
peripheral blood vessel (non-hepatic portal route), as in a clamp or IVGTT, bias the stimulation 
of glucose uptake away from the liver and towards peripheral sites such as the muscle (4, 6, 7). 
Under true postprandial conditions, the gut and subsequent hepatic portal vein route of glucose 
entry provides a much larger stimulus for hepatic glucose uptake, such that the liver is 
responsible for between 25-30% of whole body glucose disposal (6, 7, 246, 247). Under 
physiological postprandial conditions the systemic glycaemic response is governed by the 
interaction between the rate of glucose appearance into the circulation from the gut (meal Ra), 
the suppression of EGP and the stimulation of Rd (3). Furthermore, the ability to suppress EGP 
and stimulate glucose Rd following a meal is further determined by a balance of three more 
complex and interacting factors; β-cell insulin secretion, tissue insulin sensitivity and glucose 
effectiveness (4). It is only under true physiological conditions, such as when glucose is 
ingested, do all these regulatory factors come into play.  
Here, the aim was to extend knowledge beyond the clamp or IVGTT to examine what impact 
exercise has on glucose fluxes in young healthy sedentary adults under physiologically relevant 
postprandial conditions. Accordingly, the mixed meal tolerance test combined with the variable 
infusion triple-stable isotope glucose tracer approach (i.e. tracer clamp approach (64, 86)) was 
utilised, thus permitting accurate determination of meal Ra, EGP, Rd. Furthermore, a secondary 
aim was to assess the effects of not only a single exercise bout, but also the effects of exercise 
training. Specifically, as a number of studies have demonstrated no additional benefit of 
endurance training above a single acute exercise bout for improving glucose metabolism when 
controlling for the residual effects of acute exercise (19, 172, 195), glucose fluxes were 
examined ~24 hours following an acute bout of endurance exercise and again ~24 hours after 
four weeks of additional endurance training.  
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3.1 Methods 
 
3.1.1 Ethics 
 
This study was conducted according to the Declaration of Helsinki, all subjects provided 
written informed consent after screening via medical questionnaire and all procedure were 
approved by the Deakin University Human Research Ethics Committee (ethics number 2014-
059). 
3.1.2 Participants 
 
Ten healthy men participated in the study (Table 3.1). Exclusion criteria included structured 
endurance training >90min/wk, body mass index (BMI) >30 kg.m-2, or those currently 
diagnosed with, or with a family history of diabetes.  
3.1.3 Preliminary testing 
 
Maximum pulmonary oxygen consumption (VO2max) was determined via graded exercise test 
to volitional exhaustion on an electrically-braked cadence-independent cycle ergometer 
(LODE, Groningen, Netherlands). The graded exercise test began at 75W, increasing to 125 
and 175W each for 3 minutes, in order to determine a linear steady state for VO2, thereby 
increasing by 25W every 1 minute until the participant could no longer maintain at least 40 
rpm. Oxygen uptake (VO2), carbon dioxide output and minute ventilation were measured with 
a computerised breath-by-breath analyser (Innovision, Odense, Denmark). A Polar heart rate 
monitor (Polar Electro, Finland) was fitted for continuous measurement of heart rate during the 
exercise. VO2max was defined as the greatest VO2 achieved within the test as averaged over a 
15 second period, where the criteria for achievement of VO2max were having at least 2 of; 1) 
maximal heart rate (HR) within 10bpm of age predicted max (220 – age(years)), 2) RER ≥1.1 
and 3) a plateau in VO2 of <2ml/kg/min (248).  
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3.1.4 Experimental design 
 
Participants arrived at the clinical research facility at 0700 in the overnight (10 h) fasted state, 
having refrained from exercise and alcohol consumption for 48 h and at least 96 h after the 
baseline VO2max test. Participants were provided with a standard meal (765kcal, 70% 
carbohydrate, 15% fat, 15% protein) to consume as the final meal on the day prior to each trial. 
The experimental design was undertaken as described in Section 2.1.4, with infusion patterns 
as determined during study one (Table 2.2) employed for all trials. 
3.1.5 Training protocol 
 
Starting the day following the initial experimental trial, participants completed four weeks of 
endurance cycling exercise, 5 days per week. The exercise protocol consisted of continuous 
exercise at ~70% VO2max for 60 minutes per day. A considerable amount of literature has 
demonstrated improved whole body insulin sensitivity with 4-8 weeks of exercise (165, 249-
253). One hour of moderate intensity exercise, 5days/wk for 6wk improved VO2max by 7% 
and insulin sensitivity by 37%, 24 hours after the final exercise bout (252). In healthy men, 
4wk of moderate endurance exercise improved insulin sensitivity 27%, 48 hours after the final 
exercise bout (254). Additionally, a number of studies have demonstrated improvements to 
glycaemic control using endurance training protocols of shorter duration than 4 weeks (255, 
256), suggesting that 4 weeks is sufficient to demonstrate significant changes to glucose 
metabolism.  
During each exercise session, HR and VO2 were measured at 5 minute intervals. As the 
physical conditioning of the subjects improved, the workloads increased to maintain a working 
HR equivalent to previous exercise sessions. The penultimate training session consisted of the 
post-training VO2max test (identical to preliminary testing) to standardise the final exercise 
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bout (71.11 ± 0.12% VO2max) to the equivalent, relative VO2 of the initial exercise bout (70.66 
± 0.14% VO2max).  
Participants underwent additional experimental trials approximately 24 hours following the 
initial endurance exercise bout and again, approximately 24 hours following the final 
endurance exercise training bout (Refer to Figure 3.1). A limitation of the current study is the 
lack of a control or non-exercising group, which prevents true delineation of an exercise effect. 
However, considering the significant cost associated with the triple tracer technique, as detailed 
in section 1.4.4, the addition of a control group would have doubled the experimental cost and 
burden of the trial. Thus, while the following data add valuable insight into the exercise and 
postprandial glucose flux, future studies are required to fully elucidate these effects. 
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Figure 3.1: Timeline of the experimental procedure for Study 2. 
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3.1.6 Body composition  
 
Body composition including fat-free mass, fat mass and percent body fat, were determined 
using a Lunar Prodigy whole-body DEXA (dual x-ray absorptiometry) scanner (GE Medical 
Systems, Madison, WI) in Total Body scan mode. Briefly, the participant lay still in the supine 
position and was subjected to low-dose X-rays from a mobile scanner. The different body 
components (fat, lean body mass & bone) produce distinct X-ray absorption profiles whereby 
fat and lean composition can be calculated from the linear decomposition of the localised tissue 
X-ray attenuation according to calibrated samples (257). 
3.1.7 Plasma hormones and lipids 
 
Plasma glucose and tracer concentrations were determined as previously described (refer to 
section 2.1.5). Plasma obtained from EDTA-containing tubes was collected for insulin, C-
peptide, non-esterified fatty acid (FFA), and triacylglycerol (TAG) analysis; at time points: t= 
-150 and t=0 (fasting), t=10, t=20, t=30, t=40, t=50, t=70, t=90, t=120, t=150, t=180, t=210, 
t=270mins. Plasma insulin and C-peptide determination occurred via sandwich ELISA assay 
(Insulin, ALPCO, NH, USA; C-Peptide, EMD Millipore, MA, USA). FFA (NEFA C, Wako 
Chemicals, VA, USA) and TAG (Triglycerides GPO-PAP, Roche Molecular Biochemicals, 
Sydney, New South Wales, Australia) determination occurred via colorimetric assay. 
3.1.8 Calculations 
 
The area under the curve (AUC) for glucose, insulin, C-peptide and insulin secretion rate was 
calculated using the trapezoidal method. Fasting glucose is reported as the average of time 
points -150, -60, -30, -20 and -10 and 0 min. Fasting insulin and C-peptide are reported as the 
average of time points -150 and 0 min. 
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Glucose clearance was determined by dividing Rd by the plasma glucose concentration. 
Although glucose clearance is in a sense a contrived index, it is used commonly in lifestyle 
intervention studies as an index of the efficiency at which glucose is disposed of relative to the 
prevailing glucose levels (258, 259). 
The tracer-to-tracee ratios were simply determined by dividing the total amount of glucose 
tracer in the plasma (determined by multiplying the glucose concentration by the tracer 
enrichment) by the total amount of tracee (endogenous glucose, as calculated above, and [6,6-
2H] glucose, respectively). 
A malfunction in the infusion pump for the [U-13C] glucose tracer occurred in one subject 
during the post-training trial and so the calculation of meal Ra, Rd and glucose clearance 
from this trial was excluded, but remained for all other trials and did not affect analysis of 
any other variable. 
 
3.1.9 Model analysis 
 
The mathematical model used to quantify β-cell function has been described in detail 
previously (260, 261). Insulin secretion rate (ISR) was calculated from plasma C-peptide and 
glucose concentrations by deconvolution analysis (262). In brief, the model consists of three 
units (260, 261): 1) a model for fitting the glucose data, which works to smooth plasma glucose 
concentrations; 2) a β -cell model describing the dependence of insulin (or C-peptide) secretion 
on glucose concentration; and 3) a model of C-peptide kinetics, i.e., the two-exponential model 
proposed by Van Cauter et al. (262), in which the model parameters are individually adjusted 
to the subject’s anthropometric data. 
The model provides the relationship between ISR and glucose concentration, the slope of which 
quantifies the sensitivity of β-cells to glucose concentration changes in the physiological range. 
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β-cell glucose sensitivity is a strong parameter characterizing β-cell function, is progressively 
decreased as glucose tolerance worsens (147), and is a strong correlate of mean glucose 
concentration. Insulin clearance is a significant factor affecting circulating insulin (where 
plasma insulin is the sum of insulin seretion and insulin clearance) and was calculated in the 
basal state as insulin secretion/insulin concentration and postprandially as the ratio of insulin 
secretion and insulin concentration AUCs. 
3.1.10 Statistical analysis 
 
Paired t-tests were performed to compare anthropometric and physiological data at baseline 
and after 4 weeks of training. Differences between baseline, acute exercise and exercise 
training were assessed with either a one-way or two-way repeated-measures ANOVA. 
Bonferroni post-hoc analysis was used to examine differences between the 3 conditions (i.e. 
baseline vs. acute exercise; baseline vs. exercise training; acute exercise vs. exercise training). 
All statistical analyses were performed using GraphPad Prism (version 6.0; La Jolla, CA, 
USA). All data are presented as mean ± SEM. Significance was set at P<0.05. 
At the time of the current study’s undertaking, there were few triple tracer studies using lifestyle 
interventions in human subjects to base our sample size analysis on. However, a priori power 
calculations were based on classic training studies using the euglycemic hyperinsulinemic 
which suggest that endurance training increases peripheral glucose uptake by 20-60% (21, 165, 
174, 175, 178), and using pilot data from study 1. To detect a conservative 20% increase in 
glucose Rd AUC (10155 ± 1599) with 80% power, a sample size of 10 was required. 
120 
  
3.2 Results 
3.2.1 Participant characteristics 
 
Body composition was unaltered by exercise training, and the relative intensity of the first and 
last exercise bout did not differ (Table 1). All enrolled subjects successfully completed >95% 
of training sessions within a maximum period of 30 days. The average exercise training 
intensity was 70.9 ± 0.1%. VO2max was modestly but significantly increased by approximately 
7% (P < 0.001). 
Table 3.1: Subject anthropometric and physiological data at baseline and after 4 weeks of 
exercise training. 
Characteristic Baseline Post Training P Value 
Age, years 21.9 ± 0.1 ____ ____ 
Height, cm 181.1 ± 0.1 ____ ____ 
Mass, kg 79.70 ± 0.32 80.16 ± 0.35 0.371 
Fat Mass, kg 15.11 ± 0.19 14.56 ± 0.19 0.206 
Lean Mass, kg 61.12 ± 0.09 62.16 ± 0.10 0.074 
VO2max, l.min-1  4.09 ± 0.11  4.38 ± 0.09  <0.001 
VO2max, ml.kg.min-1 50.82 ± 0.31 54.22 ± 0.25  0.005 
Acute Exercise Bout Intensity, 
% VO2max 
70.66 ± 0.14 71.11 ± 0.12 0.482 
 
Values are in Mean ± SEM, n = 10. P value determined by one-way repeated measures 
ANOVA; 
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Table 3.2: The effect of acute and chronic exercise on fasting and postprandial plasma 
hormones and metabolites.  
Concentrations Baseline Acute Ex Ex Training 
Overall 
P Value 
Fasting Glucose, mmol.l-1 5.06 ± 0.14 4.69 ± 0.12 4.65 ± 0.09 * 0.030 
Glucose AUC, mmol.l-1 x min 1420 ± 59 1268 ± 50 1225 ± 42 0.018 
Fasting Insulin, pmol.l-1 35.48 ± 8.54 29.15 ± 2.49 28.35 ± 3.83 0.957 
Insulin AUC, pmol.l-1 x min 46194 ± 7661 33197 ± 4056 * 36469 ± 4629 0.014 
Fasting C-peptide, nmol.l-1 0.19 ± 0.02 0.19 ± 0.03 0.28 ± 0.06 0.148 
C-Peptide AUC, nmol.l-1 x min 260 ± 42 222 ± 35 269 ± 43 0.059 
Fasting ISR, pmol.min.m2 28.46 ± 2.61 27.57 ± 3.90 42.01 ± 8.36 0.061 
Total ISR, pmol.min.m2 x min 27935 ± 5496 23116 ± 4413 22686 ± 3708 0.173 
Fasting TAG, mmol.l-1 1.38 ± 0.11 1.31 ± 0.13  1.15 ± 0.09 * 0.038 
Fasting FFA, mmol.l-1 0.32 ± 0.04 0.34 ± 0.04  0.31 ± 0.05 0.385 
 
AUC, area under the curve; ISR, insulin secretion rate; TAG, triglycerides; FFA, non-esterified 
fatty acids. Values are in Mean ± SEM, n = 10. Overall P value determined by one-way 
repeated measures ANOVA; *  P<0.05, versus baseline as determined by Bonferroni multiple 
comparisons test.  
122 
  
3.2.2 Plasma metabolites and hormones 
 
Fasting glucose was significantly lower following 4 weeks of exercise training compared to 
baseline (P<0.05), although the reduction seen after acute exercise did not reach statistical 
significance (P=0.139; Table 3.2). Postprandial glucose AUC also tended to be lower following 
both acute (P=0.056, Table 3.2) and chronic exercise (P=0.058, Table 3.2) compared to 
baseline. As a result, when the entire fasting and postprandial period was analysed together, 
both acute and chronic exercise significantly reduced glucose levels over the entire duration of 
the 7 h experiment (main effect for exercise, Figure 3.2A).  
Fasting insulin and C-peptide concentrations were not significantly altered by acute or chronic 
exercise. Both acute and chronic exercise significantly reduced postprandial insulin excursions 
(main effect for exercise, Figure 3.2B), resulting in a reduction in the insulin AUC (Table 3.2). 
However, both basal (1.06 ± 0.15 vs. 1.08 ± 0.17 vs. 1.86 ± 0.38 L.min-1.m-2; baseline vs. 
acute exercise vs. chronic exercise) and postprandial (0.92 ± 0.05 vs. 1.04 ± 0.07 vs. 1.03 ± 
0.08 L.min-1.m-2; baseline vs. acute exercise vs. chronic exercise) insulin clearance were not 
significantly altered by acute or chronic exercise. 
Postprandial C-peptide AUC was not significantly altered by either acute or  chronic exercise 
(P=0.059, Table 3.2). Although only modest, postprandial C-peptide concentrations were 
significantly increased at 20, 50 and 120 min with chronic exercise (Figure 3.2C). In regards 
to the C-peptide responses following acute exercise, only the 120 min time point differed from 
all other conditions, with levels being lower compared to baseline and chronic exercise (Figure 
3.2C). 
Fasting plasma TAG was significantly lower following chronic exercise compared to baseline 
but was not different to levels observed after acute exercise (Table 2; Figure 3.2D). Both acute 
and chronic exercise significantly reduced postprandial TAG concentrations (main effect for 
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exercise, Figure 3.2D). Fasting and postprandial FFA were not significantly altered by either 
acute or chronic exercise (Table 3.2; Figure 3.2E). 
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Figure 3.2: Plasma glucose concentration (A), plasma insulin concentration (B), plasma C-
peptide concentration (C), plasma triacylglycerol (D), and plasma non-esterified fatty acid 
concentration (E); in healthy young men during a 4.5h labelled mixed meal tolerance test; at 
baseline, 21 ± 1 hours after a single endurance acute exercise bout and 21 ± 1 hours after 4wk 
of endurance exercise training. Plots are mean ± SEM, n=10. * P<0.05 Pre training vs. Acute 
ex; # P<0.05, ## P<0.01 Pre training vs. Post training; ++ P<0.01 Acute ex vs. Post training.  
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3.2.3 Tracer-to-tracee ratios 
 
Tracer-to-tracee ratios for [1-13C] glucose to endogenous glucose, and [U-13C] glucose to 
[6,6-2H] glucose were maintained within a relatively narrow range, with the overall change 
over time less than 2-fold (Figure 3.3). There was no significant effect of exercise on the tracer-
to-tracee ratios. 
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Figure 3.3: Tracer-to-tracee ratios for [1-13C] glucose to endogenous glucose, and [U-13C] 
glucose to [6,6-2H] glucose were maintained within a relatively narrow range, with the overall 
change over time less than 2-fold. 
  
127 
  
3.2.4 Glucose fluxes 
 
There was no significant effect of acute or chronic exercise on fasting glucose turnover rates 
(EGP, Rd or clearance), and postprandial meal Ra and glucose Rd were also unaltered by acute 
and chronic exercise (Figure 3.4A & B).  
Exercise did however have effects on postprandial glucose clearance and EGP. Glucose 
clearance was significantly higher following both acute and chronic exercise compared to 
baseline (main effect for exercise, Figure 3.4C). Although the timing and magnitude of 
postprandial EGP suppression did not differ with either acute or chronic exercise, both exercise 
conditions resulted in a more transient EGP suppression, with glucose production returning 
toward fasting levels more rapidly beginning at 180 min (Figure 3.4D). 
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Figure 3.4: Glucose rate of disposal (A), glucose rate of appearance (B), and endogenous 
glucose production (C) in healthy young men during a 4.5h labelled mixed meal tolerance test; 
at baseline, after a single endurance acute exercise bout and after 4wk of endurance exercise 
training. Plots are mean ± SEM, n=9 (A, B) n = 10 (C). ** P<0.01, *** P<0.001 Pre training 
vs. Acute ex; ### P<0.001 Pre training vs. Post training.  
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3.2.5 β-cell function and insulin sensitivity  
 
Fasting ISR tended to be higher following both acute and chronic exercise (P=0.061, Table 
3.2). However, total postprandial ISR was not significantly altered by acute exercise or exercise 
training (Table 3.2). Postprandial ISR was however significantly higher at 20 and 30 min of 
the postprandial period following 4wk of endurance training, compared to both baseline and 
acute exercise (time x exercise interaction, Figure 3.5A).  
The insulin secretion dose-response was significantly higher following both acute chronic 
exercise compared to baseline (main effect for exercise, Figure 3.5B). For all glucose 
concentrations above 5 mM and 6.6 mM, respectively, acute and chronic exercise resulted in a 
higher insulin secretion response compared to baseline (time x exercise interaction, Figure 
3.5B). Acute exercise resulted in a significantly higher insulin secretion response compared to 
4wk exercise training for all glucose concentrations above 5.8 mM (time x exercise interaction, 
Figure 3.5B).   
When glucose clearance was expressed relative to insulin concentration as an index of insulin 
sensitivity, there was a significant increase following acute exercise compared to baseline 
(P<0.05), but not following chronic training (P=0.22) (0.09 ± 0.01 vs. 0.16 ± 0.03 vs 0.13 ± 
0.02 glucose clearance/ insulin ratio; baseline vs. acute exercise vs. chronic exercise; Figure 
3.5C). 
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Figure 3.5: Insulin secretion rate (A), β-cell glucose sensitivity (B), and insulin sensitivity 
(glucose clearance/ insulin ratio; C); in healthy young men during a 4.5h labelled mixed meal 
tolerance test; at baseline, after a single endurance acute exercise bout and after 4wk of 
endurance exercise training. Plots are mean ± SEM, n = 10. * P<0.05, *** P<0.001 Pre 
training vs. Acute Ex; ### P<0.001 Pre training vs. Post training; + P<0.05, ++ P<0.01, 
+++ P<0.001 Acute Ex vs. Post training.  
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3.3 Discussion 
 
These findings show that in sedentary yet healthy young adults, both acute and chronic 
endurance training elicit comparable reductions in postprandial glycaemia. This was associated 
with a modest reduction in postprandial insulinaemia, despite no significant change in rates of 
meal Ra, Rd or in the rapidity and magnitude of EGP suppression. Rather, it seems that acute 
and chronic endurance exercise improve postprandial glucose metabolism to the same degree, 
by subtly improving glucose clearance, i.e. the efficiency at which glucose is disposed of 
relative to the prevailing glucose levels. 
A major finding of this study was that the modest exercise-induced improvements in 
postprandial glycaemia occurred in the absence of any quantifiable changes in the stimulation 
of Rd and degree of EGP suppression (both magnitude and rapidity). Although this may seem 
counterintuitive, such a scenario is not without precedent. In fact, organ balance studies 
measuring forearm muscle glucose uptake (84, 85) as well as recent investigations using the 
triple-tracer approach (63, 65, 263), as employed here, have documented alterations in 
postprandial glycaemia without changes to absolute rates of glucose flux (i.e. uptake, disposal 
and production). When taken together with recent findings (70), the current data suggests that 
the body can manipulate postprandial glycaemic responses in order to optimise glucose flux. 
Specifically, in the case of the current findings, postprandial glucose fluxes following either 
acute or chronic endurance exercise did not significantly differ compared to those in the pre-
trained state, but occurred in the presence of a reduced glucose pool size (i.e. lower glycaemic 
excursion). Given that the mass effect of glucose to stimulate its own uptake and suppress its 
own production is a determinant of glucose tolerance (4, 77), it is possible that the lack of 
change to glucose fluxes occurred at least in part to a subtle improvement in this mechanism, 
such that less of a hyperglycaemia dependent ‘push’ was required to optimally suppress EGP 
and stimulate Rd, given that meal Ra was unaltered with exercise.  
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It is also possible that any changes in glucose flux were very subtle and that this study was not 
sufficiently powered to be able detect such subtle changes in postprandial glucose metabolism 
using the current tracer based estimations of metabolic flux. Alternatively, it is possible that a 
change in glucose flux following exercise, be it acute or chronic, momentarily enhanced EGP 
suppression or Rd compared to pre-exercise conditions, especially during the first few minutes 
following meal ingestion, with this enhancement gradually subsiding over time. In this 
scenario, despite frequent blood sampling, the moment this takes place may have been missed, 
or the tracer estimations during this early dynamic period may not be sufficiently accurate 
enough. However, it is important to acknowledge that any potential change in glucose flux that 
may have been missed due to methodological considerations is only small. Thus, the current 
study suggests that endurance exercise-induced changes to glucose flux, if present at all, are 
much smaller than those proposed in previous studies utilizing the clamp or IVGTT, which 
suggest that glucose disposal may increase by as much as 60%. 
Regardless of these subtleties, nearly identical differences in the duration of postprandial EGP 
suppression following both acute and chronic exercise were detected, such that 180 min after 
meal ingestion EGP started to return towards post-absorptive levels more rapidly than at 
baseline pre-training conditions, likely due to the effects of counter-regulatory hormones (i.e. 
catecholamines, glucagon, or growth hormone). Physiologically this makes sense as glycaemia 
had dropped to below basal levels more substantially from the 150 min time point in the 
exercise groups, thus a more rapid rise in EGP would have been required to avoid excessive 
refractory hypoglycaemia.       
Importantly, the enhanced rates of postprandial glucose clearance following both acute and 
chronic endurance exercise occurred concomitantly with a modest yet significant reduction in 
the postprandial insulin response. This suggests that both acute and chronic exercise improved 
insulin sensitivity, however, when glucose clearance was expressed relative to circulating 
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insulin concentration as an index of insulin sensitivity, only acute exercise resulted in a 
significant increase compared to baseline. Although the change in insulin sensitivity seen 
following acute exercise was of a similar magnitude to that previously measured with non-
physiologic methods such as the hyperinsulinemic clamp (12, 15, 181) there was no significant 
change to insulin sensitivity following chronic training, despite the same resultant 
improvement to glycaemia. Thus, it seems that the mechanisms responsible for physiological 
changes to postprandial glycaemic regulation are more subtle than simply large improvements 
to peripheral insulin action. Indeed, despite the abundance of research demonstrating enhanced 
peripheral insulin sensitivity (16, 21) and glucose disposal (12, 15, 16, 21, 174-176, 181) 
following acute and chronic endurance exercise using either the IVGTT (176) or 
hyperinsulinemic clamp (12, 15, 16, 21, 174-176, 181), there are a number of studies showing 
that endurance exercise does not necessarily result in large changes to insulin sensitivity (168, 
179). It has been reported that a single acute bout of high intensity exercise did not increase 
insulin stimulated glucose disposal in lean healthy individuals (168). Furthermore, it has been 
shown that chronic endurance training failed to improve insulin sensitivity despite decreased 
visceral adipose, improved VO2peak and a reduction in inflammatory markers (179). 
Considering that our data provides an integrated picture of physiological postprandial glucose 
metabolism, above that based purely on indices of insulin sensitivity, these findings suggest 
that physiological changes to glycaemia following a meal may be determined as much from 
subtle changes to dynamic ‘glucose efficiency’ as opposed solely to sizeable contributions from 
peripheral insulin action that are commonly observed when using techniques that do not 
replicate normal living conditions.  
In agreement with the prevailing view that most of the benefit of exercise training on glucose 
metabolism is derived from the last acute exercise bout (19, 172, 195), both acute and chronic 
endurance exercise elicited comparable improvements to postprandial glycaemia and 
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insulinaemia when measured 21 hours post-exercise; and there was no appreciable difference 
to glucose flux between exercise conditions. Measurement was undertaken 21 hours post-
exercise in order to avoid the immediate post-exercise period in which blood flow, muscle 
temperature and counter-regulatory hormones are elevated. Additionally, this mimics a number 
of prior studies that show insulin sensitivity as measured by the clamp is elevated 24-48 hours 
post-exercise (17, 198, 249, 264), while the benefits of exercise diminish rather quickly within 
48 to 72 hours of the last exercise sessions (265). 
However, these data demonstrate that C-peptide levels and insulin secretion rates were 
increased by chronic training within the first 60 minutes of the postprandial period, above that 
observed for either the baseline or acute exercise conditions. Endurance training ranging from 
7 days to 8 months has previously been shown to improve β-cell function in those with an 
already poor insulin secretory capacity (183), although glucose-stimulated insulin secretion is 
thought to be decreased with endurance exercise training in healthy individuals as determined 
by the hyperglycaemic clamp (188). Although speculative, it is possible that the reduction in 
fasting and postprandial triglycerides seen following endurance exercise resulted in a 
cumulative effect on the β-cell following chronic training that was not seen with acute exercise. 
It is well-known that prolonged exposure to lipids can have negative effects on β-cell function 
(266), and although our healthy population would not be considered to exhibit lipotoxicity, the 
chronic reduction in circulating triglycerides may have contributed to the observed increase to 
fasting and postprandial insulin secretion rates.  
A potential explanation for the modest changes observed in the current study (including body 
weight and VO2max), may be related to the concept of ‘substitution’, whereby participants may 
have substituted baseline non-prescribed physical activity with the prescribed physical activity,  
lowering the potential energy deficit from the intervention (267). Thus, a possible limitation of 
the current study is that non-exercise physical activity was not determined during the exercise 
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training and further studies utilising physical activity monitors would determine if this were 
the case. On the other hand, a key strength of the current study is the maintenance of body 
weight in participants, where changes in body weight and composition can have potent 
metabolic effects. Thus, this study is able to delineate the effects of exercise independent of 
alterations to body weight, by preventing any weight change during exercise training. 
In conclusion, these data show that postprandial glycaemic responses were reduced following 
acute and chronic endurance exercise, and that these changes occurred in the absence of any 
measurable change to postprandial meal glucose Ra, Rd or the degree and timing of EGP 
suppression. Glucose clearance, however, was enhanced with both acute and chronic exercise. 
This suggests that endurance training influences the efficiency of the glucoregulatory system 
whereby rates of postprandial glucose disposal and production were maintained at pre-training 
levels albeit at lower systemic glucose and insulin concentrations. Notably, there was no effect 
of chronic training over and above that of a single exercise bout on glycaemia, insulinaemia or 
glucose flux, providing further evidence that glucoregulatory benefits of endurance exercise 
are largely attributed to the residual effects of the last exercise bout.   
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4.0 Chapter 4: Study 3 - Measurement of postprandial glucose fluxes 
in response to 5 and 28 days of overfeeding in healthy humans. 
 
The ever-increasing availability of energy dense and highly palatable foods has led to more 
daily eating occasions and increased portion sizes in recent decades (268), which has in turn 
led to a widespread overconsumption of excess energy, in the form of both fat and sugar. This 
overeating is common in most individuals over brief periods of time, such as during holiday-
related feasting (10), but also occurs commonly over weeks, months or years in the form of 
chronic overeating (269). Both acute (3-7 days) and chronic (weeks or months) overfeeding, 
whether predominantly by fat or carbohydrate, or a combination of both, has been demonstrated 
to lead to increased fat mass (200, 203, 205), fat accretion (22, 222, 225-227), impaired fasting 
glucose, reduced glucose tolerance (201, 202, 205, 206), and decreased whole-body insulin 
sensitivity (200, 203, 205). Additionally, a range of tissue-specific adaptations have been 
demonstrated in response to overfeeding in humans, including impairment to β-cell insulin 
secretion and the disposition index (13), increased fasting rates of EGP (10, 13, 14), impaired 
skeletal muscle insulin signalling (11), peripheral glucose uptake and insulin sensitivity (203). 
However, the glucoregulatory alterations associated with the early stages of overfeeding, 
specifically in regards to the regulation of postprandial glucose flux, are still not fully clarified. 
Short-term experimental overfeeding is a model often used in animal studies to replicate 
overconsumption in humans. Importantly, rodent studies have demonstrated that defects in 
hepatic glucose metabolism occur within a few days of the onset of overconsumption, 
preceding the induction of peripheral defects which take several weeks to emerge (207, 210-
212). There is some evidence of this temporal relationship in humans (10, 13, 14, 203), though 
previous studies utilise only fasting measures (13), or the euglycaemic hyperinsulinaemic 
clamp (10, 14, 203), thus employing measurement restrictions that are not representative of 
normal living conditions. Additionally, these studies often assess only the acute (10, 13, 14) or 
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chronic (203) effects of overfeeding in isolation and do not assess the progression of diet-
induced dysfunctions in postprandial glycaemia. Many of the recent human studies reporting 
that overfeeding alters glycaemic regulation have also provided a high proportion of fat, often 
greater than 40% of energy intake (13, 14, 18, 200-202) that is not representative of the normal 
Australian diet which contains closer to 30% energy from fats (214).  
Considering that whole-body glycaemic control is coordinated by a variety of integrated 
physiological processes, involving multiple hormones and their target tissues, the effects of 
overfeeding on this integrated response has received relatively little attention to date, especially 
in regards to postprandial glucose flux. Hyperglycaemia and insulin resistance are often the 
first steps in deteriorating glycaemic control, preceding the development and diagnosis of T2D 
usually by many years (39, 138, 139). Understanding the effects of active weight gain in 
otherwise healthy individuals is important, as the metabolic effects of energy surplus may be 
different to that of weight-stable obesity, which likely involves a large degree of allostatic 
metabolic regulation. Thus, considering that overfeeding has potent effects on glucose 
tolerance and insulin resistance, even in the short term (200-203, 205, 206), understanding the 
glucoregulatory mechanisms governing these changes during active weight gain in response to 
both acute and chronic overfeeding should help to determine the early mechanisms leading to 
metabolic disease progression. 
Here, the aim was to examine the impact of acute (5 days) and chronic (28 days) overfeeding 
on glucose fluxes in young healthy sedentary adults under physiologically relevant 
postprandial conditions. A key aim of the current study was to determine whether the temporal 
pattern of insulin resistance development previously demonstrated in humans (10, 13, 14, 203) 
also occurred at the level of postprandial glucose fluxes, specifically whether postprandial EGP 
suppression was impaired by acute and chronic overfeeding. Accordingly, the mixed meal 
tolerance test combined with the variable infusion triple-stable isotope glucose tracer approach 
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(i.e. tracer clamp approach (64, 86)) was utilised, thus permitting accurate determination of 
meal Ra, EGP and Rd. Additionally, in many human overfeeding studies, the experimental 
diets provided an excess of energy as well as a high proportion of fat that is unlikely to be 
representative of normal overeating conditions, and so the current overfeeding diet utilised a 
mixed macronutrient composition similar to the normal Australian intake of approximately 
50% energy from carbohydrate and 30% energy from fat (214).   
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4.1 Methods 
 
4.1.1 Ethics 
 
This study was conducted according to the Declaration of Helsinki, all subjects provided 
written informed consent after screening via medical questionnaire and all procedure were 
approved by the Deakin University Human Research Ethics Committee (ethics number 2015-
163). 
4.1.2 Participants 
 
Eight young healthy men participated in the study. Participants’ characteristics are presented 
in Table 4.1. Exclusion criteria included those currently diagnosed with, or with a family 
history of diabetes, BMI > 30 kg.m-2, smoking, engaging in structured exercise >90min per 
week or being non weight-stable for at least 6 months.  
4.1.3 Experimental design 
 
Participants arrived at the clinical research facility at 0700 in the overnight (10 h) fasted state, 
having refrained from exercise and alcohol consumption for 48 h to undergo triple-stable 
isotope glucose tracer testing. The experimental design was undertaken as described in Section 
2.1.4, with infusion patterns as determined during study one (Table 2.2). 
Subjects were prohibited from changing their physical activity pattern or starting new 
medications during the study. Participants underwent an experimental trial at baseline and the 
morning after completing both acute (5 days) and chronic (28 days) overfeeding (Refer to 
Figure 4.1). For the 24 hours prior to the baseline experimental trial, participants were provided 
with an energy maintenance diet (9,783 kJ, 52% carbohydrate, 30% fat, 15% protein; Refer to 
Appendix 7.1 and 7.2) designed to be representative of the typical macronutrient composition 
of participants’ normal diet. The composition and energy content of the mixed meal tolerance 
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test (as described in detail in Section 2.1.4) was identical for the baseline, acute and chronic 
overfeeding experimental trials. 
4.1.4 Overfeeding protocol 
 
For the 24 hours preceding the acute and chronic overfeeding trials, all foods were provided at 
baseline energy requirement plus ~5000 kJ/day with a nutrient composition of 55% 
carbohydrate, 30% fat and 15% protein. During the overfeeding period, participants were 
instructed to consume their regular diets and were provided with snacks to achieve an energy 
intake of ~5,000 kJ/day (50% carbohydrate, 30% fat, 15% protein; Refer to Appendix 7.3 and 
7.4) above the baseline energy requirements. The snacks included foods such as chips, 
chocolate and meal replacement shakes.  
Participants were required to fill out checklists daily during the overfeeding period, indicating 
which snacks were consumed and to complete 3-day diet diaries three times throughout the 
trial, from days -3 to 0, 2 to 5, and 25 to 28, as well as Stanford 7 day activity recalls at baseline 
and after 28 days of overfeeding according to previously published guidelines (270, 271)(Refer 
to Appendices 7.5 and 7.6). Participants visited the lab weekly for weigh-ins, return food 
diaries, dispensation of snacks and review of checklists so that any deviations from the protocol 
were quickly identified and corrected. At the end of the study, diets were analysed for 
macronutrient composition using Foodworks 2007 based on the Australian foods database 
(Xyris Software, QLD, Australia). 
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Figure 4.1: Timeline of the experimental procedure for Study 3. 
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4.1.5 Body composition  
 
Body composition was determined using a Lunar iDEXA whole-body scanner (GE Healthcare, 
Madison, WI) in Total Body scan mode as described previously (Section 3.1.6) (257). In 
addition, the iDEXA scanner allowed the determination of visceral adipose tissue volume. 
Visceral adipose volume is computed automatically over the DEXA android region, a region-
of-interest automatically defined by the enCORE software, whose caudal limit is automatically 
placed at the top of the iliac crest and whose height is set to 20% of the distance from the top 
of the iliac crest to the base of the skull to define its cephalad limit (272, 273). The algorithm 
used to measure visceral fat uses the total abdominal thickness, based on X-ray attenuation, 
and the width of the subcutaneous fat layer along the lateral extent of the abdomen along with 
empirically derived geometric constants to estimate the quantity of subcutaneous fat in the 
android region. Visceral fat is then computed by subtracting subcutaneous fat from the total fat 
in the android region (272, 273). Visceral adipose tissue as measured by the Lunar iDEXA 
system has previously been shown to be highly correlated with a current gold standard for 
measuring visceral adipose, computerized tomography (273), and has been demonstrated to 
have a low precision error in both quality control phantoms and in humans (274). 
4.1.6 Muscle biopsies 
 
Muscle biopsy samples were taken prior to the beginning of [1-13C] glucose infusion during 
each triple tracer trial in 6 out of the 8 participants. Muscle sampling was performed according 
to the percutaneous needle biopsy sampling method of Bergstrom (275). Briefly, the skin was 
anaesthetised with an injection lidocaine (5% xylocaine; AstraZeneca, North Ryde, Australia) 
and a small scalpel incision was made through the skin and fascia of the vastus lateralis muscle. 
The biopsy needle, with an inside cutting cylinder, was inserted through the incision site into 
the underlying muscle belly. Samples of ~100-200 mg were obtained via syringe suction. 
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Visible blood and connective tissue was rapidly removed before samples were snap frozen in 
liquid nitrogen and stored in liquid nitrogen until analysis. The vastus lateralis sampling leg 
was alternated on different trial days.  
4.1.7 Skeletal muscle analysis 
 
Approximately 50mg of skeletal muscle was freeze dried under vacuum for 24 h and crushed 
into a powder with connective tissue removed. Dried, powdered skeletal muscle (~12.5mg) 
was then allocated for the determination of oxidised glutathione (GSSG; ~3mg), reduced 
glutathione (GSH; ~3mg), glycogen (~1mg) and triglycerides (~3mg). 
 
4.1.7.1 Oxidized and reduced glutathione 
 
Skeletal muscle oxidative stress was assessed via the determination of GSSG and GSH as 
previously described (276). Powdered skeletal muscle was homogenised with 5% 
metaphosphoric acid (MPA) alone for GSH or both MPA and 3 mM 1-Methyl-2-
vinylpyridinium triflate (M2VP) for GSSG and supernatants were set aside for analysis. A 
bicinchoninic assay was performed on muscle pellets dissolved in NaOH using BSA as protein 
standards according to the manufacturer's protocol (Pierce Biotech Inc., MA, USA) to 
normalise GSSG and GSH to protein content. Samples were analysed spectrophotometrically 
at 412 nm for 3 min and change in absorbance was used to determine GSSG and GSH levels 
(276, 277).  
4.1.7.2 Glycogen 
 
Powdered skeletal muscle was digested in 2M HCl and incubated at 95-100°C for 2 hours and 
then neutralised with 0.67M NaOH. Muscle homogenate along with reagent cocktail (50mM 
Tris, 1mM MgCl2, 0.5mM D.T.T, 0.3mM ATP (pH 7.0), 50uM NADP+, G-6-P-DH) and dilute 
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hexokinase were incubated at room temperature in the dark for 1 hour and subsequently 
analysed spectrophotometrically in triplicate at 365nm absorption and 455nm emission (278). 
4.1.7.3 Muscle triglyceride content 
 
Total lipids were extracted according to the method of Folch et al. (16) from the dried and 
dissected skeletal muscle in 4 ml chloroform:methanol (2:1) and left to rotate at room 
temperature overnight. Sodium chloride (0.6%) was added, and centrifugation (2000 rpm for 
10 min) resulted in a separation of the aqueous and organic phases. The organic phase 
containing the TAG was transferred to a glass vial and dried under vacuum. The isolated lipids 
were resuspended in 250 μl ethanol, and the TAG concentration was determined 
spectrophotometrically at 490 nm using an enzymatic colorimetric test kit (Triglycerides GPO-
PAP, Roche Molecular Biochemicals, Sydney, New South Wales, Australia).  
4.1.8 Analysis of glucose tracer enrichment in plasma 
 
Enrichment of all tracers in plasma samples and the labelled meal were assessed using 
chemical-ionising GC/MS, as opposed to electron isonising GC/MS used in study 2 due to the 
acquisition of a new mass GC/MS by the Deakin laboratory. The preparation of derivatives 
utilised with this process was significantly simpler than that described in section 2.1.5. In 
addition the chemical-ionising GC/MS process allowed the determination of molecular ion 
abundances (Refer to Figure 4.2) at far greater sensitivity (~100-fold) than that determined via 
the electron-ionising GC/MS (abundances of ~500,000 versus ~35,000; Refer to Figure 2.5A), 
thus allow more accurate determination of tracer enrichment profiles. 
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Figure 4.2: Total and ion abundance of glucose in plasma determined via chemical-ionising 
GC/MS.  
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Preparation of aldonitrile derivatives was undertaken as described by Antoniewicz et al. (240). 
In brief, 10 μl of plasma was mixed with 100 μl of ice-cold methanol and centrifuged for 5 
min. One hundred μl of supernatant was removed for aldonitrile propionate derivatisation and 
evaporated to dryness under vacuum at 40°C using a centrifugal evaporator. Evaporated 
glucose samples were dissolved in 50 μl of hydroxylamine hydrochloride solution (20 mg/mL 
in pyridine), and heated at 90°C for 60 min. 100 μL of propionic anhydride was added to obtain 
the aldonitrile derivatives. After 30 min incubation at 60°C, samples were evaporated to 
dryness at 40°C using a centrifugal evaporator and dissolved in 100 μL of ethyl acetate. 
Samples were injected using a 1:20 split ratio onto a HP-5MS 5 % Phenyl Methyl Siloxane 
column (30.0 m x 250 μm x 0.25 μm; Agilent technologies, Santa Clara, CA, USA) connected 
to an Agilent 7890B Gas Chromatograph. Target compounds were detected via an Agilent 
5977B Mass Spectrometer. The GC program consisted of a 35 °C/min ramp starting at 60 °C. 
A final temperature of 280 °C was then held for three minutes. Helium was used as the carrier 
gas with a flow rate of 1.2 ml/min.  
The MS was operated in the selected ion monitoring mode measuring the molecular ion at mass 
to charge ratios (m/z) 384, 385, 386, 387, 388, 389 and 390, for natural (384, M+0), [6,6 - 2H] 
(386, M+2), [1-13C] (385, M+1) and [U-13C] (390, M+6) glucose. The ion abundances were 
determined using the Mass Hunter Workstation (Agilent Technologies, Santa Clara, CA, 
USA). The raw isotopomer data were corrected for natural isotopic background skew using the 
matrix method (241). 
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4.1.9 Plasma hormones and metabolites 
 
Plasma hormones and metabolites, including glucose, insulin, C-peptide, FFA and TAG were 
determined as described in detail in section 3.1.7. 
4.1.10 Calculations 
 
Calculations of glucose flux were undertaken as described in Section 2.1.6, and all oter 
calculation were undertaken as described in Section 3.1.8. Additionally, the percentage of meal 
glucose reaching the circulation was calculated by using the difference between total glucose 
in the meal (1.2g x body weight) and total meal Ra. 
4.1.11 Model analysis 
 
Considering that the insulin secretion rate and β-cell function as determined by modelling in 
Chapter 3 provided little insight above the C-peptide time-course upon which the calculation 
was based, the model analysis was omitted from the current study. 
4.1.12 Statistical analysis 
 
Differences between baseline, acute overfeeding and chronic overfeeding were assessed with 
either a one-way or two-way repeated-measures ANOVA. Bonferroni post-hoc analysis was 
used to examine differences between the 3 conditions (i.e. baseline vs. acute overfeeding; 
baseline vs. chronic overfeeding; acute overfeeding vs. chronic overfeeding). All statistical 
analyses were performed using GraphPad Prism (version 6.0; La Jolla, CA, USA). All data are 
presented as mean ± SEM. Significance was set at P<0.05. 
A priori power calculations were undertaken based on previous rodent studies demonstrating 
that hepatic and peripheral insulin resistance can decrease by 20-40% following overfeeding 
(207, 210-212),  and using previously published human data (279). To detect a conservative 
20% decrease in glucose Rd AUC (6923 ± 806) with 80% power, a sample size of 6 is required. 
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To detect a conservative 25% decrease in total EGP suppression (1747 ± 306) with 80% power, 
a sample size of 8 is required. 
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4.2 Results 
 
4.2.1 Participant characteristics 
 
All enrolled subjects successfully completed the acute overfeeding protocol in exactly 5 days 
and the entirety of the chronic overfeeding protocol in 27-30 days.  Participants were overfed 
45.6% energy in addition to their regular diet (Table 4.1). Total dietary fat, carbohydrate and 
protein were significantly increased by overfeeding, whereas the percentage of dietary energy 
derived from fat and protein were unchanged by overfeeding. The percentage of dietary energy 
derived from carbohydrate during chronic overfeeding tended to be increased by ~3% 
compared to both baseline (P=0.053) and acute overfeeding (P=0.062)(Table 4.1). 
Acute overfeeding did not significantly increase total, lean or fat mass. Chronic overfeeding 
however, led to an average weight gain of 1.64 ± 0.40 kg over the entire 28 day period. Over 
the 28 days, fat mass increased by 1.32 ± 0.18 kg (Table 4.1). Both acute and chronic 
overfeeding significantly increased visceral fat volume by 59.5 ± 1.98 and 70.13 ± 2.73 g.cm-
2, respectively (Table 4.1).  
There was no significant change in self-reported physical activity as determined via Stanford 
7 day activity recalls between baseline and 28 days of overfeeding. 
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Table 4.1: Anthropometric and dietary data at baseline, after acute (5 days) and chronic (28 
days) of overfeeding. 
Characteristic Baseline Acute 
Overfeeding   
(5 days) 
Chronic 
Overfeeding      
(28 days) 
Overall 
P-value 
Age, years 22.88 ± 0.31 ______ ______ ______ 
Height, cm 179.00 ± 0.19 ______ ______ ______ 
Mass, kg 79.96 ± 0.80 80.65 ± 0.77 81.60 ± 0.77 * 0.013 
Lean Mass, kg 59.11 ± 0.58 60.21 ± 0.53 59.91 ± 0.53 0.105 
Fat Mass, kg 17.59 ± 0.81 17.68 ± 0.80 18.90 ± 0.79 ** ++ <0.001 
Visceral Fat 
Volume, g.cm-2 
434.38 ± 8.74 493.88 ± 8.22 * 504.5 ± 9.03 * 0.036 
Dietary Energy, 
kj 
11211 ± 353 16053 ± 629 ** 16318 ± 542 ** <0.001 
Fat,  
% total energy 
32.5 ± 1.8 34.0 ± 2.2 31.0 ± 1.9 0.205 
Fat,  
g/day 
98.2 ± 5.3 148.3 ± 11.3 ** 137.4 ± 8.9 ** <0.001 
Carbohydrate, 
% total energy 
45.2 ± 0.6 44.8 ± 1.3 48.6 ±2.2 0.023 
Carbohydrate, 
g/day 
298.6 ± 12.8 421.7 ± 16.9 ** 465.6 ± 14.5 ** <0.001 
Protein,  
% total energy 
18.1 ± 1.0 16.6 ± 1.3 16.7 ± 1.4 0.264 
Protein, g/day 118.9 ± 6.9 155.7 ± 9.2 ** 158.9 ± 9.9 ** <0.001 
 
Values are in Mean ± SEM, n = 8. N/A = not applicable. Overall P value determined by one-
way repeated measures ANOVA; * = P<0.05;** = P<0.01 versus baseline; ++ = P<0.01 
versus 5 days, as determined by Bonferroni’s multiple comparisons test.  
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4.2.2 Plasma metabolites and hormones 
 
Acute overfeeding 
Fasting glucose, C-peptide, FFA and TAG were not significantly altered by acute overfeeding 
(Table 4.2).  
Following acute overfeeding, postprandial glucose was significantly lower at 50 min compared 
to both chronic overfeeding and baseline (diet x time interaction, Figure 4.3A), though this did 
not translate into a significant difference to postprandial glucose AUC when compared to 
baseline (Table 4.2).  
Postprandial insulin and C-peptide were significantly higher at 20 and 30 min compared to 
baseline (diet x time interaction, Figure 4.3B; C). However, although acute overfeeding 
resulted in higher insulin concentrations compared to baseline (main effect for diet, Figure 
4.3B), and tended to increase the postprandial insulin AUC (P=0.075), there was no alteration 
to the postprandial C-peptide AUC (Figure 4.3C; Table 4.2). 
Fasting FFA and TAG were unaltered by acute overfeeding (Table 4.2). However, postprandial 
FFA and TAG were significantly lower than both baseline and chronic overfeeding (main effect 
for diet, Refer to Figure 4.3D; E), while the integrated average FFA and TAG levels were 
unaltered (Table 4.2). 
Chronic overfeeding 
Fasting glucose, C-peptide, FFA and TAG were not significantly altered by chronic 
overfeeding (Table 4.2).  
Following chronic overfeeding, postprandial glucose was significantly elevated compared to 
both baseline and acute overfeeding (main effect for diet, Figure 4.3A), specifically this 
increase occurred at 70, 90 and 120 min (diet x time interaction, Figure 4.3A). Additionally, 
152 
  
this was associated with a significantly increased postprandial glucose AUC compared to acute 
overfeeding (Table 4.2). 
Postprandial insulin and C-peptide were significantly greater compared to baseline (main effect 
for diet, Figure 4.3B; C), specifically this increase occurred at 90 and 120 min compared to 
both baseline and acute overfeeding (diet x time interaction, Figure 4.3B; C). However, 
although the postprandial insulin AUC tended to increase (P=0.075), there was no alteration to 
the postprandial C-peptide AUC (Table 4.2). 
Fasting FFA and TAG were unaltered by chronic overfeeding (Table 4.2, Figure 4.3D; E). 
However, following chronic overfeeding, postprandial FFA was greater when compared to 
acute overfeeding (main effect for diet, Figure 4.3D) and TAG was significantly higher when 
compared to both baseline and acute overfeeding (main effect for diet, Refer to Figure 4.3E), 
while the integrated average FFA and TAG levels were unaltered (Table 4.2). 
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Table 4.2: The effect of acute (5 days) and chronic (28 days) of overfeeding on fasting and 
postprandial plasma hormones and metabolites.  
Concentrations Baseline 
Acute 
Overfeeding  
(5 days) 
Chronic 
Overfeeding   
(28 days) 
Overall 
P value 
Fasting Glucose, mmol.l-1 4.42 ± 0.15 4.55 ± 0.13 4.58 ± 0.13 0.449 
Glucose AUC, mmol.l-1 x min 1279.0 ± 99.4 1203.1 ± 80.0 1398.2 ± 80.7 + 0.033 
Fasting Insulin, pmol.l-1 25.91 ± 8.06 30.29 ± 7.75   27.33 ± 6.67 0.072 
Insulin AUC, pmol.l-1 x min 53812 ± 11069 62315 ± 13545 71107 ± 16982 0.075 
Fasting C-peptide, nmol.l-1 0.33 ± 0.05 0.35 ± 0.06 0.34 ± 0.05 0.210 
C-Peptide AUC, nmol.l-1 x min 298.53 ± 45.23 300.55 ± 40.92 330.51 ± 47.84 0.250 
Fasting TAG, mmol.l-1 1.08 ± 0.08 1.03 ± 0.06 1.21 ± 0.16 0.848 
Average TAG, mmol.l-1 1.07 ± 0.10 0.94 ± 0.09 1.17 ± 0.15 0.274 
Fasting FFA, mmol.l-1 0.19 ± 0.03 0.15 ± 0.03 0.16 ± 0.03 0.847 
Average FFA, mmol.l-1 0.11 ± 0.01 0.09 ± 0.01 0.11 ± 0.01 0.264 
 
AUC, area under the curve; TAG, triglycerides; FFA, non-esterified fatty acids. Values are in 
Mean ± SEM, n = 10. Overall P value determined by one-way repeated measures ANOVA; * 
P<0.05 versus baseline, + P<0.05 versus acute overfeeding, as determined by Bonferroni 
multiple comparisons test. 
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Figure 4.3: Plasma glucose concentration (A), plasma insulin concentration (B), plasma C-
peptide concentration (C), plasma FFA concentration (D), and plasma TAG concentration (E); 
in healthy young men during a 4.5h labelled mixed meal tolerance test; at baseline (BL), after 
acute overfeeding (5 days) and after chronic overfeeding (28 days). Plots are mean ± SEM, 
n=8. * P<0.05, ** P<0.01, *** P<0.001 baseline vs. 5 days; # P<0.05, ## P<0.01, ###  
P<0.001 baseline vs. 28 days; + P<0.05, ++ P<0.01, +++ P<0.001 5 days vs. 28 days, as 
determined by Bonferonni post-hoc analysis.  
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4.2.3 Glucose fluxes  
 
Acute overfeeding 
The fasting rate of glucose Rd (11.17 ± 0.82 vs. 11.86 ± 0.82 vs. 10.82 ± 0.66 µmol.kg.min-1, 
baseline vs. 5 days vs. 28 days, P<0.05) was significantly increased by acute overfeeding, 
compared to both baseline and chronic overfeeding. Postprandial meal Ra and glucose Rd were 
significantly higher than baseline (main effect for diet, Figure 4.4B) and this specifically 
occurred between 10 and 90 min (diet x time interaction, P<0.0001; Figure 4.4B).  
The fasting rate of EGP (10.86 ± 0.79 vs. 11.54 ± 0.83 vs. 10.50 ± 0.66 µmol.kg.min-1, baseline 
vs. 5 days vs. 28 days, P<0.05) was also significantly increased by acute overfeeding, compared 
to both baseline and chronic overfeeding. However, there was no significant effect of acute 
overfeeding on the pattern or extent of postprandial EGP suppression (Figure 4.4D).  
Glucose clearance was significantly increased compared to both baseline and chronic 
overfeeding (main effect for diet, Figure 4.4C) and this occurred between 20 and 90 min (time 
x diet interaction, P<0.0001; Figure 4.4C). When glucose clearance was expressed relative to 
insulin concentration as an index of insulin sensitivity, acute overfeeding did not significantly 
alter the insulin sensitivity index (0.14 ± 0.04 vs. 0.11 ± 0.03 glucose clearance/ insulin ratio; 
baseline vs. 5 days). 
The total amount of meal glucose reaching the circulation tended to be greater following both 
acute and chronic overfeeding, compared to baseline (80.27 ± 4.45 vs. 88.73 ± 2.76 vs. 84.73 
± 3.85 %, baseline vs. 5 days vs. 28 days, P=0.071). 
Chronic overfeeding 
The fasting rate of glucose Rd was not significantly altered by chronic overfeeding compared 
to baseline, but was significantly lower compared to acute overfeeding. Postprandial meal Ra 
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and glucose Rd were significantly higher compared to baseline (main effect for diet, Figure 
4.4B) specifically between 10 and 40 min (diet x time interaction, P<0.0001; Figure 4.4B). 
Additionally, chronic overfeeding resulted in significantly lower meal Ra and Rd at 90 min 
compared to acute overfeeding (diet x time interaction, P<0.0001; Figure 4.4A). 
The fasting rate of EGP was unaltered, however chronic overfeeding resulted in a modest, but 
significant, increase to the postprandial suppression of EGP compared to both baseline and 
acute overfeeding (Figure 4.4D).  
Chronic overfeeding resulted in significantly lower glucose clearance compared acute 
overfeeding (main effect for diet, Figure 4.4C). Although chronic overfeeding significantly 
increased glucose clearance at 20 min compared to baseline, it was significantly lower at 50, 
70, 90 and 120 min compared to acute overfeeding, and at 120 and 150 min compared to 
baseline (time x diet interaction, P<0.0001; Figure 4.4C). When glucose clearance was 
expressed relative to insulin concentration as an index of insulin sensitivity, chronic 
overfeeding did not significantly alter the insulin sensitivity index (0.14 ± 0.04 vs 0.10 ± 0.04 
glucose clearance/ insulin ratio; baseline vs. 28 days). 
The total amount of meal glucose reaching the circulation tended to be greater following both 
acute and chronic overfeeding, compared to baseline (80.27 ± 4.45 vs. 88.73 ± 2.76 vs. 84.73 
± 3.85 %, baseline vs. 5 days vs. 28 days, P=0.071). 
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Figure 4.4: Meal glucose rate of appearance (A), glucose rate of disposal (B), glucose clearance 
(C), and endogenous glucose production (D) in healthy young men during a 4.5h labelled 
mixed meal tolerance test; at baseline, after acute overfeeding (5 days) and after chronic 
overfeeding (28 days). Plots are mean ± SEM, n=8. * P<0.05, ** P<0.01, *** P<0.001 
baseline vs. 5 days; # P<0.05, ## P<0.01, ### P<0.001 baseline vs. 28 days; + P<0.05, ++ 
P<0.01, +++ P<0.001 5 days vs. 28 days, as determined by Bonferroni post-hoc analysis. 
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4.2.4 Meal and endogenous glucose 
 
Acute overfeeding 
Following acute overfeeding, postprandial plasma meal-derived glucose concentration was 
significantly higher between 20 and 40 min compared to baseline (diet x time interaction, 
Figure 4.5A).  
Acute overfeeding subtly decreased the plasma endogenously-derived glucose compared to 
baseline (main effect for diet, Figure 4.5B). 
Chronic overfeeding 
Following chronic overfeeding, postprandial plasma meal-derived glucose concentration was 
significantly higher than both baseline and acute overfeeding (main effect for diet, Figure 
4.5A). Specifically, this occurred at 20, 40, 70, 90 and 120 min compared to baseline; and at 
90 and 120 min compared to acute overfeeding (diet x time interaction; Figure 4.5A). 
Chronic overfeeding subtly decreased the plasma endogenously-derived glucose compared to 
baseline (main effect for diet, Figure 4.5B). 
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Figure 4.5: Absolute plasma meal glucose concentration (A), and absolute plasma endogenous 
glucose concentration (B) in healthy young men during a 4.5h labelled mixed meal tolerance 
test; at baseline, after acute overfeeding (5 days) and after chronic overfeeding (28 days). Plots 
are mean ± SEM, n=8. * P<0.05, ** P<0.01 baseline vs. 5 days; # P<0.05, # P<0.05, ## 
P<0.01, ### P<0.001 baseline vs. 28 days; + P<0.05, ++ P<0.01, +++ P<0.001 5 days vs. 
28 days, as determined by Bonferroni post-hoc analysis.  
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4.2.5 Skeletal muscle metabolites and oxidative stress 
 
Skeletal muscle glycogen content, skeletal muscle TAG content and GSH: GSSG ratio were 
unaltered by acute and chronic overfeeding (Figure 4.6). 
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
1 2 0 0
1 4 0 0
m
m
o
l.
k
g
-1
 (
d
ry
 w
t)
B a s e lin e 5  d a y s 2 8  d a y s
A ) M u s c le  G ly c o g e n
0
3 0
6 0
9 0
1 2 0
1 5 0
1 8 0
n
m
o
l.
m
g
-1
 (
d
ry
 w
t)
B a s e lin e 5  d a y s 2 8  d a y s
B ) M u s c le  T A G
0
5 0
1 0 0
1 5 0
2 0 0
R
a
ti
o
B a s e lin e 5  d a y s 2 8  d a y s
C ) M u s c le  G S H :G S S G
 
Figure 4.6: Skeletal muscle glycogen (A), total triglycerides (B) and GSH: GSSG ratio (C) in 
healthy young men; at baseline, after acute overfeeding (5 days) and after chronic 
overfeeding (28 days). Differences between Baseline vs. Acute overfeeding, and Baseline vs. 
Chronic overfeeding were determined by one-way repeated measure ANOVA. Plots are mean 
± SEM, n=6. 
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4.2.6 Tracer-to-tracee ratios 
 
Tracer-to-tracee ratios for [1-13C] glucose to endogenous glucose, and [U-13C] glucose to [6,6-
2H] glucose were maintained within a relatively narrow range, with the overall change over 
time less than 2-fold (Figure 4.7). There was no significant effect of diet on the tracer-to-tracee 
ratios. 
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Figure 4.7: Tracer-to-tracee ratios for [1-13C] glucose to endogenous glucose (A), and [U-13C] 
glucose to [6,6 – 2H] glucose (B) in healthy young men; at baseline, after acute overfeeding 
(5 days) and after chronic overfeeding (28 days).  Plots are mean ± SEM, n=8.  
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4.3 Discussion 
 
The main findings of the current study were that although fasting EGP was increased following 
acute overfeeding, the degree of postprandial suppression of EGP was not decreased, while Rd 
was increased, following both acute and chronic overfeeding. However, glucose clearance was 
impaired following chronic but not acute overfeeding, and in order to maintain baseline rates 
of glucose flux there was a concomitant increase in systemic glycaemia and insulinaemia.  
The observed increase to fasting rates of EGP in response to acute overfeeding is consistent 
with previous studies that have observed rapid development of hepatic defects in response to 
overfeeding (10, 13, 213, 237). Additionally, the increase in fasting EGP following acute 
overfeeding occurred concomitantly with a tendency to increase fasting insulin, suggesting 
hepatic insulin resistance. Schwarz et al. (237) also observed increased fasting EGP in response 
to 5 days of carbohydrate overfeeding, however, this also induced secondary effects in regards 
to increasing insulin secretion and suppressing lipolysis (237), suggesting that increased fasting 
EGP may be an adaptation that works to shift whole-body fuel selection in response to dietary 
carbohydrate surplus. Although speculative, in the current study, the observed increase in 
fasting EGP following acute overfeeding may have been an adaptation to increase fasting Rd, 
whereby increased EGP provided extra glucose for tissues to oxidise, stimulating a 
compensatory moderate hyperinsulinaemia, which may have acted to reduce lipolysis.  
However, the observation that acute overfeeding was not associated with altered postprandial 
suppression of EGP was unexpected, as this seems to be in contrast to previous data that has 
demonstrated rapid onset of dysregulation in hepatic tissues in response to short-term 
overfeeding (10, 13, 209, 237). Indeed, an aim of the current study was to examine if the 
postprandial suppression of EGP would be reduced by overfeeding, whereas it was maintained, 
or even increased by acute and chronic overfeeding, respectively. However, it is important to 
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consider that previous studies have utilised steady-state measures of EGP, during fasting (13, 
209, 237) or hyperinsulinaemic clamp (10) conditions. Under postprandial, non-steady state 
conditions, rates of glucose flux are governed by the integrated regulation of β-cell insulin 
secretion, insulin sensitivity and glucose effectiveness (4). A number of researchers have 
demonstrated that effective compensation by postprandial regulatory mechanisms can 
normalise postprandial suppression of EGP, thereby enabling some individuals with impaired 
fasting glucose to maintain normal postprandial glucose concentrations (88, 280, 281). For 
example, enhanced insulin secretion can potentially compensate for a defect in insulin action 
(88). Thus, despite increased fasting rates of EGP in response to acute overfeeding in the 
current study, postprandial suppression of EGP was not altered, likely due to effective 
compensation by portal vein hyperinsulinaemia and hyperglycaemia.  
The maintenance of postprandial glycaemic excursions in the face of 5 days of overfeeding 
also occurred simultaneously with a significant increase in postprandial glucose clearance and 
Rd. This suggests that the response to short-term overfeeding is to improve the ability to 
disposal of a glucose load in order to maintain glycaemic excursions. However, while Rd was 
also modestly increased in response to chronic overfeeding, glucose clearance was reduced 
compared to baseline and acute overfeeding. This suggests that this adaptation is only transient 
and appears to become impaired after 28 days of overfeeding, and may be a factor responsible 
for the increased postprandial glycaemia. Given that insulin sensitivity was unaltered by both 
acute and chronic overfeeding, and that the mass effect of glucose to stimulate its own uptake 
and suppress its own production is a determinant of glucose tolerance (4, 77), it is possible that 
the increased postprandial glycaemia following chronic overfeeding occurred via an 
impairment in the ability of glucose itself to stimulate Rd. Peterson et al. (203) recently 
demonstrated that the early stages of overfeeding-induced alterations to glucoregulatory 
function appear to be driven more by declines in non-oxidative rather than oxidative glucose 
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metabolism and it can be hypothesised that hyperglycaemia may serve to compensate for the 
defects in non-oxidative disposal. Thus, the increased postprandial glycaemic response 
following chronic overfeeding may be an adaptive mechanism to increase stimulation of 
glucose Rd. As demonstrated in Figure 4.5, the increased postprandial glycaemia following 
chronic overfeeding was reflective of an increase in the systemic concentration of meal 
glucose, as opposed to glucose produced endogenously. Considering the similarity in the 
patterns of meal Ra and Rd, it is likely that the increase in glucose Rd following both acute and 
chronic overfeeding occurred in order to match this increase in meal Ra.  
Although speculative, the possible mechanisms that may serve to explain the increased meal 
glucose Ra in response to overfeeding include altered gastric emptying and reduced hepatic 
extraction of glucose. Considering that the rate of gastric emptying has a direct effect on the 
rate of glucose appearance after a meal (79), and that gastric emptying is accelerated early in 
the development of T2D (282), this offers a possible explanation for the increased meal Ra 
following acute and chronic overfeeding in the current study. Another possibility is that the 
increased meal glucose Ra following acute and chronic overfeeding in the current study is 
reflective of a decrease in the initial hepatic extraction of glucose. Acute and chronic 
overfeeding tended (P=0.071) to increase the amount of meal glucose reaching the circulation 
by 5-10%, which could reflect a decrease in initial hepatic uptake of glucose from the portal 
vein. Coate et al. (283) recently demonstrated that overfeeding in dogs using a mixed nutrient 
diet resulted in an inability of the liver to switch from net glucose production to net glucose 
uptake in the transition to the postprandial state. The decreased hepatic glucose uptake in the 
postprandial period was associated with a defect in hepatic glucokinase activity, and this also 
occurred despite a slight, but significant, increase in the insulin concentration reaching the 
liver, suggesting that the liver was insulin resistant (283). Considering that the results of the 
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current study under fasting conditions also suggest hepatic insulin resistance, a decrease in 
hepatic glucose extraction may serve to explain the observed increase in meal glucose Ra. 
In addition to increased postprandial glycaemia, the systemic insulinaemic response was 
increased following overfeeding. This increase was at least partly resultant from an increase in 
insulin secretion, where C-peptide was also modestly increased by overfeeding. Recently, 
Erdmann et al. (284) demonstrated that the initial hepatic clearance of insulin was reduced in 
response intentional weight gain (2 BMI points) within the normal range of subjects who are 
lean, leading to postprandial hyperinsulinaemia. However, the glucose response to a meal 
remained unchanged after weight gain (284), despite hyperinsulinaemia, demonstrating that 
the act of counterbalancing augmented insulin resistance came at the expense of increased 
systemic insulin. Additionally, when changes to body weight and the degree of insulin 
resistance become greater, it has also been demonstrated that both the augmentation of both 
postprandial insulin secretion, as well as insulin clearance rate are required for maintenance of 
glucose homeostasis in overweight and obese subjects (285). However, in regard to the current 
overfeeding study, it seems that the contribution of changes to insulin clearance, if altered at 
all, was minimal, considering that the pattern of both postprandial C-peptide and insulin were 
similar following overfeeding. 
The macronutrient composition of overfeeding is a key consideration in regards to alterations 
to body composition, where the relatively modest increase in fat mass after 28 days of 
overfeeding in the current study is likely related to the macronutrient composition of the 
overfeeding diet, in addition to an increase in energy expenditure. . Horton et al. (215) showed 
that 14 days of overfeeding when 50% excess energy was provided as fat led to greater relative 
adipose tissue accumulation than with 50% excess energy derived from carbohydrate 
consumption, despite no difference in total weight gain. Additionally, the decrease in excess 
energy storage of 10-15% when energy was derived from carbohydrates compared to fats was 
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due primarily to progressive increases in total energy expenditure and carbohydrate oxidation 
(215).  The effect of acute overfeeding on total and visceral fat accumulation is less clear, with 
many studies utilising only body weight measures, as opposed to body composition. In the 
current study, total body mass was unchanged in response to acute overfeeding, consistent with 
previous studies utilising both high fat (11, 13, 209) and mixed nutrient (11, 13, 209) acute 
(<5d) overfeeding. Although a recent study demonstrated a significant increase in weight ( 
~1%) in response to a single day of high-fat overfeeding, the study diet utilised a relatively 
extreme model, increasing energy intake by 78%, with 68% of total energy derived from fats 
(286). Interestingly, in the current study visceral adipose volume was increased after both acute 
and chronic overfeeding, despite no change to total or fat mass after 5 days. However, despite 
the same resultant change to visceral adipose volume, the postprandial glycaemic response was 
only increased following chronic overfeeding. On the other hand, Knudsen et al. (287) recently 
demonstrated that alterations to glucose metabolism in response to combined overfeeding and 
inactivity occurred before  any change to visceral adipose tissue volume. Taken together, these 
findings suggest that the initial steps in the development of disturbed glucose metabolism are 
not necessarily linked to visceral fat accumulation (287, 288). 
Following chronic overfeeding, the increase in systemic glycaemia occurred together with an 
increase in total fat mass. A proposed mechanism linking increased fat mass with altered 
glucose metabolism is the shunting of excess lipid from enlarged adipose into non-adipose 
tissues such as skeletal muscle or liver, where it interferes with insulin signalling and causes 
tissue insulin resistance (289). However, while some literature suggests that increases in 
intramuscular triglyceride are associated with increased insulin resistance (290, 291), other 
data suggest that these may not be related (11, 230). Interestingly, Adochio et al. (11) saw 
significantly increased intramyocellular lipid content following both high carbohydrate and 
high fat overfeeding, regardless of the macronutrient content of the diet. However, this increase 
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in intramyocellular lipid occurred in the setting of unchanged whole-body insulin sensitivity 
(11). The current study saw no significant increase in skeletal muscle triglycerides despite 
significant increases to visceral and total fat, consistent with a recent study which also 
demonstrated that healthy subjects did not display a significant change to intramuscular 
triglycerides despite a large increase to total body fat and intrahepatic lipids in response to 8 
weeks of 40% overfeeding (292). Although it is surprising that chronic overfeeding did not 
increase skeletal muscle triglycerides, we cannot rule out increases in other lipid species. 
Additionally, the current study also observed no alteration to skeletal muscle oxidative stress 
as determined via the GSH: GSSG ratio, although clear limitation of this study is the small 
sample size of participants that underwent skeletal muscle biopsies. On the other hand, this 
may be explained by previous data that has demonstrated accumulation of ROS in skeletal 
muscle may be related to the increased fat composition of the overfeeding diets. Indeed, 
Anderson et al. (236) established an association of increased mitochondrial H2O2 emissions 
with high-fat diet–induced insulin resistance in human skeletal muscle. Additionally, it has 
been demonstrated in sedentary healthy men and women that urinary F2-isoprostanes (a marker 
of in vivo oxidative stress) are increased after 28 days of high fat overfeeding, and skeletal 
muscle protein carbonyls increased after both 3 and 28 days (18). Recent studies also provided 
evidence that the rate of mitochondrial H2O2 emission is significantly greater when basal 
respiration is supported by fatty acid– versus carbohydrate-based substrates (293, 294). 
Therefore, it is possible that the lack of significant change to skeletal muscle oxidative stress 
and lipid content in the current study may be related to the maintenance of the macronutrient 
balance of the diet. 
In conclusion, these findings suggest that the glucoregulatory system is able to maintain 
glycaemic control in the face of short-term periods of mixed nutrient overfeeding. It appears 
that this occurs by an increase in the capacity of the glucoregulatory system to dispose of a 
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glucose load as evidenced by increased glucose clearance. Interestingly, visceral adipose was 
increased after only 5 days of overfeeding, before any alteration to glycaemia, and was not 
increased further after 28 days, suggesting that at least the initial alterations to glucose 
metabolism in response to overfeeding are not solely due to changes in visceral fat 
accumulation. A key and unexpected finding of the current study was that postprandial 
suppression of EGP was not impaired by acute or chronic overfeeding. Although the rate of 
glucose Rd was increased and postprandial EGP suppression was increased following chronic 
exposure to mixed nutrient overfeeding, glucose clearance was reduced compared to 5 days, 
and this occurred concomitantly with an increase in postprandial glycaemia and insulinaemia. 
Thus, while chronic overfeeding did not decrease the absolute rates of postprandial glucose 
flux, the act of counterbalancing augmented glucoregulation occurred at the expense of 
increased systemic insulinaemia and glycaemia.  
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5.0 Chapter 5: Overall Discussion 
 
The present thesis investigated postprandial glucoregulatory responses to endurance exercise 
and overfeeding, including the measurement of glucose fluxes (EGP, meal Ra, glucose Rd, 
glucose clearance) using the stable-isotope triple glucose tracer technique. Initially a pilot study 
(Chapter 2) was undertaken in order to determine the optimal intravenous stable-isotope 
infusion rates to allow for the determination of postprandial glucose fluxes. As demonstrated 
in Chapter 2, the tracer-to-tracee ratios obtained during the current studies were sufficiently 
constant in order to provide accurate calculation of postprandial glucose flux despite high 
individual variation. Therefore, the subsequent investigations were able to provide key insights 
into the relationship between both acute and chronic endurance exercise (Chapter 3), and mixed 
nutrient overfeeding (Chapter 4) on postprandial glucose fluxes under settings that closely 
reflect real-life, physiological conditions. The data obtained in Chapters 3 and 4 of this thesis 
add to a growing body of evidence demonstrating that the glucoregulatory system is able to 
respond to perturbations such as diet and exercise by subtly altering postprandial system 
efficiency in order to optimise rates of glucose flux.  
As demonstrated in Chapter 3, both acute and chronic endurance exercise improved glucose 
clearance (i.e. the efficiency at which glucose is disposed of relative to the prevailing glucose 
levels), and pre-exercise rates of postprandial EGP and Rd were maintained despite a reduced 
glucose pool. Thus, it seems that this subtle alteration to glucoregulatory system efficiency was 
sufficient to alter systemic glycaemia without any detectable changes to the absolute rate of 
glucose flux (meal Ra, suppression of EGP, and stimulation of glucose Rd). These findings 
concur with a number of recent (63, 65, 70, 263), and classic papers (84, 85, 295), suggesting 
that changes to glucose fluxes under normal living conditions do not necessarily accompany 
alterations to systemic glycaemia, likely due to multi-organ compensatory mechanisms (295). 
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Although this may seem counter-intuitive, these findings are consistent with classic studies 
examining exercise training responses using the euglycaemic hyperinsulinaemic clamp (258, 
259), albeit the current study was conducted under more physiologically relevant conditions. 
For example, similar to what has been reported in clamp studies, the current study demonstrated 
increased glucose clearance in response to acute and chronic endurance exercise, which 
occurred together with a subtle enhancement in insulin sensitivity, as evidenced by small 
reductions to the postprandial insulin response. However, in the current exercise study, the 
postprandial glucose response was decreased, and Rd maintained at pre-exercise levels (i.e. not 
increased), so it appears that system efficiency was improved.  
An interesting finding was that the postprandial glycaemic response was altered to the same 
degree following both acute and chronic exercise, providing further evidence that, in healthy 
humans, there appears to be no additional benefit of endurance training above a single acute 
exercise bout for improving postprandial glycaemia when controlling for the residual effects 
of acute exercise (19, 172, 195). However, chronic but not acute endurance exercise resulted 
in a significant increase in early postprandial insulin secretion, despite no change to the 
integrated insulin and C-peptide response. Although the effects were small, it seems that 
chronic endurance training improved the timing and pattern of insulin release, which may be 
important for determining physiological changes to glycaemia in response to lifestyle 
alterations (71, 72).  
As demonstrated in chapter 4, in the face of chronic exposure to excess energy intake (28 days 
of overfeeding), the postprandial glucose and insulin responses were elevated in comparison to 
pre-overfeeding levels. This also occurred despite modestly increased postprandial EGP 
suppression, and although meal Ra increased modestly, so too did Rd. However, glucose 
clearance was no longer increased, and was significantly decreased in comparison to acute 
overfeeding, suggesting that this may be a contributing factor in the initial overfeeding-induced 
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increase in systemic glycaemia. Thus, after 28 days of overfeeding, the glucoregulatory system 
appeared to require higher glucose and insulin concentrations in order to maintain appropriate 
glucose fluxes.  
The need to stimulate increased postprandial glucose Rd following both acute and chronic 
overfeeding occurred in response to an increase in the systemic meal glucose Ra. Whether by 
an increase in the rate of gastric emptying, or a decrease in the initial hepatic sequestration of 
glucose, or both, the increased meal Ra resulted in an increase in the total amount of meal 
glucose reaching the systemic circulation following both acute and chronic overfeeding. This 
finding suggests that the population trends toward increased numbers of daily eating occasions 
and increased portion sizes seen in recent decades (268) may lead to an adaptation in the 
splanchnic tissues, at least transiently, to increase meal glucose Ra, and may be a factor driving 
the increased prevalence of metabolic abnormalities such as T2D (296). Taken together, the 
current overfeeding study along with previous data (296), indicate that excessive food intake, 
even if it is nutritionally balanced, may have an impact on either gastric emptying, intestinal 
glucose absorption, and/ or hepatic glucose uptake. Unfortunately, the methodology employed 
in this study is not able to differentiate between these different splanchnic processes.   
When designing a study looking at the effect of lifestyle interventions on metabolic health 
outcomes, it is important to consider utilizing outcome measures that best reflect real life 
physiological conditions. For a lifestyle intervention to achieve meaningful outcomes to 
metabolic health, it should ideally lead to robust changes to either fasting and/or postprandial 
glycaemia and/or insulinaemia. Interestingly, numerous studies have shown robust positive 
effects on aspects of glucose metabolism under induced experimental conditions following 
lifestyle interventions. However, these improvements did not always translate into meaningful 
improvements to key clinical outcomes measures. For example, a multitude of studies have 
demonstrated improvements to insulin sensitivity during the clamp or IVGTT following 
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exercise, yet these have often not resulted in concomitant changes to fasting or postprandial 
glycaemia and insulinaemia (17, 24, 111, 166, 175, 176, 182, 183). Thus, the benefit and 
popularity of such techniques likely results from the fact that induced experimental measures 
are more likely to show clear, albeit not necessarily physiologically applicable, results. 
However, the findings of studies 2 and 3 highlight the presence of multiple subtle 
glucoregulatory mechanisms supporting a very fine level of control under more physiological 
‘real-life’ conditions. Postprandial glucose and insulin were reduced after acute and chronic 
exercise but were not accompanied by measurable changes in meal Ra, Rd and the degree of 
EGP suppression, while peak postprandial EGP suppression was maintained, and glucose Rd 
was increased following chronic overfeeding when compared to baseline due to a modest 
deterioration of glycaemia and insulinaemia. In an evolutionary context, when considering the 
importance of glucose as a fuel for cellular metabolism, these findings suggest that the 
glucoregulatory system has developed complex control pathways incorporating considerable 
redundancy to ensure adequate rates of glucose flux to maintain glucose supply to tissues at 
rest and during physical activity, despite perturbations to the system such as periods of feast 
and famine. 
This evolutionary background provides important context to understanding control 
mechanisms in the modern environment of overconsumption and sedentary lifestyles. While 
the magnitude of the results demonstrated in this thesis were small, they included subtle 
changes to fasting and postprandial glycaemia and insulinaemia, under physiologically relevant 
conditions, suggesting that these changes, if maintained, could manifest into more pronounced 
clinical outcomes if the interventions were more chronic. For example, although the effect of 
overfeeding on glycaemia and insulinaemia in this thesis was modest, if overfeeding was 
maintained chronically over months or years, as might occur in the development of obesity, 
postprandial hyperinsulinaemia and hyperglycaemia could further impair insulin action due to 
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persistent exposure of cells to harmful effects, perhaps via negative feedback mechanisms, 
while also placing an increased insulin secretory burden on the β-cells (177, 245, 297). In this 
regard, vascular function may become the casualty of excess nutrient storage, where associated 
tissue insulin resistance results in elevated blood glucose and lipids, eventually contributing to 
atherosclerosis and its cardiac, cerebral and peripheral vascular sequelae. Indeed, an important 
consideration of the current studies is that the participants were apparently healthy, lean young 
men and it is conceivable that the same interventions in metabolically at-risk populations, such 
as overweight individuals, would produce responses of a greater magnitude. In a similar regard, 
it has been demonstrated that there may be gender differences in the metabolic response to 
lifestyle interventions. Cornier et al. (10) demonstrated impairment in insulin-mediated 
suppression of EGP during the euglycaemic hyperinsulinaemic clamp in women, an effect that 
was not seen in men. Future studies are required to determine whether similar results are 
demonstrated in metabolically impaired individuals and if sex differences are present in regards 
to the effect of lifestyle interventions on postprandial glucose fluxes.  
While an advantage of the current studies was the ability to quantify rates of glucose flux under 
actual postprandial conditions, it is also possible that subtle intervention-induced changes in 
glucose flux went undetected using the current tracer based estimations. Perhaps an even more 
frequent sampling strategy and/ or larger numbers of participants would be required to reliably 
detect any small change to glucose flux (298), especially considering the moderate effects 
observed in the current apparently healthy subjects. Likewise, and perhaps more importantly, 
alterations to meal Ra or Rd, especially early in the postprandial period (first 10-15 min), may 
go undetected due to high initial variance in the infused meal mimicking tracer to exogenous 
glucose concentration ratios (meal ingested tracer), making calculations during this period 
somewhat problematic for a few reasons. First, neither tracer was present before the meal was 
eaten, and one tracer may initially enter the circulation prior to the other, with the ratio thus 
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starting either from zero or infinity, depending on which tracer appeared in the system first 
(64). Second, glucose absorption is likely more variable immediately after eating than it is once 
the stomach begins emptying nutrients at a relatively constant rate into the duodenum (64). 
Therefore, it is more difficult to assess how much meal mimicking glucose tracer needs to be 
infused in the first few minutes after food ingestion, although this is may not be a major 
limitation since gastric emptying and therefore meal glucose appearance is likely to be minimal 
before this time. 
Another limitation of the current studies was the blood sampling method. Forearm venous 
blood sampling was performed and this may not be reflective of systemic, whole-body glucose 
metabolism (299, 300). Directly sampled arterial or alternatively, arterialised venous sampling 
is considered to provide metabolite concentrations that represent the mixed blood that directly 
supplies organs and cells, while forearm venous samples (antecubital vein) are affected by 
forearm skeletal muscle metabolic activity (i.e. blood draining the forearm tissue). Several 
previous studies have demonstrated that venous blood provides lower postprandial glucose 
concentrations compared with arterial or arterialised venous blood (299-301). Indeed, the use 
of venous blood sampling in the current studies may potentially serve to explain one of the 
interesting findings, where both acute and chronic endurance exercise resulted in a significantly 
shorter EGP nadir, with production returning more quickly towards basal. This earlier rise in 
post-exercise EGP occurred at 180 minutes, whereas reactive hypoglycaemia was present at 90 
minutes from the venous-collected samples. Thus, it is possible that this more rapid return of 
EGP toward basal following exercise may be reflective of the arterial concentration of glucose 
returning to basal levels more rapidly compared to pre-exercise conditions. In a similar regard, 
Jackson et al. (300) demonstrated in healthy men that plasma glucose concentrations were 
significantly higher in forearm arterial versus venous blood following the ingestion of a large 
glucose dose (~90 g), and that venous glucose concentrations returned to basal values at 105 
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minutes into the postprandial period, compared to arterial glucose levels which did not return 
to basal until 180 minutes (300).  
However, errors with measurement of glucose Rd may be present in the current studies, where 
Rd is calculated by subtracting the change in glucose mass from the total rate of glucose 
appearance. The change in glucose mass is calculated by multiplying the change in plasma 
glucose concentration by the total volume of glucose. Therefore, despite model-independent 
calculation of glucose flux due to minimised differences in tracer-to-tracee ratios, an error in 
the value of the total glucose mass and volume will introduce some potential error in the 
calculation of glucose Rd. However, regards to the hormonal measurements, a recent study 
demonstrated that plasma insulin and C-peptide concentration did not differ between venous 
and arterialised venous samples (299). Thus, the sampling method employed here in the 
exercise or overfeeding studies should not influence the insulin or C-peptide results, nor the 
modelling of insulin secretion rates. It is also important to note that the findings in regards to 
meal Ra and EGP should remain unaltered, where the calculations for these fluxes rely upon 
the ratio of tracer to tracee in the circulation. Considering the key principle of tracer dilution 
methodology, that Rd should not alter (dilute) the tracer to tracee ratios (i.e. disposing of equal 
proportions of labelled and unlabelled glucose), and the fact that muscle is not a glucose 
producing tissue, the metabolic activity of the forearm should not result in altered tracer 
enrichments, thus calculation of EGP or meal Ra.  
Although venous blood sampling may preclude absolute conclusions regarding whole-body 
glucose metabolism, particularly with regards to glucose Rd, our findings are consistent with 
a number of recent (63, 65, 263) and classic (84, 85) papers suggesting that glucose flux, 
particularly at the level of skeletal muscle glucose uptake, is maintained despite changes to 
glucose tolerance (due to compensation by hyperglycaemia). Additionally, the values for 
glucose Rd are similar to those of previous studies, and the absolute rates, as well as the kinetics 
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and patterns of glucose flux are comparable with previous studies where arterialised venous 
blood was sampled (63, 65, 66, 263), and from a clinical diagnostic and standardisation 
perspective, it is only venous sampling that is performed, be it for fasting or OGTT purposes. 
In summary, the findings of this thesis suggest that under physiological postprandial 
conditions, the glucoregulatory system is able to adapt with the aim of maintaining appropriate 
rates of glucose flux, such that glucose fluxes are preferentially maintained at ‘baseline’ levels, 
as opposed to inducing a greater overall stimulation of Rd or suppression of EGP. Indeed, the 
exercise study supports the concept that the glucoregulatory system becomes more efficient, 
such that pre-training postprandial glucose fluxes can occur in the presence of lowered 
glycaemic excursions. Conversely, the overfeeding study demonstrates that glycaemic 
excursions can deteriorate modestly, within a normal healthy range, in order to maintain 
adequate rates of glucose flux without the need to substantially increase rates of insulin 
secretion, whereby higher glycaemic excursion easily compensates for any modest defect in 
insulin action at the level of EGP or Rd. Therefore, these findings highlight that when glucose 
metabolism is quantified under physiologically representative conditions following an 
intervention period, the glucoregulatory system, at least acutely, can compensate for 
intervention-mediated alterations to insulin action, by subtly altering both glycaemia and 
insulinaemia. 
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7.0 Appendix 
 
Appendix 7.1: Overfeeding pre-trial standard diet. 
Day  Food  Quantity    
   Kellogg's Nutri-Grain Honey Flavoured 
Crunch  
1 Serve    
    Milk,cow,ready to drink,regular 
fat,regular   
1 school lunch carton     
    Bread,wholemeal,commercial,unfortified
,toasted   
2 regular slice <28g>     
    Butter,blend,regular,other   2 individual serve packet     
              
    McCain Lasagne   1 Serve     
              
    McCain chicken parmagiana   1 Packet     
              
    Pasta,plain boiled pasta,white pasta   165 g-Dry     
    Pasta Sauce - Dolmio plain tomato   125g     
    Uncle Tobys Crunchy Choc Chip Muesli 
Bar   
2 regular bar      
 
Appendix 7.2: Macronutrient composition of the overfeeding pre-trial standard diet. 
 Total Average (%) 
Energy (kj) 
 
9783.7 
 
 
Carbohydrate 307.75 52.85 
Fat 75.57 28.62 
Protein 90.18Error! Reference 
source not found. 
15.89 
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Appendix 7.3:  Dietary snacks used to overfeed participants. Participants consumed 5 of the 10 
snacks per day for 28 days. 
 
Food  Quantity  Energy   Protein/ Fat/ 
Carbohydrate, % 
Thins Original Thin & Crispy Potato 
Chips  
1 single serve bag  1080kj   5/58/38 
Uncle Tobys Crunchy Choc Chip 
Muesli Bar   
2 regular bar   1067kj    7/26/64 
Arnott's Tim Tam Original   3 regular biscuit   1163kj   5/46/49 
 
Cadbury Dairy Milk   
 
50g   
1103kj    6/51/41 
Golden Muffin Bites Choc Fudge 
Brownie   
2 Serve   1279kj   6/38/56 
Yoplait Blueberry Yoghurt   1 individual tub   702kj    20/29/46 
              
Sanitarium Up&Go Energize Choc   1 single serve 
beverage   
844kj     13/31/52 
Celebrity Slim Program Meal 
Replacement Shakes   
1 Serve   817kj     35/10/55 
Solo Original Lemon   375 mL   600kj     0/0/99 
Barista Bros Iced Coffee Flavoured 
Milk   
500 mL   1400kj     22/16/59 
 
Appendix 7.4: Macronutrient composition of the overfeeding dietary snacks. 
 Total (all 10 foods) Total (5 snacks; daily 
intake) 
Average (%) 
Energy (kj) 
 
10036.1 5018  
Carbohydrate 78.18 39.09 13.24% 
Fat 84.19 42.1 31.04% 
Protein 331.16 166.08 52.33% 
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Appendix 7.5:  
Overfeeding study – Diet Guidelines 
 
- It is required that you consume 5 of the provided snacks per day  
 
- You will need to select 3 of the snacks to eat per day as well as select 2 
of the beverages to consume per day 
 
- You will need to make note of each snack and beverage you consume on 
the provided daily checklist 
 
- There is space on each page in which you can fill in any additional 
information pertaining to what you ate, including unfinished snacks. 
 
 
- An example checklist for one week has been filled out below 
 
 
 
 
- It is important that in addition to consuming the above foods, that you 
continue eating your normal diet. 
 
- You will be provided also be provided with a ‘3-day diet diary’. You will 
be guided on how to complete the form, in which you will list every food 
you consume throughout a 3-day period. This will be filled out once 
before, and three times during the 4 weeks. 
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EXAMPLE - Daily Diet Checklist 
Date:  11/07/16           Date:   12/07/16              Date:  13/07/16 
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips 1 Crinkle cut chips   Crinkle cut chips 1 
Muesli Bar (x2)     1  * Muesli Bar (x2)   Muesli Bar (x2)  
Dairy Milk Chocolate 1  Dairy Milk Chocolate   Dairy Milk Chocolate 1 
Tim Tams (x3)  Tim Tams (x3) 1  Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2) 1  Muffin bites (x2) 1 
Yoghurt   Yoghurt 1  Yoghurt  
Beverages   Beverages   Beverages  
Up and Go 1  Up and Go   Up and Go 1 
Meal replace Shake   Meal replace Shake 1  Meal replace Shake  
Lemonade 1  Lemonade   Lemonade 1 
Iced Chocolate   Iced Chocolate 1  Iced Chocolate  
     
Date:  14/07/16           Date:   15/07/16              Date:  16/07/16 
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips  Crinkle cut chips   Crinkle cut chips 1 
Muesli Bar (x2) 1 Muesli Bar (x2) 1  Muesli Bar (x2)  
Dairy Milk Chocolate  Dairy Milk Chocolate   Dairy Milk Chocolate  
Tim Tams (x3) 1 Tim Tams (x3) 1  Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2)   Muffin bites (x2)   1 * 
Yoghurt   1 *  Yoghurt 1  Yoghurt 1 
Beverages   Beverages   Beverages  
Up and Go 1  Up and Go   Up and Go 1 
Meal replace Shake 1  Meal replace Shake   Meal replace Shake 1 
Lemonade   Lemonade 1  Lemonade  
Iced Chocolate   Iced Chocolate 1  Iced Chocolate  
Date: 17/07/16           Notes: 
Snacks Quantity 
consumed 
 11/07/16 – Consumed only 1 muesli bar 
 
14/07/16 – Finished only half of the yoghurt 
 
16/06/16 – Consumed only 1 muffin bite 
Crinkle cut chips 1  
Muesli Bar (x2)   
Dairy Milk Chocolate 1  
Tim Tams (x3) 1  
Muffin bites (x2)   
Yoghurt   
Beverages   
Up and Go 1  
Meal replace Shake 1  
Lemonade   
Iced Chocolate   
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Daily Diet Checklist 
Date:                           Date:                                Date:   
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips  Crinkle cut chips   Crinkle cut chips  
Muesli Bar (x2)  Muesli Bar (x2)   Muesli Bar (x2)  
Dairy Milk Chocolate  Dairy Milk Chocolate   Dairy Milk Chocolate  
Tim Tams (x3)  Tim Tams (x3)   Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2)   Muffin bites (x2)  
Yoghurt   Yoghurt   Yoghurt  
Beverages   Beverages   Beverages  
Up and Go   Up and Go   Up and Go  
Meal replace Shake   Meal replace Shake   Meal replace Shake  
Lemonade   Lemonade   Lemonade  
Iced Chocolate   Iced Chocolate   Iced Chocolate  
     
Date:                           Date:                                Date:   
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips  Crinkle cut chips   Crinkle cut chips  
Muesli Bar (x2)  Muesli Bar (x2)   Muesli Bar (x2)  
Dairy Milk Chocolate  Dairy Milk Chocolate   Dairy Milk Chocolate  
Tim Tams (x3)  Tim Tams (x3)   Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2)   Muffin bites (x2)  
Yoghurt   Yoghurt   Yoghurt  
Beverages   Beverages   Beverages  
Up and Go   Up and Go   Up and Go  
Meal replace Shake   Meal replace Shake   Meal replace Shake  
Lemonade   Lemonade   Lemonade  
Iced Chocolate   Iced Chocolate   Iced Chocolate  
Date:                          Notes: 
Snacks Quantity 
consumed 
  
Crinkle cut chips   
Muesli Bar (x2)   
Dairy Milk Chocolate   
Tim Tams (x3)   
Muffin bites (x2)   
Yoghurt   
Beverages   
Up and Go   
Meal replace Shake   
Lemonade   
Iced Chocolate   
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Daily Diet Checklist 
Date:                                      Date:                                      Date:   
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips  Crinkle cut chips   Crinkle cut chips  
Muesli Bar (x2)  Muesli Bar (x2)   Muesli Bar (x2)  
Dairy Milk Chocolate  Dairy Milk Chocolate   Dairy Milk Chocolate  
Tim Tams (x3)  Tim Tams (x3)   Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2)   Muffin bites (x2)  
Yoghurt   Yoghurt   Yoghurt  
Beverages   Beverages   Beverages  
Up and Go   Up and Go   Up and Go  
Meal replace Shake   Meal replace Shake   Meal replace Shake  
Lemonade   Lemonade   Lemonade  
Iced Chocolate   Iced Chocolate   Iced Chocolate  
     
Date:                                    Date:                                      Date:   
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips  Crinkle cut chips   Crinkle cut chips  
Muesli Bar (x2)  Muesli Bar (x2)   Muesli Bar (x2)  
Dairy Milk Chocolate  Dairy Milk Chocolate   Dairy Milk Chocolate  
Tim Tams (x3)  Tim Tams (x3)   Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2)   Muffin bites (x2)  
Yoghurt   Yoghurt   Yoghurt  
Beverages   Beverages   Beverages  
Up and Go   Up and Go   Up and Go  
Meal replace Shake   Meal replace Shake   Meal replace Shake  
Lemonade   Lemonade   Lemonade  
Iced Chocolate   Iced Chocolate   Iced Chocolate  
Date:                          Notes: 
Snacks Quantity 
consumed 
  
Crinkle cut chips   
Muesli Bar (x2)   
Dairy Milk Chocolate   
Tim Tams (x3)   
Muffin bites (x2)   
Yoghurt   
Beverages   
Up and Go   
Meal replace Shake   
Lemonade   
Iced Chocolate   
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Daily Diet Checklist 
Date:                                             Date:                                     Date:   
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips  Crinkle cut chips   Crinkle cut chips  
Muesli Bar (x2)  Muesli Bar (x2)   Muesli Bar (x2)  
Dairy Milk Chocolate  Dairy Milk Chocolate   Dairy Milk Chocolate  
Tim Tams (x3)  Tim Tams (x3)   Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2)   Muffin bites (x2)  
Yoghurt   Yoghurt   Yoghurt  
Beverages   Beverages   Beverages  
Up and Go   Up and Go   Up and Go  
Meal replace Shake   Meal replace Shake   Meal replace Shake  
Lemonade   Lemonade   Lemonade  
Iced Chocolate   Iced Chocolate   Iced Chocolate  
     
Date:                                    Date:                                        Date:   
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips  Crinkle cut chips   Crinkle cut chips  
Muesli Bar (x2)  Muesli Bar (x2)   Muesli Bar (x2)  
Dairy Milk Chocolate  Dairy Milk Chocolate   Dairy Milk Chocolate  
Tim Tams (x3)  Tim Tams (x3)   Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2)   Muffin bites (x2)  
Yoghurt   Yoghurt   Yoghurt  
Beverages   Beverages   Beverages  
Up and Go   Up and Go   Up and Go  
Meal replace Shake   Meal replace Shake   Meal replace Shake  
Lemonade   Lemonade   Lemonade  
Iced Chocolate   Iced Chocolate   Iced Chocolate  
Date:                          Notes: 
Snacks Quantity 
consumed 
  
Crinkle cut chips   
Muesli Bar (x2)   
Dairy Milk Chocolate   
Tim Tams (x3)   
Muffin bites (x2)   
Yoghurt   
Beverages   
Up and Go   
Meal replace Shake   
Lemonade   
Iced Chocolate   
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Daily Diet Checklist 
Date:                                   Date:                                      Date:   
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips  Crinkle cut chips   Crinkle cut chips  
Muesli Bar (x2)  Muesli Bar (x2)   Muesli Bar (x2)  
Dairy Milk Chocolate  Dairy Milk Chocolate   Dairy Milk Chocolate  
Tim Tams (x3)  Tim Tams (x3)   Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2)   Muffin bites (x2)  
Yoghurt   Yoghurt   Yoghurt  
Beverages   Beverages   Beverages  
Up and Go   Up and Go   Up and Go  
Meal replace Shake   Meal replace Shake   Meal replace Shake  
Lemonade   Lemonade   Lemonade  
Iced Chocolate   Iced Chocolate   Iced Chocolate  
     
Date:                                   Date:                                     Date:   
Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
 Snacks Quantity 
consumed 
Crinkle cut chips  Crinkle cut chips   Crinkle cut chips  
Muesli Bar (x2)  Muesli Bar (x2)   Muesli Bar (x2)  
Dairy Milk Chocolate  Dairy Milk Chocolate   Dairy Milk Chocolate  
Tim Tams (x3)  Tim Tams (x3)   Tim Tams (x3)  
Muffin bites (x2)  Muffin bites (x2)   Muffin bites (x2)  
Yoghurt   Yoghurt   Yoghurt  
Beverages   Beverages   Beverages  
Up and Go   Up and Go   Up and Go  
Meal replace Shake   Meal replace Shake   Meal replace Shake  
Lemonade   Lemonade   Lemonade  
Iced Chocolate   Iced Chocolate   Iced Chocolate  
Date:                          Notes: 
Snacks Quantity 
consumed 
  
Crinkle cut chips   
Muesli Bar (x2)   
Dairy Milk Chocolate   
Tim Tams (x3)   
Muffin bites (x2)   
Yoghurt   
Beverages   
Up and Go   
Meal replace Shake   
Lemonade   
Iced Chocolate   
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Appendix 7.6 
3-day food diary & 
physical activity recall 
  
1.  The following food diary is to be completed over 3 days prior to 
each laboratory visit. Please include one weekend day as part of this 
period. An example day’s completion is provided at the start of the 
booklet.   
If after reading these instruction you have further questions, contact 
Dale Morrison on 0413137853 or djmorr@deakin.edu.au 
                                                                                                                                                                                                                                                                                                                                                                                                                                       
2.        Sections for breakfast, morning tea, lunch, afternoon tea, dinner 
and additional food/drinks are provided each day for you to report 
your food/drink consumption. 
 
3.  In the “FOOD/DRINK” column, you should state the type of 
food/drink consumed. In the “DESCRIPTION AND PREPARATION” 
column, you should provide some information in relation to how the 
food/drink was prepared, the brand name of the food/drink (if 
relevant), and a description of the specific food/drink (e.g. type, 
flavour, and if fresh, frozen or canned). In the “AMOUNT” column, 
provide a brief description using common household measures of how 
much of the particular food/drink was consumed (e.g. teaspoons, cups, 
approximate physical dimensions – if necessary refer to the back of this 
document for some example serving sizes)  
 
 
Any additional information pertaining to what you ate, such as a recipe 
for a homemade food, should be included on the final page in 
“ADDITIONAL INFORMATION”. 
                                                                                                                                                       
4.  It is IMPORTANT that you accurately report what you have 
consumed. It is also important that you do not alter your normal diet 
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during the recording period, such as for purposes of appearing 
healthier than usual or for ease of reporting.                          
 
 
5.   Details about each food and beverage item you consume are crucial 
to us, so please include as many details as you can!  
Describe the food as accurately as possible eg. milk - what kind (whole, 
2%, non-fat); bread - (whole wheat, white, buttered). 
The more details you include, the less likely you will be to receive a call 
from us later on to get those details.      
 
 
6.   At the end of day 3, please complete the attached physical activity 
questionnaire. This questionnaire relates to physical activity 
undertaken over the previous week.                    
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TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
BREAKFAST 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 210 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
MORNING TEA 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
LUNCH 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
  
 211 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AFTERNOON TEA 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 212 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
DINNER 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 213 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
ADDITIONAL FOODS/DRINKS 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADDITIONAL INFORMATION 
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TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 215 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BREAKFAST 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 216 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MORNING TEA 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
  
 217 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
LUNCH 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 218 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
AFTERNOON TEA 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
DINNER 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
  
 219 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADDITIONAL FOODS/DRINKS 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
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TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADDITIONAL INFORMATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 221 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 222 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
BREAKFAST 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 223 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
MORNING TEA 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
LUNCH 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
  
 224 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AFTERNOON TEA 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 225 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
DINNER 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 226 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
ADDITIONAL FOODS/DRINKS 
FOOD/DRINK DESCRIPTION AND PREPARATION AMOUNT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADDITIONAL INFORMATION 
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TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 228 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical activity recall 
 
 
 
 
A. DURING THE LAST WEEK how many times did you walk continuously, for at least 10 
minutes, for recreation/exercise or to get to or from places?               times 
 
What do you estimate was the total time that you spent walking in this way?                  
______________mins 
 
 
B. DURING THE LAST WEEK how many times did you do any vigorous physical activity 
which made you breathe harder or puff and pant? (e.g. jogging, cycling, aerobics, 
competitive tennis, etc.)                  times 
 
What do you estimate was the total time that you spent doing this vigorous physical 
activity?                   mins 
 
 
 229 
TRIAL CODE  __________________                                PARTICIPANT CODE ____________________ 
DATE  ___/ ___/ _____ DAY OF WEEK __________________ 
C. DURING THE LAST WEEK how many times did you do any other more moderate physical 
activity that you haven’t already mentioned? (e.g. gentle swimming, social tennis, golf) 
                  times 
 
What do you estimate was the total time that you spent doing these moderate 
physical activities?                   mins 
 
 
 
 
 
 
 
 
 
 
 
Photographs of sample serving sizes 
Orange juice/beverages 
 
                     1/2 cup                                                       1 cup                                            1 ½ cups 
             
Breakfast cereal 
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                    1/2 cup                                                 1 cup                                                  1 ½ cup 
 
 
                    1/2 cup                                                 1 cup                                                  1 ½ cup 
 
Soup 
                       
                    1/2 cup                                                 1 cup                                                 2 cups 
Chopped cooked steak/meats 
 
                      1/3 cup                                               2/3 cup                                                    1 cup 
 
Beef stew with vegetables 
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                        1/2 cup                                           1 cup                                                     2 cups 
 
Apple Pie 
 
           7 x 3 cm (about 50g)                      7 x 7 cm (about 100g)                    7 x 14 cm (about 200g) 
 
Whole fruit 
  
               1 medium apple                                 1 cup cherries                  1 large banana (about 20cm long) 
Chopped fruit (examples): 
 
Rockmelon 
 
                    1/2 cup                                   1 cup (about ¼ melon)                            1 ½ cup 
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Pineapple 
 
                     1/2 cup                                                  1 cup                                                1 ½ cup 
Grapes 
 
                      1/2 cup                                                1 cup                                                 1 ½ cup 
Fruit salad 
 
                     1/2 cup                                                  1 cup                                                  1 ½ cup 
 
 
 
Vegetables (examples): 
 
Boiled broccoli 
  
                       1/4 cup                                                 1/2 cup                                                1 cup 
 233 
 
Boiled pumpkin 
 
                         1/4 cup                                                        1/2 cup                                                      1 cup 
Green Beans 
 
                        1/4 cup                                                 1/2 cup                                               1 cup 
 
Mixed cooked vegetables 
 
                        1/4 cup                                               1/2 cup                                                1 cup 
Corn 
         
1 small/1/2 medium cob (8cm long)    1 medium cob (13cm long)              1 large cob (20cm long) 
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Boiled Swede 
 
                1/4 cup chopped                               1/2 cup chopped                               1 cup chopped 
 
Onions 
 
                    1/4 cup diced                                    1/2 cup diced                                      1 cup diced 
Tomatoes 
 
                 1/4 cup chopped                            1/2 cup chopped                                1 cup chopped 
 
Mixed salad (including lettuce, tomatoes, onion etc.) 
 
                      1/2 cup                                                1 cup                                                   2 cups 
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Parsley (on small plate) 
 
                   5g or 5 sprigs                                  10g or 10 sprigs                                20g or 20 sprigs 
 
Boiled potato 
 
     1 small potato (about 90g)        1 medium potato (about 120g)          1 large potato (about 180g) 
 
Baked potato 
 
                 1 small potato                                 1 medium potato                               1 large potato 
 
Hot potato chips 
 
 
                      1/2 cup                                               3/4 cup                                                1 cup 
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Mashed potato 
  
                         1/2 cup                                                  3/4 cup                                                1 cup 
 
(some photographs from Nelson et al. Food Portion sizes: A Photographic Atlas. MAFF 1997) 
 
   
